US20190105335A1 - Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of sensory discomfort - Google Patents
Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of sensory discomfort Download PDFInfo
- Publication number
- US20190105335A1 US20190105335A1 US16/350,559 US201816350559A US2019105335A1 US 20190105335 A1 US20190105335 A1 US 20190105335A1 US 201816350559 A US201816350559 A US 201816350559A US 2019105335 A1 US2019105335 A1 US 2019105335A1
- Authority
- US
- United States
- Prior art keywords
- dipa
- treatment
- skin
- compounds
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 120
- 230000001953 sensory effect Effects 0.000 title abstract description 45
- 239000003860 topical agent Substances 0.000 title 1
- 208000003251 Pruritus Diseases 0.000 claims abstract description 111
- 150000001875 compounds Chemical class 0.000 claims abstract description 107
- 239000000203 mixture Substances 0.000 claims abstract description 67
- -1 DIPA compounds Chemical class 0.000 claims abstract description 65
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 50
- 208000035475 disorder Diseases 0.000 claims abstract description 40
- 230000000699 topical effect Effects 0.000 claims abstract description 39
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 26
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 25
- 208000035824 paresthesia Diseases 0.000 claims abstract description 23
- 206010013886 Dysaesthesia Diseases 0.000 claims abstract description 18
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 14
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 13
- 206010012442 Dermatitis contact Diseases 0.000 claims abstract description 11
- 208000010247 contact dermatitis Diseases 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 67
- 230000035807 sensation Effects 0.000 claims description 44
- 208000024780 Urticaria Diseases 0.000 claims description 33
- 210000000744 eyelid Anatomy 0.000 claims description 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 239000003085 diluting agent Substances 0.000 claims description 9
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 8
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 8
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 7
- 206010000496 acne Diseases 0.000 claims description 7
- 208000006877 Insect Bites and Stings Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 210000003734 kidney Anatomy 0.000 claims description 6
- 206010008635 Cholestasis Diseases 0.000 claims description 5
- 206010060800 Hot flush Diseases 0.000 claims description 5
- 201000009053 Neurodermatitis Diseases 0.000 claims description 5
- 206010042496 Sunburn Diseases 0.000 claims description 5
- 230000007870 cholestasis Effects 0.000 claims description 5
- 231100000359 cholestasis Toxicity 0.000 claims description 5
- 238000000502 dialysis Methods 0.000 claims description 5
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 208000017940 prurigo nodularis Diseases 0.000 claims description 5
- 206010013082 Discomfort Diseases 0.000 claims description 4
- 206010024434 Lichen sclerosus Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 206010048222 Xerosis Diseases 0.000 claims description 4
- 208000002782 Acneiform Eruptions Diseases 0.000 claims description 3
- 206010052568 Urticaria chronic Diseases 0.000 claims description 3
- 208000024376 chronic urticaria Diseases 0.000 claims description 3
- 206010033372 Pain and discomfort Diseases 0.000 claims description 2
- 230000009245 menopause Effects 0.000 claims description 2
- 210000002374 sebum Anatomy 0.000 claims description 2
- 201000009495 Hypotrichosis Diseases 0.000 claims 2
- 230000003676 hair loss Effects 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 1
- 102100032373 Coiled-coil domain-containing protein 85B Human genes 0.000 abstract description 66
- 101000868814 Homo sapiens Coiled-coil domain-containing protein 85B Proteins 0.000 abstract description 66
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical class CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 abstract description 64
- 208000002193 Pain Diseases 0.000 abstract description 33
- 230000036407 pain Effects 0.000 abstract description 28
- 230000007794 irritation Effects 0.000 abstract description 18
- 208000024891 symptom Diseases 0.000 abstract description 18
- 230000001225 therapeutic effect Effects 0.000 abstract description 15
- 206010040830 Skin discomfort Diseases 0.000 abstract description 13
- 230000008642 heat stress Effects 0.000 abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 11
- 201000004624 Dermatitis Diseases 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 10
- 230000036565 night sweats Effects 0.000 abstract description 8
- 206010029410 night sweats Diseases 0.000 abstract description 8
- 206010052143 Ocular discomfort Diseases 0.000 abstract description 7
- 230000001587 cholestatic effect Effects 0.000 abstract description 7
- 230000001457 vasomotor Effects 0.000 abstract description 7
- 238000011010 flushing procedure Methods 0.000 abstract description 6
- 206010015958 Eye pain Diseases 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 220
- 230000000694 effects Effects 0.000 description 69
- 238000001816 cooling Methods 0.000 description 63
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 63
- 210000004027 cell Anatomy 0.000 description 45
- 102000003610 TRPM8 Human genes 0.000 description 44
- 101150111302 Trpm8 gene Proteins 0.000 description 44
- 239000003814 drug Substances 0.000 description 44
- 238000012360 testing method Methods 0.000 description 44
- 102000005962 receptors Human genes 0.000 description 34
- 108020003175 receptors Proteins 0.000 description 34
- 239000000243 solution Substances 0.000 description 32
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 30
- 239000010410 layer Substances 0.000 description 29
- 239000000126 substance Substances 0.000 description 29
- 229940079593 drug Drugs 0.000 description 28
- 230000004044 response Effects 0.000 description 26
- 230000009471 action Effects 0.000 description 25
- 239000000499 gel Substances 0.000 description 23
- 239000007788 liquid Substances 0.000 description 23
- 239000003795 chemical substances by application Substances 0.000 description 21
- 239000002826 coolant Substances 0.000 description 20
- 241000700159 Rattus Species 0.000 description 19
- 238000009472 formulation Methods 0.000 description 19
- 210000005036 nerve Anatomy 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 18
- 206010061218 Inflammation Diseases 0.000 description 18
- 230000004054 inflammatory process Effects 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 239000006071 cream Substances 0.000 description 17
- 210000001640 nerve ending Anatomy 0.000 description 17
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 16
- 210000001508 eye Anatomy 0.000 description 16
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- 229960002504 capsaicin Drugs 0.000 description 15
- 235000017663 capsaicin Nutrition 0.000 description 15
- 229940041616 menthol Drugs 0.000 description 15
- 238000006748 scratching Methods 0.000 description 15
- 230000002393 scratching effect Effects 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 14
- 230000001815 facial effect Effects 0.000 description 13
- 239000004615 ingredient Substances 0.000 description 13
- 210000004761 scalp Anatomy 0.000 description 13
- 210000000434 stratum corneum Anatomy 0.000 description 13
- 210000004556 brain Anatomy 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 210000001061 forehead Anatomy 0.000 description 12
- 230000028161 membrane depolarization Effects 0.000 description 12
- RCEFMOGVOYEGJN-UHFFFAOYSA-N 3-(2-hydroxyphenyl)-6-(3-nitrophenyl)-1,4-dihydropyrimidin-2-one Chemical compound OC1=CC=CC=C1N1C(=O)NC(C=2C=C(C=CC=2)[N+]([O-])=O)=CC1 RCEFMOGVOYEGJN-UHFFFAOYSA-N 0.000 description 11
- HNUALPPJLMYHDK-UHFFFAOYSA-N C[CH]C Chemical compound C[CH]C HNUALPPJLMYHDK-UHFFFAOYSA-N 0.000 description 11
- 229920000742 Cotton Polymers 0.000 description 11
- 230000004913 activation Effects 0.000 description 11
- 239000012153 distilled water Substances 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 210000000216 zygoma Anatomy 0.000 description 11
- 230000006399 behavior Effects 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 230000006378 damage Effects 0.000 description 10
- 230000003389 potentiating effect Effects 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- 108091006146 Channels Proteins 0.000 description 9
- 241000282412 Homo Species 0.000 description 9
- 208000008454 Hyperhidrosis Diseases 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 239000000556 agonist Substances 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- 230000003502 anti-nociceptive effect Effects 0.000 description 9
- 239000002537 cosmetic Substances 0.000 description 9
- 206010016256 fatigue Diseases 0.000 description 9
- 210000003128 head Anatomy 0.000 description 9
- 230000007803 itching Effects 0.000 description 9
- 230000036515 potency Effects 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 230000035900 sweating Effects 0.000 description 9
- 101100059320 Mus musculus Ccdc85b gene Proteins 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- 230000001537 neural effect Effects 0.000 description 8
- 230000035515 penetration Effects 0.000 description 8
- 230000008447 perception Effects 0.000 description 8
- 230000008591 skin barrier function Effects 0.000 description 8
- 230000003068 static effect Effects 0.000 description 8
- 206010015150 Erythema Diseases 0.000 description 7
- 102000003566 TRPV1 Human genes 0.000 description 7
- 101150016206 Trpv1 gene Proteins 0.000 description 7
- 230000002929 anti-fatigue Effects 0.000 description 7
- 230000035597 cooling sensation Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 210000002615 epidermis Anatomy 0.000 description 7
- 230000000763 evoking effect Effects 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 210000000088 lip Anatomy 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000002674 ointment Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 210000001044 sensory neuron Anatomy 0.000 description 7
- 238000011200 topical administration Methods 0.000 description 7
- 239000004909 Moisturizer Substances 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 229920000297 Rayon Polymers 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 206010042674 Swelling Diseases 0.000 description 6
- 230000037147 athletic performance Effects 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 6
- 210000000038 chest Anatomy 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000002085 irritant Substances 0.000 description 6
- 231100000021 irritant Toxicity 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000001333 moisturizer Effects 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 5
- 206010003645 Atopy Diseases 0.000 description 5
- 206010006784 Burning sensation Diseases 0.000 description 5
- 206010008531 Chills Diseases 0.000 description 5
- 108090000862 Ion Channels Proteins 0.000 description 5
- 102000004310 Ion Channels Human genes 0.000 description 5
- 230000003187 abdominal effect Effects 0.000 description 5
- 238000004378 air conditioning Methods 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 239000003965 antinociceptive agent Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 5
- 229960002470 bimatoprost Drugs 0.000 description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 230000002500 effect on skin Effects 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- 238000010304 firing Methods 0.000 description 5
- 230000004907 flux Effects 0.000 description 5
- 210000004392 genitalia Anatomy 0.000 description 5
- 210000003127 knee Anatomy 0.000 description 5
- 208000019423 liver disease Diseases 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- MPQXHAGKBWFSNV-UHFFFAOYSA-N oxidophosphanium Chemical class [PH3]=O MPQXHAGKBWFSNV-UHFFFAOYSA-N 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 229940126702 topical medication Drugs 0.000 description 5
- 230000026683 transduction Effects 0.000 description 5
- 238000010361 transduction Methods 0.000 description 5
- FINKDHKJINNQQW-UHFFFAOYSA-N 5-methyl-2-propan-2-ylcyclohexane-1-carboxamide Chemical class CC(C)C1CCC(C)CC1C(N)=O FINKDHKJINNQQW-UHFFFAOYSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 241000282465 Canis Species 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 108010076876 Keratins Proteins 0.000 description 4
- 102000011782 Keratins Human genes 0.000 description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 208000003464 asthenopia Diseases 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 230000003292 diminished effect Effects 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 230000002631 hypothermal effect Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000030214 innervation Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 230000003040 nociceptive effect Effects 0.000 description 4
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 4
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 4
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 235000014102 seafood Nutrition 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 230000024883 vasodilation Effects 0.000 description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- 0 *P(=O)(C(C)C)C(C)C Chemical compound *P(=O)(C(C)C)C(C)C 0.000 description 3
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 3
- ULOIAOPTGWSNHU-UHFFFAOYSA-N 2-butyl radical Chemical compound C[CH]CC ULOIAOPTGWSNHU-UHFFFAOYSA-N 0.000 description 3
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000010637 Aquaporins Human genes 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 239000004342 Benzoyl peroxide Substances 0.000 description 3
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 206010010741 Conjunctivitis Diseases 0.000 description 3
- 206010013774 Dry eye Diseases 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- 206010015946 Eye irritation Diseases 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 101100047459 Homo sapiens TRPM8 gene Proteins 0.000 description 3
- 206010020864 Hypertrichosis Diseases 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 239000000150 Sympathomimetic Substances 0.000 description 3
- 108010036769 TRPA1 Cation Channel Proteins 0.000 description 3
- 102000012253 TRPA1 Cation Channel Human genes 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 206010047141 Vasodilatation Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 229940125715 antihistaminic agent Drugs 0.000 description 3
- 235000019400 benzoyl peroxide Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000001217 buttock Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 238000000315 cryotherapy Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003344 environmental pollutant Substances 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 231100000013 eye irritation Toxicity 0.000 description 3
- 210000000720 eyelash Anatomy 0.000 description 3
- 210000000245 forearm Anatomy 0.000 description 3
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000002657 hormone replacement therapy Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 239000003589 local anesthetic agent Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229940055577 oleyl alcohol Drugs 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- 210000000578 peripheral nerve Anatomy 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 231100000719 pollutant Toxicity 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 210000000438 stratum basale Anatomy 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- 230000000475 sunscreen effect Effects 0.000 description 3
- 239000000516 sunscreening agent Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000001975 sympathomimetic effect Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 210000003901 trigeminal nerve Anatomy 0.000 description 3
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 3
- 210000001186 vagus nerve Anatomy 0.000 description 3
- 210000003905 vulva Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- MOYVYITZUDVPSN-UHFFFAOYSA-N 1-[bis(2-methylpropyl)phosphoryl]pentane Chemical compound CCCCCP(=O)(CC(C)C)CC(C)C MOYVYITZUDVPSN-UHFFFAOYSA-N 0.000 description 2
- WPWHSFAFEBZWBB-UHFFFAOYSA-N 1-butyl radical Chemical compound [CH2]CCC WPWHSFAFEBZWBB-UHFFFAOYSA-N 0.000 description 2
- FMBOYVCKMUQEOE-UHFFFAOYSA-N 1-di(butan-2-yl)phosphoryl-3-methylbutane Chemical compound C(C)(CC)P(=O)(CCC(C)C)C(C)CC FMBOYVCKMUQEOE-UHFFFAOYSA-N 0.000 description 2
- OPDSICNRESDXCY-UHFFFAOYSA-N 1-di(butan-2-yl)phosphorylbutane Chemical compound C(C)(CC)P(=O)(C(C)CC)CCCC OPDSICNRESDXCY-UHFFFAOYSA-N 0.000 description 2
- ZMTHELGORKPZOH-UHFFFAOYSA-N 1-di(butan-2-yl)phosphorylheptane Chemical compound CCCCCCCP(=O)(C(C)CC)C(C)CC ZMTHELGORKPZOH-UHFFFAOYSA-N 0.000 description 2
- RSFUTVOECBDVJD-UHFFFAOYSA-N 1-di(butan-2-yl)phosphorylhexane Chemical compound CCCCCCP(=O)(C(C)CC)C(C)CC RSFUTVOECBDVJD-UHFFFAOYSA-N 0.000 description 2
- MGFOHCLAICDPHP-UHFFFAOYSA-N 1-di(butan-2-yl)phosphoryloctane Chemical compound CCCCCCCCP(=O)(C(C)CC)C(C)CC MGFOHCLAICDPHP-UHFFFAOYSA-N 0.000 description 2
- MOISWZCRUUWWBV-UHFFFAOYSA-N 1-di(butan-2-yl)phosphorylpentane Chemical compound CCCCCP(=O)(C(C)CC)C(C)CC MOISWZCRUUWWBV-UHFFFAOYSA-N 0.000 description 2
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 2
- 206010059313 Anogenital warts Diseases 0.000 description 2
- 108010063290 Aquaporins Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108091005462 Cation channels Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 208000000907 Condylomata Acuminata Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 208000035874 Excoriation Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101100482468 Homo sapiens TRPA1 gene Proteins 0.000 description 2
- 101100208023 Homo sapiens TRPV1 gene Proteins 0.000 description 2
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010024438 Lichenification Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027627 Miliaria Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 102000003568 TRPV3 Human genes 0.000 description 2
- 101150043371 Trpv3 gene Proteins 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 208000009621 actinic keratosis Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 2
- 201000004201 anogenital venereal wart Diseases 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000000058 anti acne agent Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000001139 anti-pruritic effect Effects 0.000 description 2
- 229940124340 antiacne agent Drugs 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000035571 calor Effects 0.000 description 2
- 229930003827 cannabinoid Natural products 0.000 description 2
- 239000003557 cannabinoid Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 229960002842 clobetasol Drugs 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 239000000039 congener Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000036757 core body temperature Effects 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- USZAGAREISWJDP-UHFFFAOYSA-N crisaborole Chemical compound C=1C=C2B(O)OCC2=CC=1OC1=CC=C(C#N)C=C1 USZAGAREISWJDP-UHFFFAOYSA-N 0.000 description 2
- 229950008199 crisaborole Drugs 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 229940124447 delivery agent Drugs 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229960000520 diphenhydramine Drugs 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 230000035620 dolor Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 229950003468 dupilumab Drugs 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 210000000256 facial nerve Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 210000002454 frontal bone Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000003410 keratolytic agent Substances 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000013160 medical therapy Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 210000004175 meibomian gland Anatomy 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 201000004169 miliaria rubra Diseases 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000008035 nerve activity Effects 0.000 description 2
- 230000036403 neuro physiology Effects 0.000 description 2
- 210000000929 nociceptor Anatomy 0.000 description 2
- 108091008700 nociceptors Proteins 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- AUONHKJOIZSQGR-UHFFFAOYSA-N oxophosphane Chemical group P=O AUONHKJOIZSQGR-UHFFFAOYSA-N 0.000 description 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
- 230000036314 physical performance Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002964 rayon Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000036185 rubor Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002265 sensory receptor cell Anatomy 0.000 description 2
- 108091008691 sensory receptors Proteins 0.000 description 2
- 102000027509 sensory receptors Human genes 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 231100000046 skin rash Toxicity 0.000 description 2
- 230000003238 somatosensory effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- DHEQXMRUPNDRPG-UHFFFAOYSA-N strontium nitrate Chemical compound [Sr+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O DHEQXMRUPNDRPG-UHFFFAOYSA-N 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000027682 synaptic transmission, glycinergic Effects 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001331 thermoregulatory effect Effects 0.000 description 2
- 230000003867 tiredness Effects 0.000 description 2
- 208000016255 tiredness Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000013271 transdermal drug delivery Methods 0.000 description 2
- 102000042565 transient receptor (TC 1.A.4) family Human genes 0.000 description 2
- 108091053409 transient receptor (TC 1.A.4) family Proteins 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 230000002568 urticarial effect Effects 0.000 description 2
- 239000005526 vasoconstrictor agent Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- MQHBQPSOFQJWAP-HXQWUSOTSA-L *.B.C.CC(C)[Mg]Br.CCC(C)[Mg]Br.CCCCCCCI.CCCCCCCP(=O)(C(C)C)C(C)CC.CCCOP(OCC)OCC.Cl.F.[2HH].[H]P(=O)(C(C)C)C(C)CC.[H]P(=O)(OCC)C(C)CC Chemical compound *.B.C.CC(C)[Mg]Br.CCC(C)[Mg]Br.CCCCCCCI.CCCCCCCP(=O)(C(C)C)C(C)CC.CCCOP(OCC)OCC.Cl.F.[2HH].[H]P(=O)(C(C)C)C(C)CC.[H]P(=O)(OCC)C(C)CC MQHBQPSOFQJWAP-HXQWUSOTSA-L 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 238000010953 Ames test Methods 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 206010068172 Anal pruritus Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- 208000003014 Bites and Stings Diseases 0.000 description 1
- 241000219475 Bougainvillea Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- BHVXUSRMAHHTOZ-UHFFFAOYSA-N C(C)(C)C(CCCCC)([PH2]=O)C(C)CC Chemical compound C(C)(C)C(CCCCC)([PH2]=O)C(C)CC BHVXUSRMAHHTOZ-UHFFFAOYSA-N 0.000 description 1
- JLVVVIPEPBBMOK-UHFFFAOYSA-N C(C)(C)C(CCCCCC)([PH2]=O)C(C)CC Chemical compound C(C)(C)C(CCCCCC)([PH2]=O)C(C)CC JLVVVIPEPBBMOK-UHFFFAOYSA-N 0.000 description 1
- CXEOXNVNLSIGKC-UHFFFAOYSA-N C(C)(C)C(CCCCCCCC)([PH2]=O)C(C)CC Chemical compound C(C)(C)C(CCCCCCCC)([PH2]=O)C(C)CC CXEOXNVNLSIGKC-UHFFFAOYSA-N 0.000 description 1
- DHOTYMJGZIUWRT-UHFFFAOYSA-N CCCCCCCCCP(=O)(C(C)C)C(C)C Chemical compound CCCCCCCCCP(=O)(C(C)C)C(C)C DHOTYMJGZIUWRT-UHFFFAOYSA-N 0.000 description 1
- ODGQZAOYJLSCTK-UHFFFAOYSA-N CCCCCCCCCP(=O)(C(C)C)C(C)CC Chemical compound CCCCCCCCCP(=O)(C(C)C)C(C)CC ODGQZAOYJLSCTK-UHFFFAOYSA-N 0.000 description 1
- NKWBJIISHMGTKA-UHFFFAOYSA-N CCCCCCCCP(=O)(C(C)C)C(C)C Chemical compound CCCCCCCCP(=O)(C(C)C)C(C)C NKWBJIISHMGTKA-UHFFFAOYSA-N 0.000 description 1
- XFKJNSAVQPGXHT-UHFFFAOYSA-N CCCCCCCCP(=O)(C(C)C)C(C)CC Chemical compound CCCCCCCCP(=O)(C(C)C)C(C)CC XFKJNSAVQPGXHT-UHFFFAOYSA-N 0.000 description 1
- TXGFWTAHDCIQST-UHFFFAOYSA-N CCCCCCCP(=O)(C(C)C)C(C)C Chemical compound CCCCCCCP(=O)(C(C)C)C(C)C TXGFWTAHDCIQST-UHFFFAOYSA-N 0.000 description 1
- YFSNFQVBUJCLSI-UHFFFAOYSA-N CCCCCCCP(=O)(C(C)C)C(C)CC Chemical compound CCCCCCCP(=O)(C(C)C)C(C)CC YFSNFQVBUJCLSI-UHFFFAOYSA-N 0.000 description 1
- JOADUZBIKKNGNT-UHFFFAOYSA-N CCCCCCP(=O)(C(C)C)C(C)C Chemical compound CCCCCCP(=O)(C(C)C)C(C)C JOADUZBIKKNGNT-UHFFFAOYSA-N 0.000 description 1
- RYEWURRJKTXYOC-UHFFFAOYSA-N CCCCCCP(=O)(C(C)C)C(C)CC Chemical compound CCCCCCP(=O)(C(C)C)C(C)CC RYEWURRJKTXYOC-UHFFFAOYSA-N 0.000 description 1
- GBKFUAHGIDAQFG-UHFFFAOYSA-N CCCCCP(=O)(C(C)C)C(C)C Chemical compound CCCCCP(=O)(C(C)C)C(C)C GBKFUAHGIDAQFG-UHFFFAOYSA-N 0.000 description 1
- 101100482465 Caenorhabditis elegans trpa-1 gene Proteins 0.000 description 1
- 241000287498 Calypte anna Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000255930 Chironomidae Species 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- OIRAEJWYWSAQNG-UHFFFAOYSA-N Clidanac Chemical compound ClC=1C=C2C(C(=O)O)CCC2=CC=1C1CCCCC1 OIRAEJWYWSAQNG-UHFFFAOYSA-N 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- 108010065372 Dynorphins Proteins 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019332 Heat exhaustion Diseases 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000633069 Homo sapiens Transient receptor potential cation channel subfamily V member 1 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- PJAAESPGJOSQGZ-DZGBDDFRSA-N Isovelleral Chemical compound O=CC1=C[C@@H]2CC(C)(C)C[C@@H]2[C@@]2(C)C[C@]21C=O PJAAESPGJOSQGZ-DZGBDDFRSA-N 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000019738 Limestone Nutrition 0.000 description 1
- 241000289581 Macropus sp. Species 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241000255129 Phlebotominae Species 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036772 Proctalgia Diseases 0.000 description 1
- 102100024622 Proenkephalin-B Human genes 0.000 description 1
- 208000009544 Pruritus Ani Diseases 0.000 description 1
- 208000036741 Pruritus generalised Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 241000208422 Rhododendron Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229940123223 TRPA1 agonist Drugs 0.000 description 1
- 108091008866 TRPA1-like Proteins 0.000 description 1
- 229940080309 TRPM8 agonist Drugs 0.000 description 1
- 229940126422 TRPV1 antagonist Drugs 0.000 description 1
- 108010025083 TRPV1 receptor Proteins 0.000 description 1
- 206010043087 Tachyphylaxis Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 description 1
- 206010056651 Vestibulitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 241000289674 Vombatidae Species 0.000 description 1
- 208000003728 Vulvodynia Diseases 0.000 description 1
- 206010069055 Vulvovaginal pain Diseases 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- HDYRYUINDGQKMC-UHFFFAOYSA-M acetyloxyaluminum;dihydrate Chemical compound O.O.CC(=O)O[Al] HDYRYUINDGQKMC-UHFFFAOYSA-M 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 210000003626 afferent pathway Anatomy 0.000 description 1
- 229940060265 aldara Drugs 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 229940009827 aluminum acetate Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 210000000617 arm Anatomy 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 229960004335 azelastine hydrochloride Drugs 0.000 description 1
- YEJAJYAHJQIWNU-UHFFFAOYSA-N azelastine hydrochloride Chemical compound Cl.C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 YEJAJYAHJQIWNU-UHFFFAOYSA-N 0.000 description 1
- 201000003893 balanitis xerotica obliterans Diseases 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960004311 betamethasone valerate Drugs 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000005422 blasting Methods 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229960000962 bufexamac Drugs 0.000 description 1
- MXJWRABVEGLYDG-UHFFFAOYSA-N bufexamac Chemical compound CCCCOC1=CC=C(CC(=O)NO)C=C1 MXJWRABVEGLYDG-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- IQMPTKBNOOTRSQ-UHFFFAOYSA-N butan-2-yl-(2-methyloctan-3-ylidene)-oxidophosphanium Chemical compound C(C)(C)C(CCCCC)=P(=O)C(C)CC IQMPTKBNOOTRSQ-UHFFFAOYSA-N 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 208000007287 cheilitis Diseases 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 239000002561 chemical irritant Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 210000003109 clavicle Anatomy 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 229950010886 clidanac Drugs 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229940124446 critical care medicine Drugs 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- DIOQZVSQGTUSAI-NJFSPNSNSA-N decane Chemical compound CCCCCCCCC[14CH3] DIOQZVSQGTUSAI-NJFSPNSNSA-N 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003657 dexamethasone acetate Drugs 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000037080 exercise endurance Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 210000001752 female genitalia Anatomy 0.000 description 1
- IDKAXRLETRCXKS-UHFFFAOYSA-N fenclofenac Chemical compound OC(=O)CC1=CC=CC=C1OC1=CC=C(Cl)C=C1Cl IDKAXRLETRCXKS-UHFFFAOYSA-N 0.000 description 1
- 229950006236 fenclofenac Drugs 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960002679 fentiazac Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960003469 flumetasone Drugs 0.000 description 1
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 229960001048 fluorometholone Drugs 0.000 description 1
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 210000001932 glossopharyngeal nerve Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 229940115747 halobetasol Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000010879 hemorrhoidectomy Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 102000052408 human TRPA1 Human genes 0.000 description 1
- 102000045979 human TRPM8 Human genes 0.000 description 1
- 102000045756 human TRPV1 Human genes 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229940083183 imidazoline receptor agonists Drugs 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- ZUBZATZOEPUUQF-UHFFFAOYSA-N isopropylhexane Natural products CCCCCCC(C)C ZUBZATZOEPUUQF-UHFFFAOYSA-N 0.000 description 1
- 210000005128 keratinized epithelium Anatomy 0.000 description 1
- 230000035984 keratolysis Effects 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 239000006028 limestone Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 238000013187 longer-term treatment Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- WSHFRLGXCNEKRX-UHFFFAOYSA-M magnesium;butane;bromide Chemical compound [Mg+2].[Br-].CC[CH-]C WSHFRLGXCNEKRX-UHFFFAOYSA-M 0.000 description 1
- YNLPNVNWHDKDMN-UHFFFAOYSA-M magnesium;butane;chloride Chemical compound [Mg+2].[Cl-].CC[CH-]C YNLPNVNWHDKDMN-UHFFFAOYSA-M 0.000 description 1
- LVKCSZQWLOVUGB-UHFFFAOYSA-M magnesium;propane;bromide Chemical compound [Mg+2].[Br-].C[CH-]C LVKCSZQWLOVUGB-UHFFFAOYSA-M 0.000 description 1
- 210000000260 male genitalia Anatomy 0.000 description 1
- 210000004373 mandible Anatomy 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 210000004228 maxillary nerve Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 238000004776 molecular orbital Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 239000008164 mustard oil Substances 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
- 229960000805 nalbuphine Drugs 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000000133 nasal decongestant Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 210000000584 nodose ganglion Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 229960001528 oxymetazoline Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000009955 peripheral mechanism Effects 0.000 description 1
- 210000005223 peripheral sensory neuron Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229960003733 phenylephrine hydrochloride Drugs 0.000 description 1
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 210000004044 posterior horn cell Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 description 1
- 229960002244 promethazine hydrochloride Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000006903 response to temperature Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000036411 sensory physiology Effects 0.000 description 1
- 230000031893 sensory processing Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 210000005127 stratified epithelium Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 229910001631 strontium chloride Inorganic materials 0.000 description 1
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 238000004781 supercooling Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- MDDUHVRJJAFRAU-YZNNVMRBSA-N tert-butyl-[(1r,3s,5z)-3-[tert-butyl(dimethyl)silyl]oxy-5-(2-diphenylphosphorylethylidene)-4-methylidenecyclohexyl]oxy-dimethylsilane Chemical compound C1[C@@H](O[Si](C)(C)C(C)(C)C)C[C@H](O[Si](C)(C)C(C)(C)C)C(=C)\C1=C/CP(=O)(C=1C=CC=CC=1)C1=CC=CC=C1 MDDUHVRJJAFRAU-YZNNVMRBSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000008542 thermal sensitivity Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 229940042129 topical gel Drugs 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 1
- 210000000836 trigeminal nuclei Anatomy 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- LEHFPXVYPMWYQD-XHIJKXOTSA-N ulobetasol Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]2(C)C[C@@H]1O LEHFPXVYPMWYQD-XHIJKXOTSA-N 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000012905 visible particle Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Definitions
- the present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein (DIPA-1-5, DIPA-1-6, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”) that are useful, for example, in the treatment of symptoms and disorders (e.g., diseases) of the skin. Examples of symptoms are abnormal sensations such as irritation, burning sensations, itch, or pain, collectively called a skin dysesthesia.
- the present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.
- Heat abstraction from the body's surfaces can refresh the senses, relieve discomfort, attenuate pain, and suppress inflammation. Abstraction of heat from body surfaces evokes sensations that are termed cool, refreshing cool, chilly, cold, icy cold and painful cold. For example, air blown onto the face from a fan or an air-conditioner can reduce tiredness and increase alertness. A wet towel applied to the forehead can relieve discomfort from a fever or a headache.
- the methods of heat abstraction, with gas, liquids, or solids, achieve their effects by physically lowering tissue temperatures and by activating signals to the brain.
- Chemical sensory/cooling agents are molecules that can mimic the sensations of heat abstraction without a change in tissue temperatures.
- the exact sensations produced by chemicals depend on the selection of the active ingredient, the target site, the drug formulation, and the method of delivery. With agents currently in use, some degree of chemical cooling on the scalp and skin of the face, nostrils, and philtrum can be achieved, but the effects do not last long. For the skin of the torso and limbs overt sensations of coolness and cold are more difficult to elicit and sustain, and require high concentrations of the active agent, for example, the use of 36% l-menthol oil to treat the itch of insect bites.
- the skin has a keratinized layer of dead cells called the stratum corneum that acts as a daunting barrier to drug penetration into the epidermis and dermis.
- the neuronal receptive fields to detect temperature changes are located in the epidermal sub-layers.
- chemical cooling agent can be ambiguous because, for example, chemicals such as ethyl chloride as a gas, ethanol as a liquid, liquid nitrogen, or carbon dioxide as a solid, applied to the skin can evoke heat abstraction sensations by reducing tissue temperatures.
- chemical cooling agents will refer only to agents that elicit sensations of heat abstraction but do not lower tissue temperatures.
- the inventor has previously identified several p-menthane carboxamide compounds that, when applied to the philtrum skin, simulate effects of heat abstraction for >1.5 hr without decreasing tissue temperature (Wei, E T. Sensory/cooling agents for skin discomfort. Journal Skin Barrier Research 14: 5-12, 2012). These compounds are relatively water-insoluble.
- the site where temperature is detected on the skin qualitatively affects perception of thermal comfort. Temperature sensitivity over the body surface varies over ⁇ 100 fold. The face, especially area around the eyes [periorbital] and mouth [perioral] are very sensitive, but the extremities have poor sensitivity, and the rest of the body is intermediate [Stevens et al. Temperature sensitivity of the body surface over the life span. Somatosensory Motor Research 15: 13-28, 1998]. The sensory innervation of the skin is mediated by peripheral nerves that transmit signals to the brain.
- the 1-dialkyl-phosphinoyl-alkanes are solvent-like molecules that require several [1 to 3] steps for synthesis. They are also known as trialkylphosphine oxides or dialkylphosphorylalkanes. Here, they are referred to as dialkyl-phosphinoyl-alkanes [DAPA]. If two of the alkyl groups are isopropyl, the DAPA is abbreviated as DIPA [di-isopropyl-phosphinoyl-alkane],
- FIG. 1 is an illustration of the human face showing the innervation of the cheekbone skin by the zygomatic facial nerve (ZFN) and the infraorbital nerve (ION). The receptive fields of these nerve endings were used for testing compounds applied to the cheekbone skin. Diagram adapted from Hwang et al. [Cutaneous innervation of the lower eyelid. J. Craniofacial Surgery 19: 1675-1677, 2008].
- FIG. 2 shows the cooling sensations evoked by topical wiping of different concentrations of DIPA-1-8 onto the skin above the zygomatic process.
- the cooling activity can be measured as the intensity/duration area-under-curve (AUC) or as time for half maximal effect (T -1/2 ), using software of the GraphPad Prism package.
- the graph shows the dose-response curve for the compound DIPA-1-8 applied at 0.5, 1 and 2% (5, 10, and 20 mg/mL dissolved in distilled water).
- FIG. 3 shows the cooling sensations evoked by topical wiping of different compounds onto the skin above the zygomatic process.
- the cooling activity is expressed as the integrated intensity/duration area-under-curve (AUC), using software of the GraphPad Prism package. Test concentration was 2% (20 mg/mL in distilled water).
- the diisopropyl analogs are DIPA 3,3-X and isopropyl, sec-butyl analogs are Mixed 3,4-X.
- the “X” refers to the number of carbons on the third alkyl group. It can be seen that the Mixed analogs are much less active on the cheekbone skin than the corresponding diisopropyl analogs.
- FIG. 4 Is a graph of fluorescence response ( ⁇ ratio 340/380) in TRPM8 transfected cells as a function of the logarithm of the concentration of the test compound, expressed in ⁇ M, for DIPA-1-7 (black circle), 3,4-7 (open squares), or 3,4-6 (open triangles).
- the assays were conducted by Andersson et al. of King's College, London, UK, using his methods described in “Modulation of the cold-activated channel TRPM8 by lysophospholipids and polyunsaturated fatty acids. Journal Neuroscience 27 (12): 3347-3355, 2007.
- FIG. 5 shows chart traces that illustrate, in the first trace ( FIG. 5A “Wild Type”), the inhibition of capsaicin-induced depolarization of the isolated mouse vagus by the DIPA-1-7 embodiment, superfused at a concentration of 1 mg/mL, and, in the second trace ( FIG. 5B “TRPM8 KO”), the significant absence of inhibition in the isolated TRPM8 KO (knockout) mouse vagus by DIPA-1-7, superfused at a concentration of 1 mg/mL.
- FIG. 6 shows the method for estimating the in vivo transdermal activity of the DIPA-embodiment compounds applied 20 ⁇ L with a micropipette to the center of a circle enclosed by cream on abdominal skin of an anesthetized rat. Shaking frequency was counted for 40 min after topical application. It can be seen that the embodiments DIPA-1-5, DIPA-1-6, and DIPA-1-7 evoke robust shaking, but this is not seen with other analogs.
- FIG. 7 shows the flux of DIPA-1-7 and DIPA-1-9 through excised hairless mouse skin in vitro.
- Test chemicals dissolved in a gel were placed in an incubation for 8 hr and the permeated amount of the chemical measured by a high pressure liquid chromatograph equipped with a refractive detector. These tests were conducted by Prof Choi of Chosun University, Korea.
- the flux of 1-7 was ⁇ 5 ⁇ greater than 1-9.
- Standard enhancers with polyhydric alcohols, such as a propylene glycol-oleyl alcohol mixture (50:50) or Lauroglycol 90, designed to increase permeation added to the 1-7 gel decreased the rate of permeation by ⁇ 50%, indicating the importance of water solubility for permeation.
- DIPA compounds 1-di-isopropyl-phosphinoyl-alkanes described herein are collectively referred to herein as “DIPA compounds”.
- the skin is a frequent site of injury. Inflammation is the response of tissues to injury and the cardinal signs of inflammation are a feeling of heat [calor] at the site of injury, redness [rubor], swelling [tumor] and pain [dolor] in and around the injured tissues.
- the newly synthesized DIPA molecules relieve signs of skin discomfort such as irritation, burning sensations, itch, and pain from inflamed/damaged skin.
- the unusual property of the DIPA molecules is water solubility and the ability to penetrate the keratinized layers of the skin [stratum corneum] to reach receptive targets underneath.
- the targets are located on sensory nerve endings and when activated, relieve skin dysesthesia and has a disease-modifying effect.
- the water solubility at therapeutically effective concentrations permits ease of formulation for delivery to target receptors.
- compositions comprising one or more DIPA compound, as described herein, and a pharmaceutically acceptable carrier or diluent.
- Particularly preferred embodiments include one or more DIPA compounds and a delivery agent carrying the one or more compounds, where, the delivery agent is suitable for topical delivery.
- These preparations, as described herein may be used in a method of treatment of the human or animal body by therapy, for example, for use a method of treatment of a disorder (e.g., a disease) as described herein.
- the present discovery relates to certain compounds (the DIPA compounds described herein) which, when delivered onto the skin, selectively and potently evoke sensations of “dynamic cool” for at least several hours.
- the dynamic cool can be repeated without significant diminution of the effects and can be sustained for the whole day.
- these compounds have applications in the treatment of skin discomfort, especially skin irritation, itch, and pain.
- the structures of the preferred embodiments are shown below.
- the new water-soluble compounds e.g., 1-di-isopropyl-phosphinoyl-heptane
- potently [ ⁇ 5 mg per dose] and rapidly produce on skin robust and intense cooling sensations.
- This type of drug action is unusual and has not been previously recognized to be achievable on keratinized surfaces and has lead to new applications as described herein.
- a chemical feature, the minimum active alkyl side chain adjacent to the phosphine oxide allows exposure of the polar phosphine oxide group to water, and increases water solubility.
- DIPA is the abbreviation for 1-[Diisopropyl-phosphinoyl]-alkane.
- the third alkyl group in the molecule may be described by a number: hence, 4, 5, 6, 7, 8, 9, and 10 correspond to the butyl, pentyl, hexyl, heptyl, octyl, nonyl, and decanyl side chain, respectively.
- These alkanes are linear or “normal [n]” in configuration, with the phosphinoyl group attached to the primary, or “1-” position, of the carbon chain in the third sidechain.
- These compounds are also known as trialkylphosphine oxides or 1-dialkylphosphorylalkanes.
- TRP transient receptor potential
- the transient receptor potential (TRP) family of cation channels are peripheral detectors of nociceptive and painful stimuli. Many of these receptors are located on the nerve membranes of sensory neurons and respond to chemical irritants and changes in local temperature by activating nerve action potentials which are the signals to be perceived and acted upon by the brain.
- the TRP receptors are the transducers of sensory information, and it is this transduction and effector system that regulates and protects the organism from external irritants.
- Receptive field of a sensory neuron is the region in space in which a stimulus will modify the firing of the neuron.
- the receptive field is spatially determined by the distribution of the nerve endings of the neuron.
- the nerve endings are interdigitated with the cell layers at the basal layer of the epithelium.
- a receptive field even though smaller than a mm 2 , when activated by the appropriate stimulus, e.g. nociceptive or pruritic, can totally dominate the attention of the brain and mind. Witness what happens when a sharp pin or sting comes into contact with skin or when a dog is pre-occupied with a flea bite.
- Dermatological disorders are diseases of the skin, nails or hair.
- the skin has multiple keratin layers.
- the cornea, tongue and parts of the buccal cavity are also keratinized and thus considered as part of the skin.
- the body's internal surfaces, the mucous membranes, do not have a keratin layer and thereby is not considered skin.
- the skin is the largest organ of the body, but the epidermis is only about 1 mm thick.
- the epidermis is densely infiltrated with nerve endings.
- the epidermal turnover time that is, the time to replace itself, is about 1.5 months.
- Atopic dermatitis is an inflammatory disease of the skin. All parts of the skin may become itchy and inflamed, but the lesions are usually conspicuous on the flexures of the elbows and knees, possibly because of increased sweating in these skin areas. Many atopic dermatitis patients also have allergic rhinitis and asthma. Symptoms are more frequent in children and young adults than adults. Recently, two new medications have been approved by the US FDA for atopic dermatitis: dupilumab (a monoclonal antibody) and crisaborole (an ointment). Both medications have a slow onset of therapeutic action of >6 weeks. Dupilumab is very expensive for an one year treatment. The efficacy of crisaborole is modest and it is a greasy ointment that is not favored by atopic patients. There is room for improvement.
- Urticaria also known as hives is a disease characterized by the sudden onset of “wheals” (areas of red skin, with raised and itchy bumps) on any parts of the body.
- the wheals can be quite large and alarming, but are not life-threatening.
- the triggers are usually allergy to a food item, such as seafood, but there are multiple triggers.
- the skin layer is intact, but it is the release of histamine from mast cells in the epidermis and dermis that is the likely cause of the wheal and itch.
- the condition is treatable with oral antihistamines and in more severe cases with oral prednisone, but onset of drug effect takes about 12 hours.
- Urticaria is a recurrent condition and in some patients may persist for more than 6 weeks (chronic urticaria). The itching skin and cosmetic disfigurement of the red wheals are annoying features of urticaria.
- Itch-scratch cycle Scratching can make an itch feel better, but a vicious itch-scratch cycle can cause more damage to the skin, perpetuate inflammation, and lead to excoriations and to disfiguring lichenification.
- the itch-scratch cycle is a well-known phenomenon in childhood and canine atopy where shields are put up to prevent the subject from scratching at the sites of inflammation and itch. Itch prevents a good night's sleep and an atopic dermatitis patient will scratch themselves vigorously even when asleep. An effective medication should prevent itch within minutes after application and act sufficiently long to allow the subject to go to sleep.
- the subject should be instructed to apply the medication after washing, to use on an as-needed basis, and to apply at night before sleep, because scratching can take place after the subject is asleep. This is especially important for children.
- the medication should also put a break on the itch-scratch cycle.
- the DIPA compounds of the present discovery are achiral and are examples of 1-di-alkyl-phosphinoyl-alkanes [(O ⁇ )PR 1 R 2 R 3 ] wherein each of R 1 , R 2 , and R 3 is an alkyl group, and in particular where R 1 and R 2 are isopropyl, and R 3 is a linear alkyl group of 5 to 9 carbons, and which have the following general formula of Formula 1:
- the DIPA compounds were prepared by the following general method: 100 mL (23.7 g, ⁇ 200 mmol) of isopropylmagnesium chloride (or sec-butylmagnesium chloride in the case of the di-sec-butyl derivatives) were obtained from Acros, as a 25% solution in tetrahydrofuran (THF) and placed under nitrogen in a 500 mL flask (with a stir bar). Diethylphosphite solution in THF (from Aldrich, D99234; 8.25 g, 60.6 mmol in 50 mL) was added drop-wise. After approximately 30 minutes, the reaction mixture warmed up to boiling.
- THF tetrahydrofuran
- reaction mixture was stirred for an extra 30 minutes, followed by a drop-wise addition of the appropriate n-alkyl iodide solution in THF (from TCl; 60 mmol in 20 mL). The reactive mixture was then stirred overnight at room temperature.
- the reaction mixture was diluted with water, transferred to a separatory funnel, acidified with acetic acid ( ⁇ 10 mL), and extracted twice with ether. The ether layer was washed with water and evaporated (RotaVap Buchi, bath temperature 40° C.). The light brown oil was distilled under high vacuum.
- the final products verified by mass as determined by mass spectrometry, were transparent liquids that were colorless. Synthesis was conducted by professional chemists at Phoenix Pharmaceuticals, Inc. (Burlingame, Calif.), Uetikon Laboratories (Lahr, Germany) and Dong Wha Pharmaceuticals (Seoul, Korea).
- Table 2 compounds are embodiments of the invention.
- the following compounds (Table 3) were also prepared by this general synthetic method and used for comparisons.
- the 3,4-X series are “mixed” isopropyl-sec-butyl compounds (Table 3). These were synthesized by Dr. Jae Kyun Lim of Dong Wha Pharmaceuticals, using the method described below.
- triethyl phosphite (A) was reacted with sec-butyl magnesium bromide (B) and then hydrolysed with dilute hydrochloric acid to give the mono-alkyl compound (C).
- the product (C) was then reacted isopropyl magnesium bromide (D) to give the di-alkyl compound (E), which was then reacted with a suitable alkyl iodide (F) to give the target trialkyl phosphine (G).
- DIPA compounds are colorless liquids with a density less than water.
- the preferred embodiments DIPA-1-7, DIPA-1-8 and DIPA-1-9 exert an icy sensation that can modulate skin dysesthesia caused, for example, by various dermatitis (e.g. atopic or urticarial) and on mucous membranes (esp. DIPA-1-8 and DIPA-1-9).
- dermatitis e.g. atopic or urticarial
- mucous membranes esp. DIPA-1-8 and DIPA-1-9.
- Similar structures were described by Rowsell and Spring U.S. Pat. No. 4,070,496 (1978) ⁇ 40+ years ago but have remained dormant in the scientific literature.
- the '496 structures (see table) ALL have their “head” (phosphine oxide group) covered by larger, more lipophilic groups.
- '496 did not include the di-isopropyl analogs.
- the applicant synthesized these analogs (which are achiral, by contrast to the structures of '496 which are >95% chiral).
- the water solubility of the DIPA if at least 10 ⁇ greater than the di-sec-butyl or the mixed isopropyl-sec-butyl analogs.
- the DIPA analogs are now mobile in the extracellular fluids and permeate between cells to access nerve endings in the stratum basale.
- DIPA compounds When DIPA compounds are applied to the facial skin as an aqueous solution at 1-10 mg/mL or a 1% hydrogel there is little irritation.
- contacting the periorbital or zygomatic skin with a solution at a concentration of 1-10 mg/mL produce a sensation of “dynamic cool” that is felt within one minute after application.
- DIPA-1-7 especially, has intense dynamic cooling.
- DIPA-1-8 and DIPA-1-9 have minimal residual irritation, and so are especially useful for the longer term treatment of ocular discomfort.
- the efficacy of DIPA-1-9 in the treatment of patients with the “dry eyes syndrome” is demonstrated in Case Study 7. DIPA-1-7 is more useful for application wherein the sensory effect is immediate and energizing.
- DIPA-1-7 and DIPA-1-8 are useful for treatment of skin dysesthesias (e.g., skin irritation, itchy skin, or painful skin), heat discomfort, and heat stress.
- DIPA-1-8 is slightly longer-acting than DIPA-1-7, but is easily active across the skin, and has a lower risk for systemic absorption.
- composition e.g., a pharmaceutical composition
- a pharmaceutical composition comprising a DIPA compound, as described herein, and a pharmaceutically acceptable carrier, diluent, or excipient.
- a method of preparing a composition comprising mixing a DIPA compound, as described herein, and a pharmaceutically acceptable carrier, diluent, or excipient.
- the composition comprises the DIPA compound at a concentration of 0.005-2.0% wt/vol.
- the composition is a liquid or semi-liquid composition (lotion, cream, or ointment), and comprises the DIPA compound at a concentration of 0.5-20 mg/mL.
- the composition is a liquid composition, and comprises the DIPA compound at a concentration of 1-5 mg/mL.
- the composition is a liquid composition, and comprises the DIPA compound at a concentration of 5-10 mg/mL.
- the composition is a liquid composition, and comprises the DIPA compound at a concentration of 10-20 mg/mL.
- the composition may be provided with suitable packaging and/or in a suitable container.
- the composition may be provided as a swab, wipe, pad, or towellette (e.g., suitably sealed in a wrap) carrying a DIPA compound or a composition comprising a DIPA compound.
- the composition may be provided as a patch, e.g., a controlled-release patch, e.g., suitable for application to the skin, e.g., the skin above the supraclavicular fossa or the steronomastoid muscle.
- the composition may be provided as an aerosolized spray delivered from a pressurized container.
- the composition may be provided in a manually-activated sprayer (e.g., with a suitable small orifice) linked to a reservoir containing a DIPA compound or a composition comprising a DIPA compound, for example, capable of delivering an unit volume (e.g., of 0.05 to 0.15 mL), for example, to the skin surface.
- a manually-activated sprayer e.g., with a suitable small orifice
- a composition comprising a DIPA compound for example, capable of delivering an unit volume (e.g., of 0.05 to 0.15 mL), for example, to the skin surface.
- Another aspect of the present discovery pertains to use of a DIPA compound, as described herein, in the manufacture of a medicament, for example, for use in a method of treatment, for example, for use a method of treatment of a disorder (e.g., a disease) as described herein.
- the medicament comprises the DIPA compound.
- Another aspect of the present discovery pertains to a method of treatment, for example, a method of treatment of a disorder (e.g., a disease) as described herein, comprising administering to a subject in need of treatment a therapeutically-effective amount of a DIPA compound, as described herein, preferably in the form of a pharmaceutical composition.
- a disorder e.g., a disease
- a DIPA compound as described herein, preferably in the form of a pharmaceutical composition.
- the treatment is treatment of: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; atopic dermatitis; contact dermatitis; prurigo nodularis; urticaria; milaria rubra; lichen sclerosus atrophicus; acne; acneiform eruptions; pruritus of the elderly, pruritus from cholestasis and liver disease; pruritus from lymphoma; pruritus from kidney disease dialysis; seborrheic dermatitis; psoriasis; rosacea; ocular pain and discomfort; heat discomfort; heat stress; flushing and/or night sweats (vasomotor symptoms) in post-menopausal women; fatigue; tiredness; depression; cognitive dysfunction; and to enhance cognitive function.
- sensory discomfort e.g., caused by irritation, itch, or pain
- a skin dysesthesia e.g., caused by irritation, itch, or pain
- a skin dysesthesia e
- sensor discomfort relates to irritation, itch, pain, or other dysesthesias (abnormal sensations; such as burning sensations, or feeling the presence of a foreign body, or pins and needles) from the body surfaces.
- dysesthesias abnormal sensations; such as burning sensations, or feeling the presence of a foreign body, or pins and needles
- the term implies activation of nociceptors located on sensory nerve endings of the body. Nociceptors are stimulated, for example, by high or low temperatures, mechanical pressure, chemicals (e.g., capsaicin, acidity, pollutants, etc.), injury, inflammation, and inflammatory mediators.
- a DIPA compound, such as DIPA-1-8, that decreases sensory discomfort, can be termed an anti-nociceptive agent.
- the sensory discomfort is irritation, itch, or pain. In one embodiment, the sensory discomfort is caused by a skin dysesthesia. In one embodiment, the skin dysesthesia is skin irritation, itchy skin, or painful skin. In one embodiment, the sensory discomfort is caused by atopic dermatitis. In one embodiment, the sensory discomfort is caused by canine atopic dermatitis. In one embodiment, the treatment is treatment of a skin dysesthesia. In one embodiment, the treatment is treatment of dermatitis. In one embodiment, the treatment is treatment of atopic dermatitis. In one embodiment, the treatment is treatment of canine atopic dermatitis. In one embodiment, the treatment is treatment of contact dermatitis. In one embodiment, the treatment is treatment of urticaria.
- the treatment is treatment of the pruritus of the elderly. In one embodiment, the treatment is treatment of the pruritus of milaria rubra. In one embodiment, the treatment is treatment of the pruritus of liver disease (cholestasis). In one embodiment, the treatment is treatment of the pruritus of patients on kidney dialysis. In one embodiment, the treatment is treatment of the pruritus of patients with lymphoma. In one embodiment, the treatment is treatment of the dysesthesia of psoriasis. In one embodiment, the treatment is treatment of the dysesthesia of neurogenic/neuropathic itch. In one embodiment, the treatment is treatment of the dysesthesia of lichen planus atrophicus. In one embodiment, the treatment is treatment of ocular discomfort.
- the ocular discomfort is caused by eye strain; eye fatigue; eye surgery; an airborne irritant or pollutant that interacts with the eye surface; extended wear of contact lenses; excessive exposure to the sun; conjunctivitis; or the dry eyes syndrome.
- the treatment is treatment of heat discomfort.
- the treatment is treatment of heat discomfort for the purpose of improving athletic performance.
- the treatment is treatment of heat stress.
- the treatment is treatment of flushing and/or night sweats (vasomotor symptoms) in a post-menopausal woman.
- the treatment is treatment of post-operative hypothermia or post-anaesthetic shivering.
- the treatment is treatment is to convey a sense of refreshment to the skin in a human.
- treatment pertains generally to treatment of a human or an animal (e.g., in veterinary applications), in which some desired therapeutic effect is achieved, for example, the inhibition of the progress of the disorder, and includes a reduction in the rate of progress, a halt in the rate of progress, alleviation of symptoms of the disorder, amelioration of the disorder, and cure of the disorder.
- Treatment as a prophylactic measure i.e., prophylaxis
- use with patients who have not yet developed the disorder, but who are at risk of developing the disorder is encompassed by the term “treatment.”
- Treatment to enhance the basal levels of cognitive or physical performance of individuals who are considered normal or healthy is also included.
- terapéuticaally-effective amount pertains to that amount of a compound, or a material, composition or dosage form comprising a compound, which is effective for producing some desired therapeutic effect, commensurate with a reasonable benefit/risk ratio, when administered in accordance with a desired treatment regimen.
- treatment includes combination treatments and therapies, in which two or more treatments or therapies are combined, for example, sequentially or simultaneously.
- the compounds described herein may also be used in combination therapies, e.g., in conjunction with other agents.
- One aspect of the present discovery pertains to a DIPA compound as described herein, in combination with one or more (e.g., 1, 2, 3, 4, etc.) additional therapeutic agents. The particular combination would be at the discretion of the physician or the pharmacist who would select dosages using his common general knowledge and dosing regimens known to a skilled practitioner.
- additional therapeutic agents include: an anti-inflammatory glucocorticosteroid; an analgesic; a sympathomimetic amine decongestant; an anti-histamine; a local anesthetic; an ophthalmic lubricant; a sunscreen ingredient; an anti-acne agent; a keratolytic agent; an anti-hemorrhoidal agent; an agent for vulvar itch or discomfort; an antibiotic; a skin moisturizer; or an anti-skin ageing agent.
- the DIPA compound or pharmaceutical composition comprising the DIPA compound may suitably be administered to a subject topically, for example, as described herein.
- topical application refers to delivery onto surfaces of the body in contact with air, which includes the skin, the anogenital surfaces, the transitional epithelial surfaces of the orbit, the lips, the nose, and the anus, and the aerodigestive tract (nasal membranes, oral cavity, pharyngeal and esophageal surfaces), lower respiratory tracts, and the lumen of the gastrointestinal tract.
- Particularly preferred sites of application are the surfaces innervated by the trigeminal and glossopharyngeal nerves which include the scalp, facial skin, periorbital skin, lips, nasal and oral cavities, and the throat.
- Additional preferred sites are the surfaces of the neck, elbows and knees, which are frequently associated with the pruritus of atopic eczema and psoriasis.
- Yet another preferred site is the scalp, which can be a site of inflammation in psoriasis and seborrheic dermatitis.
- the treatment is treatment by topical administration.
- the treatment is treatment by topical administration to skin.
- the treatment is treatment by topical administration to facial skin.
- the treatment is treatment by topical administration to periorbital skin, eyelid skin, zygomatic skin, malar skin, forehead skin, or scalp.
- the treatment is treatment by topical administration to skin surface of the orbit, frontal bone, or zygomatic.
- the treatment is treatment by topical administration to skin surface of the anus and/or the male or female genitalia.
- the treatment is treatment by topical administration to skin above the supraclavicular fossa or the steronomastoid muscle.
- the subject/patient may be a mammal, for example, a marsupial (e.g., kangaroo, wombat), a rodent (e.g., a guinea pig, a hamster, a rat, a mouse), murine (e.g., a mouse), a lagomorph (e.g., a rabbit), avian (e.g., a bird), canine (e.g., a dog), feline (e.g., a cat), equine (e.g., a horse), porcine (e.g., a pig), ovine (e.g., a sheep), bovine (e.g., a cow), a primate, simian (e.g., a monkey or ape), a monkey (e.g., marmoset, baboon), an ape (e.g., gorilla, chimpanzee, orangutang, gib
- a DIPA compound While it is possible for a DIPA compound to be administered alone, for example, dissolved in saline or water, it may also be prepared as a pharmaceutical formulation (e.g., composition, preparation, medicament) comprising at least one DIPA compound, as described herein, together with one or more other pharmaceutically acceptable ingredients well known to those skilled in the art, including, but not limited to, pharmaceutically acceptable carriers, diluents, excipients, adjuvants, fillers, buffers, preservatives, anti-oxidants, lubricants, stabilisers, solubilisers, surfactants (e.g., wetting agents), masking agents, colouring agents, flavoring agents, and sweetening agents.
- the formulation may further comprise other active agents.
- the present discovery further provides pharmaceutical compositions, as described above, and methods of making pharmaceutical compositions, as described above. If formulated as discrete units (e.g., swab, wipe, pads, towellettes, gels, lotion, cream, etc.), each unit contains a predetermined amount (dosage) of the compound.
- pharmaceutically acceptable pertains to compounds, ingredients, materials, compositions, dosage forms, etc., which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of the subject in question (e.g., human) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- Each carrier, diluent, excipient, etc. must also be “acceptable” in the sense of being compatible with the other ingredients of the formulation.
- Suitable carriers, diluents, excipients, etc. can be found in standard pharmaceutical texts, for example, Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing Company, Easton, Pa., 1990; and Handbook of Pharmaceutical Excipients, 5th edition, 2005.
- the formulations may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the compound with a carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the compound with carriers (e.g., liquid carriers, finely divided solid carrier, etc.), and then shaping the product, if necessary.
- carriers e.g., liquid carriers, finely divided solid carrier, etc.
- Formulations may suitably be in the form of liquids, solutions (e.g., aqueous, non-aqueous), suspensions (e.g., aqueous, non-aqueous), emulsions (e.g., oil-in-water, water-in-oil); elixirs, syrups, electuaries, mouthwashes, drops, tablets (including, e.g., coated tablets), granules, powders, lozenges, pastilles, capsules (including, e.g., hard and soft gelatin capsules), cachets, pills, ampoules, boluses, suppositories, pessaries, tinctures, gels, pastes, ointments, creams, lotions, oils, foams, sprays, mists, or aerosols.
- solutions e.g., aqueous, non-aqueous
- suspensions e.g., aqueous, non-aqueous
- the DIPA compound may be used as an adjunct in a pharmaceutical formulation or cosmetic formulation.
- appropriate dosages of the DIPA compounds, and compositions comprising the DIPA compounds can vary from patient to patient. Determining the optimal dosage will generally involve the balancing of the level of therapeutic benefit against any risk or deleterious side effects.
- the selected dosage level will depend on a variety of factors including, but not limited to, the activity of the particular DIPA compound, the route of administration, the time of administration, the duration of the treatment, other drugs, compounds, and/or materials used in combination, the severity of the disorder, and the species, sex, age, weight, condition, general health, and prior medical history of the patient.
- the amount of DIPA compound and route of administration will ultimately be at the discretion of the physician, pharmacist, veterinarian, or clinician, although generally the dosage will be selected to achieve local concentrations at the site of action which achieve the desired effect without causing substantial harmful or deleterious side-effects.
- Administration can be effected in one dose, continuously or intermittently (e.g., in divided doses at appropriate intervals) throughout the course of treatment. Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the formulation used for therapy, the purpose of the therapy, the target cell(s) being treated, and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician, veterinarian, or clinician.
- Epithelial cells line ducts, cavities and surfaces of organs throughout the body. When there are two or more layers of epithelia, it is called stratified epithelium. Historically, stratified epithelia were divided into two broad categories: keratinized stratified epithelia, and non-keratinized stratified epithelia. Keratinized epithelium, such as the epidermis of the skin, has an exterior layer of dead cells [stratum corneum] composed of keratin proteins that are tough and water-impermeable. By contrast, non-keratinizing stratified epithelia are located on “soft tissues” of the body such as the lining of the nasal and throat cavities and the oesophageal surface. Keratinizing tissues withstand injury better than non-keratinizing tissues. Non-keratinizing epithelial surfaces must be kept moist by glandular (serous and mucous) secretions in order to avoid desiccation.
- the stratum corneum (keratinized layer of dead cells) is a daunting barrier to drug penetration to neuronal receptive fields embedded in epithelial tissues underneath the keratin.
- the barrier thickness and the layers of dead cells vary.
- the heel and palm have the most dead cell layers ( ⁇ 82 layers).
- the genitalia (e.g. penile shaft) and eyelids have fewer layers (4 to 8 layers).
- the skin of the face has about 10 to 14 layers, and the torso has about 12 to 16.
- the limbs have somewhat more layers ( ⁇ 15+). Dermatitis occurs frequently occur on the extremeties (e.g. elbow and knee flexures in atopic dermatitis) and on the trunk and scalp for psoriasis. Hand eczema frequently occurs on the hand (contact dermatitis). Urticaria can occur all over the body, the wheals appearing on the torso, neck and buttocks.
- the stratum corneum is not a solid brick and mortar wall, but has water pores, like limestone, through which water soluble molecules may pass between cells and through cells.
- the intracellular water transport channels on keratinocytes are called aquaporins (Patel R et al. Aquaporins in the Skin. Adv Exp Med Biol. 2017; 969:173-191).
- the active ingredient must reach the nerve endings, which are located in the basal layer of the skin (stratum basale).
- a surprising finding here was the ability of DIPA compounds to inhibit dysesthesia when applied as a water solution on a wipe. The likely explanation is that the DIPA is passing between cells through water channels, and not across cells.
- the current topical antinociceptive (pain-suppressant) compounds that have efficacy on sensory discomfort of keratinized skin are high concentrations of I-menthol (36% alcoholic solution) or a local anesthetic gel. But these two types of topical medications have problems of greasy feel and irritation, and of hypersensitivity reactions.
- the targets for topical delivery of the DIPA compounds are located on the nerve endings of the receptive fields of peripheral and cranial sensory nerves.
- the receptive fields of the ophthalmic and maxillary branches of the trigeminal nerve are the preferred target sites.
- FIG. 1 is an illustration of the human face showing the innervation of the cheekbone skin by the zygomatic facial nerve (ZFN) and the infraorbital nerve (ION). The receptive fields of these nerve endings were used for testing compounds applied to the cheekbone skin. Diagram adapted from Hwang et al. [Cutaneous intervention of the lower eyelid. J. Craniofacial Surgery 19: 1675-1677, 2008].
- the primary site of testing was the zygomatic (cheekbone) skin.
- the cooling agent may also be applied to the skin above the supraclavicular fossa or the chest. To reduce sensory discomfort on the skin, the cooling agent may be directly applied to the sites of injury and/or inflammation.
- cooling agent can be sprayed or applied (e.g., with a swab or pad or within a gel, lotion, cream or ointment) over the skin of the orbit, the cheekbone (zygomatic), or on the skin beneath the eye, between the cheekbone and nose.
- the important receptive fields are from the sub-divisions of the trigeminal nerve, namely, the zygomaticfacial nerve of the maxillary nerve (V2) and the supraorbital and supratrochlear branches of the frontal nerve (V1).
- DIPA compounds leave a reservoir in the skin after application, so that after the initial sensations have dissipated, the dynamic cooling sensation returns when the skin is moist again.
- This feature is especially beneficial for use of DIPA-1-7 and DIPA-1-8 in conditions of elevated environmental temperature.
- sweating is activated by heat, the sweat re-solubilizes DIPA-1-7 and DIPA-1-8 and enhances and perpetuates the sensory effect.
- This self-regulating feedback mechanism makes the effect of DIPA-1-7 and DIPA-1-8 more robust, efficacious, and prolonged.
- the delivery of the DIPA compounds can be achieved with the compound dissolved in a liquid vehicle, e.g., in water or saline, or a solution, a hydrogel, a lotion, on a swab, wet wipe, or as an aerosolized mist in a solid or semi-solid vehicle, e.g., a cream or an ointment.
- a liquid vehicle e.g., in water or saline, or a solution, a hydrogel, a lotion, on a swab, wet wipe, or as an aerosolized mist in a solid or semi-solid vehicle, e.g., a cream or an ointment.
- Gels are semisolid, jelly-like formulations with varying degrees of viscosity.
- a gel forms a solid three-dimensional network that spans the volume of a liquid medium. Gels are made with gelling agents that cross-link or associate with a liquid phase.
- gelling agents are: cellulose derivatives [methylcellulose, carboxymethylcellulose, hydroxylpropylcellulose; carbomers [carbopol®910, carbopol®941]; poloxamers [Pluronic®, Tween]; carbomer polymers, and natural polymers such as tragacanth, acacia, gelatin, sodium alginate, alginic acid, and xanthan gum.
- a single-phase system is a gelling agent plus an active ingredient that dissolves [in water] without visible particles and looks clear.
- a topical gel optimally liquefies when in contact with skin or mucous membranes.
- the compounds of Formula 1 are attractive for delivery as gels because they dissolve in water and form a one-phase system at therapeutic concentrations.
- the methods for formulating topical gels are well-known to the art and extensively described in such sites in Lubrizol.com [a company that manufactures ingredients for cosmetics, personal care, skin care, and eye care].
- a preferred concentration of the DIPA compound is 0.01 to 2.0% wt/vol. Unless otherwise stated, wt/vol is measured in units of g/cm 3 or g/mL and so 0.01% wt/vol is obtained from 0.1 mg (0.0001 g) DIPA compound in 1 cm 3 of composition; and 2% wt/vol is obtained from 20 mg (0.02 g) DIPA compound in 1 cm 3 of composition.
- a preferred delivered volume is 0.02 to 0.15 mL.
- Such a volume, delivered for example as a lotion or a wipe, does not cause much residual liquid at the delivery site, as the liquid is absorbed.
- a preferred concentration of the DIPA compound is in the range of 0.5 to 30 mg/mL.
- a preferred concentration is 1 to 5 mg/mL.
- a preferred concentration is 5 to 10 mg/mL.
- a preferred concentration is 10 to 30 mg/mL.
- a preferred amount of the DIPA compound delivered at the site of application is 0.01 to 5 mg; for example, 0.1 to 5 mg.
- Wiping of the DIPA compound on the target skin can be done with pre-medicated wipes, which are well-known in personal care products, for example, to wipe a baby's skin after a diaper change, or to remove make-up on the face (e.g., Pond's 6′′ ⁇ 8′′ (15 cm ⁇ 20 cm) Clean Sweep Cleansing and Make-up Remover Towelettes).
- these wipes are packaged as a single-use sealed unit or in a multi-unit dispenser.
- suitable wrapper materials are those which are relatively vapor impermeable, to prevent drying out of the wipe, and able to form a “peelable” seal.
- wipe materials for practicing this discovery include polyamide (20% Nylon)-polyester, rayon (70%)-polyester (30%) formed fabric, polypropylene nonwoven, polyethylene terephthalate (PET), polyester polypropylene blends, cotton, viscose, rayon, or microfibers (synthetic fibers that measure less than one denier or one decitex).
- PET polyethylene terephthalate
- polyester polypropylene blends cotton, viscose, rayon, or microfibers (synthetic fibers that measure less than one denier or one decitex).
- a solution containing a DIPA compound may be supplied in a reservoir bottle with individual applicators, or as a pre-packaged individual unit.
- Puritan 803-PCL applicators are ideal cotton-tipped applicators attached to a 3-inch ( ⁇ 7.5 cm) polystyrene rod for delivery of a DIPA compound onto the periorbital skin. Examples of how such applicators can be individually packaged are the SwabDoseTM from Unicep Corporation (1702 Industrial Drive, Sandpoint, Id., USA), and the Pro-Swabs from American Empire Manufacturing (3828 Hawthorne Court, Waukegan, Ill., USA). Each applicator tip is saturated by dipping the absorbent material of the tip (e.g., 40 to 100 mg of cotton) in 0.1 to 1.5 mL of an aqueous solution of a DIPA compound and packaged in an individual container.
- the absorbent material of the tip e.g., 40 to 100 mg of cotton
- the individual For application to the face, the individual is instructed to gently apply the cream, lotion, gel, or wet wipe onto, or to spray, to the target facial skin with the eyelids shut, or other skin surface(s).
- the instructions for application may include teaching the individual to repeat application, or “topping up”, to ensure that sufficient composition is delivered to the target.
- the individual can adjust the dosage (e.g., by dabbing at the medial or lateral edges of the orbit), as needed, to achieve the desired effect. It has been observed that individuals learn how to effectively apply the cooling agent after one or two trials and do so without risks of discomfort (e.g., eye discomfort).
- the DIPA compound may be wiped or sprayed, for example, to deliver volumes of approximately 0.15 mL per unit.
- a dropper may be used with a wipe with an ultrasoft material such as 100% viscose or cotton.
- peripheral sensory neurons express receptors and ion channels on their membranes and detect various stimuli. Stimuli (chemical or physical) are converted by the receptor to electrical signals which are transmitted to the central nervous system (brain) and become a sensation. These sensory receptors are transducers and the process is called transduction.
- DIPA compounds applied topically relieve heat stress and skin discomfort by evoking a sense of “dynamic cool” at sites of application.
- the feeling is of robust freshness, as if suddenly a fresh, cool breeze was blown on the skin (e.g., on the face) or cold water was splashed onto the skin. This effect especially with DIPA-1-7 is intense.
- This transduction process, receptor mechanisms, and the significance of dynamic cooling for anti-fatigue, anti-heat stress, and anti-pruritic actions are further discussed herein.
- Small myelinated (A ⁇ ) and unmyelinated fibers (C fibers) increase afferent firing rate when skin temperature is lowered, for example, between 35° C. and 15° C. These neuronal signals that detect heat abstraction are transmitted to the central nervous system and generate conscious perception of coolness and cold. When skin temperature is raised from 35° C. and 40° C., firing rates are increased in C fibers and these fibers signal warmth [Hutchinson et al. Quantitative analysis of orofacial thermoreceptive neurons in the superficial medullary dorsal horn of the rat. J. Neurophysiol.77, 3252-66, 1997].
- the receptive mechanisms and “cable lines” for cool/cold and warm are separate and distinct, but reciprocally inhibit each other in the brain and perhaps also in the periphery.
- the sensory receptors are modality specific and do not respond to mechanical stimulation.
- the target binding sites for cooling agents are thought to be located on TRP ion channel receptors that depolarize in response to a drop in temperature. Heat abstraction decreases the threshold for discharge of the receptor, and the facilitated depolarization initiates the axonal responses that create the neuronal signal.
- Dynamic cooling (versus static cooling/cold) is essential for a robust sensory effect. For example, if one is tired and driving a vehicle, turning on the air-conditioning and blasting the air onto the face will counteract fatigue [dynamic cooling]. But just turning on the air conditioner to lower ambient temperature and being chilled inside the vehicle [static cooling] will not make much of a difference.
- the benefits of the topical sensory therapy are illustrated by the Case Studies described herein.
- TRP-ion channel receptors (A1, M8, and V1 to 4) are the principal physiological elements for physiological temperature detection.
- the TRPM8 receptor is the one that responds to sensory/cooling agents such as menthol and icilin [McKemy et al. Identification of a cold receptor reveals a general role for TRP channels in thermosensation, Nature, 416, 52-58, 2002].
- TRPM8 is a protein with 1104-amino acid residues and has six transmembrane domains. Activation of this receptor by lowering ambient temperature results in opening of pores of transmembrane loop and non-specific cation entry into the cell. Depolarization of TRPM8 receptors on sensory neurons may then transmit signals primarily via A ⁇ (and some C) fibres to the brain.
- TRPM8 While this concept for the role of TRPM8 in sensory physiology may be valid for physical changes in temperature, the interpretation of the sensory effects of chemical agents such as menthol and icilin are more complex. Menthol not only stimulates TRPM8 in vitro, but also TRPV3, a receptor associated with warmth and glycinergic transmission [Macpherson et al. More than cool: promiscuous relationships of menthol and other sensory compounds. Mol Cell Neurosci 32:335-343, 2006: Sherkheli et al., Supercooling agent icilin blocks a warmth-sensing ion channel TRPV3, Scientific World Journal, 2012; Cho et al.
- TRPA1-like channels enhance glycinergic transmission in medullary dorsal horn neurons. J Neurochem 122:691-701, 2012].
- menthol and icilin are “promiscuous” cooling agents and their specific sensory effects may not be associated with any one particular receptor protein.
- a laboratory reagent specific and selective for TRPM8 will be valuable for experiment and is not currently available.
- the Applicant has screened a large database of cooling agents but, surprisingly, only the DIPA compounds produced super-robust dynamic cooling on skin. DIPA-1-8 and DIPA-1-9 also produces strong cooling and its actions are prolonged, but it does not quite have the super “wow” cooling effects of DIPA-1-6 and DIPA-1-7. Other cooling agents are less stimulating or have shorter durations of action and thus less suitable for the uses contemplated herein. Thus, the DIPA compounds, by contrast to menthol and icilin, are ideal selective reagents on TRPM8 function.
- DIPA-1-7, DIPA-1-8, and DIPA-1-9 bind to a site on a voltage-gated ion channel receptor located on a nerve ending that is sensitive to a decrement in physical temperature. This event facilitates neuronal depolarization to a cooling/cold signal, and an action potential is transmitted via A ⁇ and C fibers towards the central nervous system. If the nerve ending is located on the facial skin, the signal is recordable from dorsal surface of the trigeminal nucleus in the brainstem. Further rostral transmission and integration of signals give rise to the perception of coolness/cold and its topographical association with the site of stimulation.
- “Wet-dog shaking” has been studied in detail in animals. Rats can shake their head, the upper torso, or the shaking can be sufficiently violent to affect the whole body and make the animal lose its balance. DIPA-1-7 and DIPA-1-8 elicit the vigorous type of shaking.
- the purpose or survival value of shaking to fur-coated and feathered organisms is to remove water droplets trapped on or near the skin. Removal of the water droplets on or near the skin by shaking reduces the organism's need to expend energy to remove the water by evaporation.
- the likely equivalent behaviour to shaking in humans is shivering, a condition caused by generalized sensations of coolness/cold. Human subjects recovering from the deep hypothermia of anaesthesia manifest vigorous shaking; a condition called post-anaesthetic shivering. Human subjects can also do a “wet shake” by deliberate effort when coming out of a swimming pool.
- isopropyl with a “looser” affinity can associate and disassociate with the receptor more rapidly, favouring the generation of a dynamic onset and offset response of the receptor.
- This rapid interaction with the binding site will favour a more “dynamic” and intense stimulation of cooling and give rise to the phenomenon known as shaking.
- DIPA-1-7 has a dual action on TRP receptors, so that it stimulates TRPM8 and, at higher concentrations, stimulates TRPV1.
- the dual action will give a cold-hot synergy that might lead to a more dynamic cooling sensation.
- the receptor assays in vitro provide information of relative activity, but do not yield too much information.
- an active pharmaceutical ingredient (API) formulated for delivery to the keratinized skin should be stable, non-toxic, and sufficiently long-acting and potent to activate the mechanisms that result in an anti-fatigue, anti-heat, or anti-nociceptive effect.
- the API should be dissolved and evenly dispersed in a composition so that during manufacture the formulation maintains a constant concentration.
- the final product should meet standards of cleanliness and sterility.
- the API can be a liquid at standard conditions of temperature and pressure (STP) and that is evenly dissolved in aqueous solutions at neutral pH and/or isotonicity. Sterility of the final product can be optimally achieved by using purified reagents and filtration through micropore filters, heating, or irradiation.
- Standard excipients such as emulsifying agents, isotonic saline, solvents, stabilizing agents, and preservatives, may be added to optimize the formulations, but the important ingredients should be preferably soluble in aqueous media such as purified water or a standard dermatological solvent.
- the perceived sensation is a function of the particular cooling agent, the dose, the vehicle used to carry the cooling agent, the method of topical delivery, and the nature of the target surfaces.
- the Applicant has screened a number of candidate compounds, such as p-menthane carboxamides, on the facial skin (Wei. Sensory/cooling agents for skin discomfort. Journal Skin Barrier Research 14: 5-12, 2012).
- the studies here identify DIPA compounds as having the preferred desired properties of an ideal anti-fatigue, anti-heat, and anti-nociceptive agent.
- the DIPA compounds when applied to keratinized skin, have sensory/cooling effects that mimic heat abstraction, but without a change in tissue temperatures. These compounds, can also penetrate the skin barrier, reach nerve endings in the epidermis and dermis, and enter the systemic circulation to exert cooling actions. These effects are obtained at small volumes, e.g., 0.1 to 0.5 mL, applied at a concentration of 1 to 20 mg/mL, or 0.1 to 2% wt/vol. The onset of effect is rapid, less than 5 minutes, and the sense of coolness is robust, refreshing, and strong. Compounds with similar bioactivity on the keratinized skin are not currently known or used in cosmetic or therapeutic applications. A number of new applications are possible with a molecule having such unusual properties.
- DIPA-1-7 can be used, for example, to increase athletic performance, to counteract the discomfort of vasomotor symptoms, and to counteract the discomfort of inflammation.
- DIPA-1-7 applied to the facial skin may be used to enhance cognition and to alert and increase vigilance.
- DIPA-1-7 may also be used as a diagnostic agent for cold allodynia and hyperalgesia, as a laboratory reagent to characterize TRPM8 functions, and as an adjunct in the formulations of numerous topical pharmaceuticals.
- DIPA compounds can be used for dermatological disorders.
- the improvement in athletic performance can be attained by increasing the perception of coolness, without modifying core temperature.
- Investigators showed that trained marathon runners wearing a commercial cooling collar (Black Ice LLC, Lakeland Tenn.) extended the time to reach volitional exhaustion by 13.5% [Tyler et al. Cooling the neck region during exercise in heat. J. Athletic Training, 46, 61-68, 2011]. Cooling of the neck dampened the perceived level of thermal strain and delayed the point of voluntary termination of exercise. Participants tolerated a higher body temperature and heart rate when their neck regions were cooled.
- Vasomotor Symptoms (“Hot Flushes/Night Sweats” in Post-Menopausal Women)
- MacDonald et al. has proposed a mechanism by which the itch-scratch cycle exacerbates tissue injury (Acta Dermato-Venereologica 97 (8): 1010, 2017). He stated that double-stranded RNA released from injured keratinocytes stimulates TOLL-3 receptors to generate more cytokines and chemokines, and thus inflammation is enhanced and perpetuated.
- An anti-itch molecule may therefore not only provide symptomatic relief but also have a more subtle disease-modifying therapeutic effect in disorders such as atopic dermatitis wherein itch is localized and the itch-scratch cycle is a vicious contributor to the pathology of excoriations and lichenification.
- the irritated skin thickens and becomes chronically inflamed and fragile because of scratching, and is likely to breakdown with more scratching and rubbing.
- the ability to add a break to scratching is not restricted only to atopic dermatitis but also applicable to other dermatological disorders such as seborrheic dermatitis, acne or acneiform eruptions.
- the acne lesion is an inflammatory disorder of the sebaceous glands in the skin, and the subject picks and squeezes the lesions constantly.
- the mechanical damage to the inflamed skin aggravates the underlying tissue reactions. If a break can be applied to the tissue manipulation, then the lesion is given time to heal more quickly.
- the term “adjunct” is an additional substance, treatment, or procedure used for increasing the efficacy or safety of the primary substance, treatment, or procedure or for facilitating its performance.
- the DIPA compounds relieve sensory discomfort of the skin, have anti-nociceptive activity, and are active at less than 1 minute after application. They are ideal adjuncts for pharmaceuticals and for cosmetics applied to the skin.
- DIPA-1-7 may help reduce the dose or the frequency of application of the primary ingredient, yet achieve an equivalent therapeutic effect.
- This adjunct benefit will be especially beneficial in the use of skin steroids because of the well-known undesirable effects of collagen degradation, tissue thinning, and increased susceptibility to infections.
- An adjunct that reduces dosage or promote greater efficacy of the primary ingredient has value.
- Other primary anti-pruritics are aluminum acetate, and strontium chloride or strontium nitrate.
- compositions of the present discovery may also be used as adjuncts for procedures such as phototherapy, laser therapy, cryotherapy, or UV-therapy of the skin.
- compositions that may be used, in combination or in sequence with adjunct DIPA compounds include anti-inflammatory steroidal agents, anti-inflammatory analgesic agents, antihistamines, sympathomimetic amine vasoconstrictors, local anesthetics, antibiotics, anti-acne agents, topical retinoids, drug for genital warts and skin cancer, drugs for wrinkles and ageing skin, anti-hemorrhoidal agents, drugs for vulvar itch, drugs to stimulate hypertrichosis, skin moisturizers, and agents for keratolysis.
- steroidal anti-inflammatory agents examples include hydrocortisone, clobetasol, clobetasol propionate, halobetasol, prednisolone, dexamethasone, triamcinolone acetonide, fluocinolone acetonide, fluocinonide, hydrocortisone acetate, prednisolone acetate, methylprednisolone, dexamethasone acetate, betamethasone, betamethasone valerate, flumetasone, fluticasone, fluorometholone, beclomethasone dipropionate, etc.
- anti-inflammatory analgesic agents include methyl salicylate, monoglycol salicylate, aspirin, indomethacin, diclofenac, ibuprofen, ketoprofen, naproxen, pranoprofen, fenoprofen, sulindac, fenclofenac, clidanac, flurbiprofen, fentiazac, bufexamac, piroxicam, pentazocine, etc.
- antihistamines examples include azelastine hydrochloride, diphenhydramine hydrochloride, diphenhydramine salicylate, diphenhydramine, chlorpheniramine maleate, promethazine hydrochloride, etc.
- sympathomimetic amine vasoconstrictors examples include phenylephrine hydrochloride, oxymetazoline, naphazoline, and other imidazoline receptor agonists used for nasal decongestant activity and for redness and vasodilatation on the ocular surfaces.
- Example of an agent for hypertrichosis is bimatoprost.
- the compounds of the present discovery simulate the sensations of heat abstraction, but do not alter tissue temperatures.
- the results are summarized in Table 5.
- the subjects noted the cooling effect of DIPA-1-7 on the skin which lasted for 30-45 minutes; however, skin temperatures were not affected.
- the sensation of coolness/cold is rated as 0, 1, 2, or 3 with: 0 as no change; 1 as slight coolness, or cold; 2 as clear-cut signal of coolness or cold; and 3 as strong cooling or cold.
- the sensations are recorded at intervals of 5 to 15 minutes, until at least two successive zeroes are obtained.
- the onset of drug action is taken as the time to reach 2 units of coolness intensity.
- the duration of sensory action is defined as the offset time minus the onset time.
- the offset of drug action is defined here as the time when coolness intensity drops below 2, after previously surpassing 2 units.
- An inactive compound is defined as one that does not exceed 2 units of cooling for 5 minutes or more after application.
- the offset endpoint is sometimes unstable for compounds that act for two or more hours, because the coolness/cold sensation may fluctuate due to environmental variables such as sunlight, ventilation, activity, and the “reservoir effect.” For example, DIPA-1-8 and 2-8 are exceptionally long-acting on the skin.
- test compounds were tested on zygomatic. Test compounds were applied to the skin of the zygomatic using cotton gauze (0.4 g, rectangular, 50 mm ⁇ 60 mm; from CS-being, Daisan Cotton, Japan). The test compounds were used at a concentration of 20 mg/mL in distilled water. The onset and duration of the sensory effect was measured with a stopwatch. The degree of “dynamic cool” was graded from 0 to +++, with intermediate steps of + and ++. An anti-fatigue effect was present only if there was sufficient “dynamic cool.” The results are summarized in Table 7 & 8.
- Each of 3-1 and 3-2 was also tested and found to be inactive on periorbital, and zygomatic/forehead skin.
- the newly synthesized “mixed” 1-isopropyl-sec-butyl-phosphorylalkanes (3,4-6, 3,4-7, 3,4-8 and 3,4-9) were tested on zygomatic skin ( FIG. 1 ).
- the test procedures were modified because of the limited quantities of these analogs.
- a 80%-polyester-20%-viscose rayon wipe was cut into squares (7 ⁇ 8 cm, 0.45 g each) and a precise volume (2.5 mL) of test solution is added to the wipe using a dropper bottle. Delivery and scoring of effect.
- FIG. 2 shows the cooling sensations evoked by topical wiping of different concentrations of DIPA-1-8 onto the skin above the zygomatic process.
- the cooling activity can be measured as the intensity/duration area-under-curve (AUC) or as time for half maximal effect (T -1/2 ), using software of the GraphPad Prism package.
- the graph shows the AUC dose-response curve for the compound DIPA-1-8 applied at 0.5, 1 and 2% (5, 10, and 20 mg/mL dissolved in distilled water).
- FIG. 3 A comparison of the DIPA diisopropyl analogs (3,3-X) versus the mixed propyl-sec-butyl analogs (3,4-X) are shown in FIG. 3 .
- Statistical significant difference P ⁇ 0.01 are seen between 3,3-x and the asymmetrical chiral 3,4-x analogs.
- the 3,4-8 and 3,4-9 formed a milky/small oil droplet emulsion at 20 mg/mL.
- DIPA-1-7 selectively produced the unusual sensation of “dynamic cool” and also had anti-fatigue effects. From the data shown above, it can be seen that, among these compounds, DIPA-1-7 evoked “dynamic cool” on both periorbital and zygomatic/forehead surface. Another compound with similar properties was DIPA-1-8, but this compound is was more cold/icy cold, although it had the desirable property of a longer duration of action on the zygomatic/forehead surface. The long duration of action of DIPA-1-7 and DIPA-1-8 on the skin adds value as an anti-fatigue agent, especially for the fatigue of chronic illness. As shown in the case studies described below, a single application of DIPA-1-7 is sufficient to counteract fatigue and heat stress for at least three to four hours.
- DIPA-1-9 A special value of DIPA-1-9 is the comfortable cooling it provides and its long duration of action after zygomatic and periorbital application, and the absence of any stinging. Thus, it has a special therapeutic niche for the relief of skin discomfort.
- DIPA-1-7 and DIPA-1-8 are unexpected, surprising, and has practical applications for counter-acting fatigue and anti-nociception.
- a special value of DIPA-1-9 is the comfortable cooling it provides and its long duration of action after periorbital application, and the absence of any stinging. Thus, it has a special therapeutic niche for the relief of ocular discomfort.
- Test compounds and positive control solutions were prepared by diluting stock solutions in a HEPES-buffered physiological saline (HBPS) solution.
- the test compound and control formulations were loaded in polypropylene or glass-lined 384-well plates, and placed into the FLIPR instrument (Molecular Devices Corporation, Union City, Calif., USA).
- the positive control reference compound was L-menthol, a known TRPM8 agonist.
- the test cells were Chinese Hamster Ovary (CHO) cells stably transfected with human TRPM8 cDNAs.
- FLIPR TETRA TM assay cells were plated in 384-well black wall, flat clear-bottom microtiter plates (Type: BD Biocoat Poly-D-Lysine Multiwell Cell Culture Plate) at approximately 30,000 cells per well. Cells were incubated at 37° C. overnight to reach a near confluent monolayer appropriate for use in a fluorescence assay. The test procedure was to remove the growth media and to add 40 ⁇ L of HBPS containing Fluo-8 for 30 minutes at 37° C. 10 ⁇ L of test compound, vehicle, or control solutions in HBPS were added to each well and read for 4 minutes.
- FIG. 3 is a graph of response (Relative Fluorescence Units; % of maximum) as a function of the logarithm of the concentration of the test compound (denoted agonist), expressed in ⁇ M, for each of DIPA-1-5 (circles), DIPA-1-6 (squares), DIPA-1-7 (inverted triangle), DIPA-1-8 (diamonds), or DIPA-1-9 (up-right triangle).
- the EC 50 of the more potent compounds fell within a narrow range with overlapping 95% Confidence Intervals.
- the potency of DIPA-1-7, DIPA-1-8, and DIPA-1-9 are similar and significantly greater than the potencies of DIPA-1-5 and DIPA-1-6.
- the structural modifications of comparative compounds 3-1 and 3-2 resulted in a significant loss of bioactivity
- TRPV1 channels human TRPV1 gene expressed in HEK293 cells
- TRPA1 channels human TRPA1 gene expressed in CHO cells
- the test cells were Chinese Hamster Ovary (CHO) cells or Human Embyronic Kidney (HEK) 293 cells transfected with human TRPV1 or TRPA1 cDNAs.
- the positive control reference compound was capsaicin (a known TRPV1 agonist) or mustard oil (a known TRPA1 agonist).
- DIPA-1-7 and DIPA-1-8 did not exhibit any agonist on antagonist activity on TRPA1 channels at maximum tested concentrations of 100 ⁇ M. A weak TRPV1 agonist activity was found for DIPA-1-7, but this was not dose-dependent.
- the potency of three analogs for activation of TRPM8 (cooling receptor) in transfected cells is shown in FIG. 4 .
- the units ( ⁇ ratio) on the ordinate measures entry of fluorescent calcium probes into transfected cells.
- FIG. 4 is a graph of fluorescence response ( ⁇ ratio 340/380) in TRPM8 transfected cells as a function of the logarithm of the concentration of the test compound, expressed in ⁇ M, for DIPA-1-7 (black circle), 3,4-7 (open squares), or 3,4-6 (open triangles).
- the assays were conducted by Andersson et al. of King's College, London, UK, using his methods described in “Modulation of the cold-activated channel TRPM8 by lysophospholipids and polyunsaturated fatty acids. Journal Neuroscience 27 (12): 3347-3355, 2007.
- the 3,3-7 (DIPA-1-7) is substantially more potent ( ⁇ 10 ⁇ and ⁇ 5 ⁇ ) than 3,4-6 and 3,4-7. Note that 3,4-6 and 3,4-7 species do not reach the same degree maximal efficacy on activation of the receptor, even at supra-maximal concentrations.
- segments of vagus nerve caudal to the nodose ganglion, were removed from mice with fine forceps and segments placed in oxygenated Krebs solution and bubbled with 95% O 2 /5% CO 2 .
- the desheathed nerve trunk was mounted in a ‘grease-gap’ recording chamber and constantly superfused with Krebs solution with a flow rate of approximately 2 mL/min, and the electrical activity of the nerve monitored with electrodes.
- the temperature of the perfusate was kept constant at 37° C. by a water bath. Nerve depolarizations were induced by superfusion of the nerve with capsaicin (1 ⁇ M).
- DIPA-1-7 was applied at 1 mg/mL (4 ⁇ M) for 10 minutes in the perfusate followed by capsaicin.
- the nerves were then washed with Krebs until the responses had returned to baseline and challenged again with capsaicin.
- the results and tracings obtained in normal and TRPM8 knockout mouse are shown in FIG. 5 .
- FIG. 5 shows chart traces that illustrate, in the first trace (“Wild Type”), the inhibition of capsaicin-induced depolarization of the isolated mouse vagus by DIPA-1-7, superfused at a concentration of 1 mg/mL, and, in the second trace (“TRPM8 KO”), the significant absence of inhibition in the isolated TRPM8 KO (knockout) mouse vagus by DIPA-1-7, superfused at a concentration of 1 mg/mL.
- the first two peaks show the depolarization response of the mouse vagus to capsaicin (“Caps”). After DIPA-1-7 is applied (1 mg/mL), the response is suppressed in the normal mouse vagus (“Wild Type”), but not in the TRPM8 knock-out (“TRPM8 KO”) mouse vagus.
- the percent inhibition of capsaicin-induced depolarization of the isolated normal mouse vagus caused by DIPA-1-7 was about 75%; the percent inhibition of capsaicin-induced depolarization of the isolated TRPM8 knock-out mouse vagus caused by DIPA-1-7 was about 20%.
- Capsaicin is a TRPV1 agonist and the search for an effective TRPV1 antagonist has been the super-intense quest of many pharmaceutical companies for the past ten or more year.
- DIPA-1-7 is an effective “physiological” antagonist of TRPV1 at low concentrations.
- DIPA-1-7 did not evoke depolarization, indicating that it is free of agonist activity at this “pain” receptor.
- Drug-induced shaking in animals has been reviewed (see, e.g., Wei, 1981). Under the right conditions, drug-induced shaking can be observed in the pentobarbital-anesthetized rat, enhanced by hypothermia and cold, and inhibited by elevating body temperature.
- Test compounds were evaluated for “wet-dog shaking” as a model of dynamic cooling. Using a standardized procedure, test compounds were compared in their ability to stimulate the shaking response by perioral administration and by topical delivery to the abdominal skin
- DIPA-1-5, DIPA-1-6, and DIPA-1-7 produced an average shaking frequency of 86, 56, and 36 shakes, respectively.
- the strong activity of DIPA-1-5 was unusual. Applied to the skin, DIPA-1-5 has a refreshing “dynamic cool”, but the duration of action of only about 30 min was significantly less than that for DIPA-1-6 and DIPA-1-7. The shorter duration of action of DIPA-1-5 limits its practical utility. It is possible that its smaller molecular size facilitates absorption and allows greater access to systemic receptors, and therefore more shaking.
- Topical. Shaking is an excellent indicator of in vivo effect. Methods were developed to determine if shaking was seen after topical application of DIPA compounds. The abdominal skin of the pentobarbital-anesthetized rat was shaved and 20 ⁇ L of the pure unadulterated DIPA chemical was applied with a micropipette on a ⁇ 1 cm diameter circle of skin, enclosed with a ring of cream [Baby cream “Nevskaya kosmetika Detskyi” Nevskaya Kosmetika Inc., Saint-Petrsburg 192029], as shown in the FIG. 6 . The number of shakes was counted for 1 hr after application.
- FIG. 6 shows the method for measuring the transdermal activity of DIPA-compounds applied 20 ⁇ L with a micropipette to the center of a circle enclosed by cream on the abdominal skin of an anesthetized rat. Shaking frequency was counted for 1 hr after topical application. The data and results for topical for perioral responses are summarized in the Table 10. The data are further plotted graphically in FIG. 6 , to show the lack of correlation of TRPM8 potency to in vivo bioactivity.
- DIPA-1-7 may be used to penetrate thick keratotic skin lesions, for example in psoriasis or in contact dermatitis of the hands, to alleviate itch and pain.
- the adjustment of DIPA-1-7 concentrations in polyhydric solvent such as 1,2-propanediol can be used to control the degree of absorption of DIPA-1-7, an art well-known to formulation experts.
- DIPA-1-5 and DIPA-1-6 The surprising potency of DIPA-1-5 and DIPA-1-6 was unexpected. These molecules work for a shorter time on skin cooling than DIPA1-7. These smaller molecules may penetrate faster through the skin barrier and go into the systemic circulation. However, the value of this fast action is uncertain. In most contemplated topical applications of this discovery, the preference is for the drug action to remain localized and not systemic.
- the receptor targets on the nerve endings are embedded in the epithelial cell layers.
- the epidermis is only ⁇ 1 mm thick, but a number of dead cell layers (stratum corneum), of denatured proteins impede access of the agonist molecule to the nerve endings.
- the heel of the feet is the thickest barrier, 86 cell layers for the heel, and followed by the palm of the hand, then the back of the hand. If you put an ice cube on the heel, you feel a bit of cold: but you will jump when you put it on the sole of the feet which has fewer layers. Unless the skin of these surface are structurally damaged, e.g. by inflammation, applying a cooling agent will not work, because the molecules do not access the nerve endings.
- the genital skin (glans of the penis and vulva) and the eyelids are the thinnest, with 4 to 8 cell layers.
- the extremities, arms and legs, and the trunk (back) have thicker surfaces.
- the scalp is intermediate.
- the face varies: the cheek is relatively insensitive, but areas around cheekbone and nasolabial folds are thin and sensitive.
- DIPA-1-7, DIPA-1-8, and DIPA-1-9 have high water solubility and skin penetration.
- Increasing water solubility to increase bioactivity is counterintuitive in standard drug design for enhancement of transdermal drug permeation.
- formulation experts try to break down the stratum corneum with enhancers and chemists try to increase lipid solubility of the molecule (e.g. M. Prausnitz et al. Skin barrier and transdermal drug delivery. Chpt. 124, Medical Therapy, 2012). Nevertheless, the strategy used here was met with clinical success.
- Dipa are at least 2 to 3 ⁇ more water soluble than Dapa.
- the polar phosphine oxide is not masked by the extra branched chain carbons.
- the Dipa are more hydrophilic than Dapa.
- Studies of skin permeation in vitro on hairless mouse skin confirmed the unusual penetrating power of the Dipa structure.
- the pharmacological differences of the Dipa from Dapa congeners were strikingly different. Both Dipa and Dapa were active by intravenous injection, but only Dipa was active by or topical or oral routes of administration, indicating penetration across the dermal and gastrointestinal membranes of the Dipa, but not Dapa structures.
- FIG. 7 shows the flux of DIPA-1-7 and DIPA-1-9 through excised hairless mouse skin in vitro.
- Test chemicals dissolved in a gel were placed in an incubation for 8 hr and the permeated amount of the chemical measured by a high pressure liquid chromatograph equipped with a refractive detector. These tests were conducted by Prof Choi of Chosun University, Korea.
- the flux of 1-7 was ⁇ 5 ⁇ greater than 1-9.
- Standard enhancers with polyhydric alcohols, such as a propylene glycol-oleyl alcohol mixture (50:50) or Lauroglycol 90, designed to increase permeation added to the 1-7 gel decreased the rate of permeation by ⁇ 50%, indicating the importance of water solubility for permeation.
- Standard enhancers with polyhydric alcohols such as a propylene glycol-oleyl alcohol mixture (50:50) or Lauroglycol 90, designed to increase permeation added to the 1-7 gel DECREASED the rate of permeation by ⁇ 50%, indicating the importance of water solubility for permeation.
- a 50:50 propylene glycol-DIPA-1-7 mixture was inactive when tested on the skin of animals, with shaking as an endpoint, whereas the pure DIPA-1-7 was very active.
- normal solvents or enhancers of dermatological molecules impede rather than facilitate passage of the DIPA through the skin barriers.
- the mobility of the DIPA molecules in an aqueous environment through a skin barrier is unusual and surprising. Hence, if the polar “head” is masked by one or more carbon (e.g. methyl) groups, water solubility and permeability decrease.
- the symmetrical (achiral) arms may enable an efficient swimming of the DIPA through the pores of the stratum corneum and into the extracellular fluid, until the TRPM8 receptors in the stratum basale are reached.
- the DIPA configuration may be viewed as a “sperm” like head (the oxygen cloud about the phosphorus atom) that permits a polar interaction with water.
- the “swimming” motion may be impaired if the branched arms are asymmetrical (chiral).
- DIPA-1-7 the most potent compound for dynamic cooling, was tested at other topical sites on the cranium.
- a 20 mg/mL solution was applied, using a cotton wipe, onto the skin above the buccal cheek, the parotid-masseteric cheek, temple, and the skin above the periauricular region, and the posterior mandible using the appropriate craniometric points (pterion, coronion, condylion, and gonion, respectively) as landmarks.
- the appropriate craniometric points pterion, coronion, condylion, and gonion, respectively
- DIPA-1-7 Mild cooling was observed on the buccal cheek for approximately 30 minutes, but this effect may have been due to the spread of the solution onto the receptive field of the infraorbital nerve. It should be noted, however, the sensory effects of topical application of DIPA-1-7 may be influenced by inflammatory lesions that can alter permeability, for example, acne or acneiform lesions on the skin of the cheek.
- the head is known to be a site where cooling helps relieve heat discomfort.
- eleven male subjects were exposed to mild heat.
- a local cooling protocol was initiated with water-perfused stimulators placed on the head, chest, abdomen, or thigh. Cooling of the face and thigh was felt by the subjects to be more effective than cooling of the chest and abdomen in reducing the heat discomfort.
- DIPA-1-7 Use of DIPA-1-7 on the orbital and zygomatic/forehead skin, for example, in an office environment or in heat stress, may be inconvenient if the subjects uses cosmetic make-up at these sites.
- DIPA-1-7 at 20 mg/mL, can produce a dynamic cooling effect when applied on the scalp, especially near the hairline. This effect is sufficient to counter fatigue caused by heat.
- rubbing DIPA-1-7 on the skin in the centre of the chest, above the sternum can counteract the discomforts of heat.
- cosmetics are not affected, yet an invigorating coolness, that counteracts the debilitating effect of heat, is achieved.
- DIPA-1-7 The ability of DIPA-1-7 to cause cooling of the scalp and hairline is also important for treating itch at these sites in conditions such as psoriasis, dandruff, and seborrheic dermatitis.
- DIPA compounds were effective even when the keratinized skin is “intact”, i.e. the stratum corneum is normal, and one would not expect a topical medication to penetrate and to be active.
- DIPA-1-7 was given dosages units containing 1.5 to 1.75 mL of DIPA-1-7 stored in 2.0 mL microcentrifuge tubes (Nova Biostorage Plus, Canonsburg, Pa. 15317) and cotton gauze (0.4 g, rectangular, 50 mm ⁇ 60 mml; from CS-being, Daisan Cotton, Japan).
- the DIPA-1-7 was provided as a solution in distilled water, at a DIPA-1-7 concentration of 5 mg/mL to 20 mg/mL.
- the subjects were given instructions on how to place wet the gauze and how to wipe over the skin. Approximately 0.15 mL to 0.35 mL per unit wipe were delivered by these methods of application. Subjects were instructed to rinse with water if any surface become irritable; however, irritation and discomfort were not seen with DIPA-1-7, DIPA-1-8, or DIPA-1-9 at the test concentrations.
- Atopic dermatitis A 8-year old boy had atopic dermatitis since childhood and exhibited the standard scars on the flexures of his elbow and knees. He had been treated with topical steroids, but the skin had become thin and easily broken. He objected to topical ointments because of the excessive “greasy” feel and stickiness, and because he felt they were not effective in stopping the itch. He also used moisturizers. The itch interfered with his sleep, especially during periods when his allergic rhinitis flared up. His parents were concerned with the scratching at night, poor scholastic performance, and lack of concentration.
- the subject was given 8 ⁇ 8 cm wipes saturated with 2 mL of DIPA-1-7 at 10 mg/mL in water, and given instructions to use the wipes after washing, to wipe over skin sites that itched in the evening, as he prepared for sleep.
- the wipes were immediately effective in reducing itch and scratching and facilitated sleep.
- Over a 2-week period of use the skin lesions became less red, formed scabs, and progressed to heal. It was clear that the itch-scratch cycle had been attenuated. The boy became more cheerful and he paid more attention to his schoolwork. His parents were extremely pleased.
- Pruritis and Xerosis of the Elderly An eighty-six year old retired widower decided to move from California to a hotel suite in Hong Kong for permanent residence. He had been an avid and skilled golfer for many years and had actinic keratosis and a dry skin. Over time, his skin became itchy, especially on the forearms and back torso. Scratching with a wooden stick on his back at first helped, but the skin became damaged, infected, and inflamed. He applied Eucerin's “Atopic Control” which helped relieve the dryness, but found it to be expensive, heavy and “greasy”, although it definitely provided some protection and relief.
- the topical application of the DIPA-1-8 relieved his itch within 3 to 5 min after wiping, and he stopped complaining of skin discomfort. He said the wipes when applied to the face, also gave the sensation of wetness, and thus may be useful for cosmetic applications. He continued the use of the wipes on an as need basis and his skin, formed scabs, healed, and resumed a normal appearance. His only negative comment was that the solution made him feel too cool when the air conditioning was on a high setting. He continued using the wipes until death from a bulbar stroke three years later.
- Urticaria Urticaria is an allergic condition in humans manifested by skin rashes (wheals). The symptoms of redness, swelling, and itch on the skin are caused primarily by release of histamine from mast cells into the dermal layers.
- a frequent trigger for hives is the ingestion of seafood.
- DIPA-1-7 formulated 1.5% wt/vol in a gel made by Dong Wha Pharmaceuticals (Seoul, Korea).
- a female subject with a history of hives went to a seaside resort in the South of France and consumed over two days seafood pasta, minced crab, and mixed seafood soups.
- the gel was applied again 3.5 hr later, and then the subject given three tablets of fexofenadine (120 mg) and a tablet of chlorphenhydramine (4 mg). All the signs and symptoms of the hives were viewed as being diminished by at least 50% and “under the control” by the subject in 12 hr, and the skin rashes disappeared after three days and did not recur.
- her optometrist with the typical complaints of dry eye disease disorder, namely, a sense of discomfort from the eye surface, blurring of vision, sensitivity to light, and problems with reading, driving, and using the smartphone screen.
- she was found to have hyperemia of the eyelid margins, blockage of the Meibomian gland ducts, some thickening of the eyelid
- BlephacleanTM eye wipes which are single unit wipes with a cleansing solution, to clear the Meibomian gland ducts and to maintain eye hygiene.
- the subject objected vehemently to the irritation caused by the cleansing wipes and her inability to continue use of the bimatoprost solution, which was quite expensive.
- the subject was recruited into a clinical trial of a DIPA-1-9 wipe, 2 mg/mL in water, and instructed to use the wipe once in the morning, once in the evening, and two more wipes on an as needed basis during the day. She felt immediately better upon using the DIPA-1-9 wipes and commented on the cooling and refreshing sensations that were now present on her ocular surface and margins.
- her bimatoprost solution now no longer irritated and her eyelashes were now thick and luxurious.
- a towelette was used for delivery instead of a wipe.
- the towelette consisted of a plastic wrap (weight 1.1 g), a 23 cm ⁇ 26 cm towel of non-woven lace (weight 3.4 to 3.5 g) and a liquid composition (14 to 15 mL) which was automatically added to and sealed off in the wrapper.
- Automated machinery for producing towelettes are well-known to the art.
- the towelettes were produced by Kank Factor, LLC, San Francisco (721 Commercial Street, San Francisco Calif. 94108, www.3LWipes.com). These towelettes were then further treated to form either embodiments for practicing the present invention or as placebo controls, as follows.
- Distilled water (as placebo controls) or DIPA-1-7 dissolved in distilled water (at a concentration of 1 to 5 mg/mL) was incorporated into the towelette.
- the volume per self-application depended on the application site, but was about 0.3 mL to 0.5 mL for the face and brow, but could be higher if wiping of the torso was also included.
- the towelettes were stored in a refrigerator but then stored at room temperature for at least 1 hour before use. Effective sterilization of the towelette could be obtained by placement in a microwave oven for 1 min [Tanaka, Y. et al. Warming and sterilizing towels by microwave irradiation. Yonago Acta Medica 41: 83-88, 1998]. Subjects were instructed to hold the towelette with both hands, and bring the towelette against the face, like how one would use a small wet face towel, and to keep the eyes closed. The skin of the face is moistened and medicated by this procedure. Once the subject has learned what to expect, the subject can adjust the dosage (e.g., by dabbing), as needed, to achieve the desired anti-fatigue/anti-heat effects. After one or two trials, individuals quickly learn how to apply the sensory agent without any risks of discomfort.
- Lichen sclerosus atrophicus A 40-year old suffered from penile lichen sclerosus. This is an inflammatory dermatosis of the glans penis and foreskin and, in this particular case, was associated with intense pruritus and dysesthesias (burning sensations).
- the patient under the supervision and care of his dermatologist, volunteered to try DIPA-1-8 on his lesion and he was supplied with various concentrations of DIPA-1-8 dissolved in distilled water. After self-experiment, he concluded that concentrations of 1 to 1.5 mg/mL of DIPA-1-8 produced significant relief, but a concentration of 2 mg/mL of DIPA-1-8 was too cold and uncomfortable.
- the solutions were applied with cotton-tipped applicators or gauze wipes.
- the advantage of using DIPA formulations for genital skin is water solubility. This minimizes the need for excipients and the likelihood of further irritation.
- the subject suggested that an aerosolized spray may also be a convenient method of drug delivery
- DIPA-1-7 and DIPA-1-8 had a longer duration of action than DIPA-1-7, and may be the preferred agent for dermatological applications.
- DIPA-1-9 at 2 mg/mL applied with with a wipe on the glans or on the vulva produced that a gentle cooling and refreshing sensation that counteracted any inflammatory discomfort.
- DIPA-1-6 Three subjects decided to systemically compare DIPA-1-6, DIPA-1-7, DIPA-1-8, and DIPA-1-9 for their sensory effects on the ocular surface.
- Each compound was prepared at 1 mg/mL in distilled water.
- the subjects were then instructed to blink. By blinking, the solution is then evenly distributed over the pre-corneal film.
- DIPA-1-6 caused significant stinging and discomfort and was therefore not further studied.
- DIPA-1-7 and DIPA-1-8 produced strong and refreshing cooling, which counter-acted eye irritation, and increased cognitive functions. For example, subjects felt they could focus on distant objects and enjoy the view. They felt mentally alert and refreshed. But, with both DIPA-1-7 and DIPA-1-8, there was a small residue left on the eyelid; subsequently using a towel to wash the face can cause eye irritation. Surprisingly, DIPA-1-9 did not produce any eye irritation when wiped over the eyelid, nor did it leave a residue.
- DIPA-1-9 has ideal properties for the treatment of ocular discomfort, e.g., discomfort caused by eye strain; eye fatigue; eye surgery; an airborne irritant or pollutant that interacts with the eye surface; extended wear of contact lenses; excessive exposure to the sun; conjunctivitis; or the dry eyes syndrome.
- the '496 structures have their “head” covered by more lipophilic groups and are chiral, and are less able to permeate to target receptors in the basal layers of the skin to achieve the same therapeutic endpoints as the preferred embodiments.
- Increasing water solubility is counterintuitive in standard drug design for enhancement of transdermal drug permeation.
- formulation experts try to break down the stratum corneum with enhancers and chemists try to increase lipid solubility of the molecule (e.g. M. Prausnitz et al. Skin barrier and transdermal drug delivery. Chpt. 124, Medical Therapy, 2012). Nevertheless, the strategy used here was met with clinical success.
- the applicant opines that the discovery of the DIPA embodiments is not obvious and is a quantum improvement in the discovery process.
- DIPA di-sec-butyl
- Both DIPA and di-sec-butyl were active by intravenous injection, but only DIPA was active by or topical or oral routes of administration, indicating better penetration across the dermal and gastrointestinal membranes of the DIPA, but not di-sec-butyl structures.
- the ability of the DIPA structures to relieve skin discomfort in patients with an intact stratum corneum and a dermatological disorder was rapid, dramatic, and unexpected.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- This application is a continuation-in-part of US 2015/0164924 A1, published on Jun. 18, 2015.
- The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein (DIPA-1-5, DIPA-1-6, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”) that are useful, for example, in the treatment of symptoms and disorders (e.g., diseases) of the skin. Examples of symptoms are abnormal sensations such as irritation, burning sensations, itch, or pain, collectively called a skin dysesthesia. Examples of skin disorders are acne, atopic dermatitis, prurigo nodularis, pruritus of the elderly, psoriasis, contact dermatitis, and acute and chronic urticaria. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.
- Heat abstraction from the body's surfaces can refresh the senses, relieve discomfort, attenuate pain, and suppress inflammation. Abstraction of heat from body surfaces evokes sensations that are termed cool, refreshing cool, chilly, cold, icy cold and painful cold. For example, air blown onto the face from a fan or an air-conditioner can reduce tiredness and increase alertness. A wet towel applied to the forehead can relieve discomfort from a fever or a headache. The methods of heat abstraction, with gas, liquids, or solids, achieve their effects by physically lowering tissue temperatures and by activating signals to the brain.
- Chemical sensory/cooling agents are molecules that can mimic the sensations of heat abstraction without a change in tissue temperatures. The exact sensations produced by chemicals depend on the selection of the active ingredient, the target site, the drug formulation, and the method of delivery. With agents currently in use, some degree of chemical cooling on the scalp and skin of the face, nostrils, and philtrum can be achieved, but the effects do not last long. For the skin of the torso and limbs overt sensations of coolness and cold are more difficult to elicit and sustain, and require high concentrations of the active agent, for example, the use of 36% l-menthol oil to treat the itch of insect bites. The skin has a keratinized layer of dead cells called the stratum corneum that acts as a formidable barrier to drug penetration into the epidermis and dermis. The neuronal receptive fields to detect temperature changes are located in the epidermal sub-layers.
- The term “chemical cooling agent” can be ambiguous because, for example, chemicals such as ethyl chloride as a gas, ethanol as a liquid, liquid nitrogen, or carbon dioxide as a solid, applied to the skin can evoke heat abstraction sensations by reducing tissue temperatures. In this application, chemical cooling agents will refer only to agents that elicit sensations of heat abstraction but do not lower tissue temperatures.
- The inventor has previously identified several p-menthane carboxamide compounds that, when applied to the philtrum skin, simulate effects of heat abstraction for >1.5 hr without decreasing tissue temperature (Wei, E T. Sensory/cooling agents for skin discomfort. Journal Skin Barrier Research 14: 5-12, 2012). These compounds are relatively water-insoluble.
- The site where temperature is detected on the skin qualitatively affects perception of thermal comfort. Temperature sensitivity over the body surface varies over ˜100 fold. The face, especially area around the eyes [periorbital] and mouth [perioral] are very sensitive, but the extremities have poor sensitivity, and the rest of the body is intermediate [Stevens et al. Temperature sensitivity of the body surface over the life span. Somatosensory Motor Research 15: 13-28, 1998]. The sensory innervation of the skin is mediated by peripheral nerves that transmit signals to the brain.
- The 1-dialkyl-phosphinoyl-alkanes [e.g. total number of carbons≤16] are solvent-like molecules that require several [1 to 3] steps for synthesis. They are also known as trialkylphosphine oxides or dialkylphosphorylalkanes. Here, they are referred to as dialkyl-phosphinoyl-alkanes [DAPA]. If two of the alkyl groups are isopropyl, the DAPA is abbreviated as DIPA [di-isopropyl-phosphinoyl-alkane],
- Rowsell and Spring [Phosphine oxides having a physiological cooling effect. U.S. Pat. No. 4,070,496. Jan 24, 1978], describes a range of phosphine oxides which have a physiological cooling effect on skin and oral cavity. See, e.g., the table in
columns 3 and 4 therein. Ten (10) of the compounds shown therein (Table 1) have one isopropyl group (shown as iso-C3H7). None of the compounds has two isopropyl groups. -
TABLE 1 Compounds in Rowsell et al., 1978 P(═O)R1R2R3 # R1 R2 R3 2 n-C7H15 iso-C3H7 sec-C4H9 3 n-C8H17 iso-C3H7 sec-C4H9 7 n-C6H13 iso-C3H7 sec-C4H9 8 n-C6H13 iso-C3H7 cyclo-C5H9 11 n-C7H15 iso-C3H7 cyclo-C5H9 12 n-C6H13 iso-C3H7 iso-C5H11 15 n-C7H15 iso-C3H7 iso-C5H11 26 n-C6H13 iso-C3H7 n-C6H13 30 n-C8H17 iso-C3H7 cyclo-C5H9 47 iso-C3H7 n-C4H9 (n-C4H9)(C2H5)CHCH2 - Siddall et al. [Simplified preparation of some trisubstituted phosphine oxides. J. Chemical Engineering Data 10: 303-305, 1965] reported the synthesis of 1-di-isopropyl-octane [DIPA-1-8], but Siddall et al. did not examine the bioactivity of this molecule.
-
FIG. 1 . is an illustration of the human face showing the innervation of the cheekbone skin by the zygomatic facial nerve (ZFN) and the infraorbital nerve (ION). The receptive fields of these nerve endings were used for testing compounds applied to the cheekbone skin. Diagram adapted from Hwang et al. [Cutaneous innervation of the lower eyelid. J. Craniofacial Surgery 19: 1675-1677, 2008]. -
FIG. 2 . shows the cooling sensations evoked by topical wiping of different concentrations of DIPA-1-8 onto the skin above the zygomatic process. The cooling activity can be measured as the intensity/duration area-under-curve (AUC) or as time for half maximal effect (T-1/2), using software of the GraphPad Prism package. The graph shows the dose-response curve for the compound DIPA-1-8 applied at 0.5, 1 and 2% (5, 10, and 20 mg/mL dissolved in distilled water). -
FIG. 3 . shows the cooling sensations evoked by topical wiping of different compounds onto the skin above the zygomatic process. The cooling activity is expressed as the integrated intensity/duration area-under-curve (AUC), using software of the GraphPad Prism package. Test concentration was 2% (20 mg/mL in distilled water). The diisopropyl analogs are DIPA 3,3-X and isopropyl, sec-butyl analogs are Mixed 3,4-X. The “X” refers to the number of carbons on the third alkyl group. It can be seen that the Mixed analogs are much less active on the cheekbone skin than the corresponding diisopropyl analogs. -
FIG. 4 . Is a graph of fluorescence response (Δ ratio 340/380) in TRPM8 transfected cells as a function of the logarithm of the concentration of the test compound, expressed in μM, for DIPA-1-7 (black circle), 3,4-7 (open squares), or 3,4-6 (open triangles). The assays were conducted by Andersson et al. of King's College, London, UK, using his methods described in “Modulation of the cold-activated channel TRPM8 by lysophospholipids and polyunsaturated fatty acids. Journal Neuroscience 27 (12): 3347-3355, 2007. -
FIG. 5 . shows chart traces that illustrate, in the first trace (FIG. 5A “Wild Type”), the inhibition of capsaicin-induced depolarization of the isolated mouse vagus by the DIPA-1-7 embodiment, superfused at a concentration of 1 mg/mL, and, in the second trace (FIG. 5B “TRPM8 KO”), the significant absence of inhibition in the isolated TRPM8 KO (knockout) mouse vagus by DIPA-1-7, superfused at a concentration of 1 mg/mL. -
FIG. 6 . shows the method for estimating the in vivo transdermal activity of the DIPA-embodiment compounds applied 20 μL with a micropipette to the center of a circle enclosed by cream on abdominal skin of an anesthetized rat. Shaking frequency was counted for 40 min after topical application. It can be seen that the embodiments DIPA-1-5, DIPA-1-6, and DIPA-1-7 evoke robust shaking, but this is not seen with other analogs. -
FIG. 7 . shows the flux of DIPA-1-7 and DIPA-1-9 through excised hairless mouse skin in vitro. Test chemicals dissolved in a gel were placed in an incubation for 8 hr and the permeated amount of the chemical measured by a high pressure liquid chromatograph equipped with a refractive detector. These tests were conducted by Prof Choi of Chosun University, Korea. The flux of 1-7 was ˜5× greater than 1-9. Standard enhancers with polyhydric alcohols, such as a propylene glycol-oleyl alcohol mixture (50:50) or Lauroglycol 90, designed to increase permeation added to the 1-7 gel decreased the rate of permeation by ˜50%, indicating the importance of water solubility for permeation. - In this discovery, it was found that structural modification of certain 1-dialkyl-phosphinoyl-alkane to the 1-di-isopropyl-phosphinoyl-alkane analog resulted in agents that will potently evoke a “dynamic cool” sensation when applied to keratinized skin. The 1-di-isopropyl-phosphinoyl-alkanes described herein are collectively referred to herein as “DIPA compounds”. The skin is a frequent site of injury. Inflammation is the response of tissues to injury and the cardinal signs of inflammation are a feeling of heat [calor] at the site of injury, redness [rubor], swelling [tumor] and pain [dolor] in and around the injured tissues. The newly synthesized DIPA molecules relieve signs of skin discomfort such as irritation, burning sensations, itch, and pain from inflamed/damaged skin.
- The unusual property of the DIPA molecules is water solubility and the ability to penetrate the keratinized layers of the skin [stratum corneum] to reach receptive targets underneath. The targets are located on sensory nerve endings and when activated, relieve skin dysesthesia and has a disease-modifying effect. The water solubility at therapeutically effective concentrations permits ease of formulation for delivery to target receptors.
- Another aspect of the present discovery pertains to a pharmaceutical composition comprising one or more DIPA compound, as described herein, and a pharmaceutically acceptable carrier or diluent. Particularly preferred embodiments include one or more DIPA compounds and a delivery agent carrying the one or more compounds, where, the delivery agent is suitable for topical delivery. These preparations, as described herein, may be used in a method of treatment of the human or animal body by therapy, for example, for use a method of treatment of a disorder (e.g., a disease) as described herein.
- The present discovery relates to certain compounds (the DIPA compounds described herein) which, when delivered onto the skin, selectively and potently evoke sensations of “dynamic cool” for at least several hours. The dynamic cool can be repeated without significant diminution of the effects and can be sustained for the whole day. Thus, these compounds have applications in the treatment of skin discomfort, especially skin irritation, itch, and pain.
- The structures of the preferred embodiments are shown below. The new water-soluble compounds [e.g., 1-di-isopropyl-phosphinoyl-heptane] potently [<5 mg per dose] and rapidly produce on skin robust and intense cooling sensations. This type of drug action is unusual and has not been previously recognized to be achievable on keratinized surfaces and has lead to new applications as described herein. A chemical feature, the minimum active alkyl side chain adjacent to the phosphine oxide, allows exposure of the polar phosphine oxide group to water, and increases water solubility.
- DIPA compounds DIPA is the abbreviation for 1-[Diisopropyl-phosphinoyl]-alkane. The third alkyl group in the molecule may be described by a number: hence, 4, 5, 6, 7, 8, 9, and 10 correspond to the butyl, pentyl, hexyl, heptyl, octyl, nonyl, and decanyl side chain, respectively. These alkanes are linear or “normal [n]” in configuration, with the phosphinoyl group attached to the primary, or “1-” position, of the carbon chain in the third sidechain. These compounds are also known as trialkylphosphine oxides or 1-dialkylphosphorylalkanes.
- TRP channels The transient receptor potential (TRP) family of cation channels are peripheral detectors of nociceptive and painful stimuli. Many of these receptors are located on the nerve membranes of sensory neurons and respond to chemical irritants and changes in local temperature by activating nerve action potentials which are the signals to be perceived and acted upon by the brain. The TRP receptors are the transducers of sensory information, and it is this transduction and effector system that regulates and protects the organism from external irritants.
- Receptive field of a sensory neuron is the region in space in which a stimulus will modify the firing of the neuron. The receptive field is spatially determined by the distribution of the nerve endings of the neuron. For the epithelium, the nerve endings are interdigitated with the cell layers at the basal layer of the epithelium. A receptive field, even though smaller than a mm2, when activated by the appropriate stimulus, e.g. nociceptive or pruritic, can totally dominate the attention of the brain and mind. Witness what happens when a sharp pin or sting comes into contact with skin or when a dog is pre-occupied with a flea bite.
- Dermatological disorders are diseases of the skin, nails or hair. The skin has multiple keratin layers. The cornea, tongue and parts of the buccal cavity are also keratinized and thus considered as part of the skin. The body's internal surfaces, the mucous membranes, do not have a keratin layer and thereby is not considered skin. The skin is the largest organ of the body, but the epidermis is only about 1 mm thick. The epidermis is densely infiltrated with nerve endings. The epidermal turnover time, that is, the time to replace itself, is about 1.5 months.
- Atopic dermatitis is an inflammatory disease of the skin. All parts of the skin may become itchy and inflamed, but the lesions are usually conspicuous on the flexures of the elbows and knees, possibly because of increased sweating in these skin areas. Many atopic dermatitis patients also have allergic rhinitis and asthma. Symptoms are more frequent in children and young adults than adults. Recently, two new medications have been approved by the US FDA for atopic dermatitis: dupilumab (a monoclonal antibody) and crisaborole (an ointment). Both medications have a slow onset of therapeutic action of >6 weeks. Dupilumab is very expensive for an one year treatment. The efficacy of crisaborole is modest and it is a greasy ointment that is not favored by atopic patients. There is room for improvement.
- Urticaria also known as hives is a disease characterized by the sudden onset of “wheals” (areas of red skin, with raised and itchy bumps) on any parts of the body. The wheals can be quite large and alarming, but are not life-threatening. The triggers are usually allergy to a food item, such as seafood, but there are multiple triggers. The skin layer is intact, but it is the release of histamine from mast cells in the epidermis and dermis that is the likely cause of the wheal and itch. The condition is treatable with oral antihistamines and in more severe cases with oral prednisone, but onset of drug effect takes about 12 hours. Urticaria is a recurrent condition and in some patients may persist for more than 6 weeks (chronic urticaria). The itching skin and cosmetic disfigurement of the red wheals are annoying features of urticaria.
- Itch-scratch cycle Scratching can make an itch feel better, but a vicious itch-scratch cycle can cause more damage to the skin, perpetuate inflammation, and lead to excoriations and to disfiguring lichenification. The itch-scratch cycle is a well-known phenomenon in childhood and canine atopy where shields are put up to prevent the subject from scratching at the sites of inflammation and itch. Itch prevents a good night's sleep and an atopic dermatitis patient will scratch themselves vigorously even when asleep. An effective medication should prevent itch within minutes after application and act sufficiently long to allow the subject to go to sleep. The subject should be instructed to apply the medication after washing, to use on an as-needed basis, and to apply at night before sleep, because scratching can take place after the subject is asleep. This is especially important for children. The medication should also put a break on the itch-scratch cycle.
- Cholestatic Itch In certain systemic diseases, such as cholestasis, kidney dialysis procedures, and lymphoma, there are blood borne pruritogens that cause generalized itching. The exact chemical identities of these pruritogens are not well established, but are likely to be bile acids in the case of liver disease and kidney dialysis patients. The itching Is intense and causes much hardship in the patients. Sigmoid opioid antagonists, such as nalbuphine, administered orally may be effective for the itch of such patients and work by antagonizing dynorphin, an endogenous pruritogen that acts on neuronal receptors in the spinal cord.
- The DIPA compounds of the present discovery are achiral and are examples of 1-di-alkyl-phosphinoyl-alkanes [(O═)PR1R2R3] wherein each of R1, R2, and R3 is an alkyl group, and in particular where R1 and R2 are isopropyl, and R3 is a linear alkyl group of 5 to 9 carbons, and which have the following general formula of Formula 1:
-
TABLE 2 DIPA compounds Formula/ Code Chemical Name Weight Chemical Structure DIPA-1-5 1-di-isopropyl- phosphinoyl- pentane C11H25OP 204.32 DIPA-1-6 1-di-isopropyl- phosphinoyl- hexane C12H27OP 218.32 DIPA-1-7 1-di-isopropyl- phosphinoyl- heptane C13H29OP 232.34 DIPA-1-8 1-di-isopropyl phosphinoyl- octane C14H31OP 246.37 DIPA-1-9 1-di-isopropyl phosphinoyl- nonane C15H33OP 260.40 - The DIPA compounds were prepared by the following general method: 100 mL (23.7 g, ˜200 mmol) of isopropylmagnesium chloride (or sec-butylmagnesium chloride in the case of the di-sec-butyl derivatives) were obtained from Acros, as a 25% solution in tetrahydrofuran (THF) and placed under nitrogen in a 500 mL flask (with a stir bar). Diethylphosphite solution in THF (from Aldrich, D99234; 8.25 g, 60.6 mmol in 50 mL) was added drop-wise. After approximately 30 minutes, the reaction mixture warmed up to boiling. The reaction mixture was stirred for an extra 30 minutes, followed by a drop-wise addition of the appropriate n-alkyl iodide solution in THF (from TCl; 60 mmol in 20 mL). The reactive mixture was then stirred overnight at room temperature. The reaction mixture was diluted with water, transferred to a separatory funnel, acidified with acetic acid (˜10 mL), and extracted twice with ether. The ether layer was washed with water and evaporated (RotaVap Buchi,
bath temperature 40° C.). The light brown oil was distilled under high vacuum. The final products, verified by mass as determined by mass spectrometry, were transparent liquids that were colorless. Synthesis was conducted by professional chemists at Phoenix Pharmaceuticals, Inc. (Burlingame, Calif.), Uetikon Laboratories (Lahr, Germany) and Dong Wha Pharmaceuticals (Seoul, Korea). - Table 2 compounds are embodiments of the invention. The following compounds (Table 3) were also prepared by this general synthetic method and used for comparisons.
-
TABLE 3 Chemical structures of test compounds. Code Chemical Name Chemical Structure 2-4 1-di(sec-butyl)- phosphinoyl- Butane 2-5 1-di(sec-butyl)- phosphinoyl- Pentane 2-6 1-di(sec-butyl)- phosphinoyl- Hexane 2-7 1-di(sec-butyl)- phosphinoyl- Heptane 2-8 1-di(sec-butyl)- phosphinoyl- Octane 3-1 1-di(iso-butyl)- phosphinoyl- Pentane 3-2 1-di(sec-butyl)- phosphinoyl- 3-methyl- butane 3,4-6 1-isopropyl- sec-butyl- phosphinoyl- hexane 3,4-7 1-isopropyl- sec-butyl- phosphinoyl- heptane 3,4-8 1-isopropyl- sec-butyl- phosphinoyl- octane 3,4-9 1-isopropyl- sec-butyl- phosphinoyl- nonane - The 3,4-X series are “mixed” isopropyl-sec-butyl compounds (Table 3). These were synthesized by Dr. Jae Kyun Lim of Dong Wha Pharmaceuticals, using the method described below.
- Briefly, as illustrated in the following scheme, triethyl phosphite (A) was reacted with sec-butyl magnesium bromide (B) and then hydrolysed with dilute hydrochloric acid to give the mono-alkyl compound (C). The product (C) was then reacted isopropyl magnesium bromide (D) to give the di-alkyl compound (E), which was then reacted with a suitable alkyl iodide (F) to give the target trialkyl phosphine (G).
- DIPA compounds are colorless liquids with a density less than water. The preferred embodiments DIPA-1-7, DIPA-1-8 and DIPA-1-9 exert an icy sensation that can modulate skin dysesthesia caused, for example, by various dermatitis (e.g. atopic or urticarial) and on mucous membranes (esp. DIPA-1-8 and DIPA-1-9). Similar structures were described by Rowsell and Spring U.S. Pat. No. 4,070,496 (1978) ˜40+ years ago but have remained dormant in the scientific literature. The '496 structures (see table) ALL have their “head” (phosphine oxide group) covered by larger, more lipophilic groups. The applicant noted that '496 did not include the di-isopropyl analogs. The applicant synthesized these analogs (which are achiral, by contrast to the structures of '496 which are >95% chiral). The applicant found that, by minimizing the two alkyl side chains to di-isopropyl, the “head” of the prototypical molecule now is more polar (hydrophilic) and more miscible in the polar environment of water. This increased water-solublility is striking (Table 4). The water solubility of the DIPA if at least 10× greater than the di-sec-butyl or the mixed isopropyl-sec-butyl analogs. The DIPA analogs are now mobile in the extracellular fluids and permeate between cells to access nerve endings in the stratum basale.
-
TABLE 4 Water solubility (mg/ml) of 1-dialkylphosphorylalkanes (R1R2R3P═O). No. 13 14 15 16 Carbons R1, R2 R3 R3 R3 R3 di-sec- pentane 22 hexane 8 heptane <3 octane <3 butyl- isopropyl- hexane 25 heptane 20 octane <3 nonane <3 sec-butyl- di- heptane >300 octane >300 nonane >300 decane <3 isopropyl- - When DIPA compounds are applied to the facial skin as an aqueous solution at 1-10 mg/mL or a 1% hydrogel there is little irritation. For certain analogs, contacting the periorbital or zygomatic skin with a solution at a concentration of 1-10 mg/mL produce a sensation of “dynamic cool” that is felt within one minute after application.
- A single application can evoke this “energizing” sensation, which can counteract fatigue for several hours. DIPA-1-7, especially, has intense dynamic cooling.
- Periorbital administration of DIPA and related di-secbutyl analogs will leave a residue on the eyelid skin. When the eyelids become wet, for example, by taking a shower or sweating, the residual compound will wash onto the cornea and cause stinging and irritation. This will limit the choice of the compound for applications wherein delivery is to the eyelid skin. Among the compounds of
Formula 1, DIPA-1-8 and DIPA-1-9 have minimal residual irritation, and so are especially useful for the longer term treatment of ocular discomfort. The efficacy of DIPA-1-9 in the treatment of patients with the “dry eyes syndrome” is demonstrated inCase Study 7. DIPA-1-7 is more useful for application wherein the sensory effect is immediate and energizing. - Both DIPA-1-7 and DIPA-1-8 are useful for treatment of skin dysesthesias (e.g., skin irritation, itchy skin, or painful skin), heat discomfort, and heat stress. DIPA-1-8 is slightly longer-acting than DIPA-1-7, but is easily active across the skin, and has a lower risk for systemic absorption.
- One aspect of the present discovery pertains to a composition (e.g., a pharmaceutical composition) comprising a DIPA compound, as described herein, and a pharmaceutically acceptable carrier, diluent, or excipient. Another aspect of the present discovery pertains to a method of preparing a composition (e.g., a pharmaceutical composition) comprising mixing a DIPA compound, as described herein, and a pharmaceutically acceptable carrier, diluent, or excipient.
- In one embodiment, the composition comprises the DIPA compound at a concentration of 0.005-2.0% wt/vol. In one embodiment, the composition is a liquid or semi-liquid composition (lotion, cream, or ointment), and comprises the DIPA compound at a concentration of 0.5-20 mg/mL. In one embodiment, the composition is a liquid composition, and comprises the DIPA compound at a concentration of 1-5 mg/mL. In one embodiment, the composition is a liquid composition, and comprises the DIPA compound at a concentration of 5-10 mg/mL. In one embodiment, the composition is a liquid composition, and comprises the DIPA compound at a concentration of 10-20 mg/mL.
- The composition may be provided with suitable packaging and/or in a suitable container. For example, the composition may be provided as a swab, wipe, pad, or towellette (e.g., suitably sealed in a wrap) carrying a DIPA compound or a composition comprising a DIPA compound. Similarly, the composition may be provided as a patch, e.g., a controlled-release patch, e.g., suitable for application to the skin, e.g., the skin above the supraclavicular fossa or the steronomastoid muscle. Similarly, the composition may be provided as an aerosolized spray delivered from a pressurized container. Similarly, the composition may be provided in a manually-activated sprayer (e.g., with a suitable small orifice) linked to a reservoir containing a DIPA compound or a composition comprising a DIPA compound, for example, capable of delivering an unit volume (e.g., of 0.05 to 0.15 mL), for example, to the skin surface.
- Another aspect of the present discovery pertains to use of a DIPA compound, as described herein, in the manufacture of a medicament, for example, for use in a method of treatment, for example, for use a method of treatment of a disorder (e.g., a disease) as described herein. In one embodiment, the medicament comprises the DIPA compound.
- Another aspect of the present discovery pertains to a method of treatment, for example, a method of treatment of a disorder (e.g., a disease) as described herein, comprising administering to a subject in need of treatment a therapeutically-effective amount of a DIPA compound, as described herein, preferably in the form of a pharmaceutical composition.
- In one embodiment (e.g., of use in methods of therapy, of use in the manufacture of medicaments, of methods of treatment), the treatment is treatment of: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; atopic dermatitis; contact dermatitis; prurigo nodularis; urticaria; milaria rubra; lichen sclerosus atrophicus; acne; acneiform eruptions; pruritus of the elderly, pruritus from cholestasis and liver disease; pruritus from lymphoma; pruritus from kidney disease dialysis; seborrheic dermatitis; psoriasis; rosacea; ocular pain and discomfort; heat discomfort; heat stress; flushing and/or night sweats (vasomotor symptoms) in post-menopausal women; fatigue; tiredness; depression; cognitive dysfunction; and to enhance cognitive function.
- The term “sensory discomfort”, as used herein, relates to irritation, itch, pain, or other dysesthesias (abnormal sensations; such as burning sensations, or feeling the presence of a foreign body, or pins and needles) from the body surfaces. The term implies activation of nociceptors located on sensory nerve endings of the body. Nociceptors are stimulated, for example, by high or low temperatures, mechanical pressure, chemicals (e.g., capsaicin, acidity, pollutants, etc.), injury, inflammation, and inflammatory mediators. A DIPA compound, such as DIPA-1-8, that decreases sensory discomfort, can be termed an anti-nociceptive agent.
- In one embodiment, the sensory discomfort is irritation, itch, or pain. In one embodiment, the sensory discomfort is caused by a skin dysesthesia. In one embodiment, the skin dysesthesia is skin irritation, itchy skin, or painful skin. In one embodiment, the sensory discomfort is caused by atopic dermatitis. In one embodiment, the sensory discomfort is caused by canine atopic dermatitis. In one embodiment, the treatment is treatment of a skin dysesthesia. In one embodiment, the treatment is treatment of dermatitis. In one embodiment, the treatment is treatment of atopic dermatitis. In one embodiment, the treatment is treatment of canine atopic dermatitis. In one embodiment, the treatment is treatment of contact dermatitis. In one embodiment, the treatment is treatment of urticaria. In one embodiment, the treatment is treatment of the pruritus of the elderly. In one embodiment, the treatment is treatment of the pruritus of milaria rubra. In one embodiment, the treatment is treatment of the pruritus of liver disease (cholestasis). In one embodiment, the treatment is treatment of the pruritus of patients on kidney dialysis. In one embodiment, the treatment is treatment of the pruritus of patients with lymphoma. In one embodiment, the treatment is treatment of the dysesthesia of psoriasis. In one embodiment, the treatment is treatment of the dysesthesia of neurogenic/neuropathic itch. In one embodiment, the treatment is treatment of the dysesthesia of lichen planus atrophicus. In one embodiment, the treatment is treatment of ocular discomfort. In one embodiment, the ocular discomfort is caused by eye strain; eye fatigue; eye surgery; an airborne irritant or pollutant that interacts with the eye surface; extended wear of contact lenses; excessive exposure to the sun; conjunctivitis; or the dry eyes syndrome. In one embodiment, the treatment is treatment of heat discomfort. In one embodiment, the treatment is treatment of heat discomfort for the purpose of improving athletic performance. In one embodiment, the treatment is treatment of heat stress. In one embodiment, the treatment is treatment of flushing and/or night sweats (vasomotor symptoms) in a post-menopausal woman. In one embodiment, the treatment is treatment of post-operative hypothermia or post-anaesthetic shivering. In one embodiment, the treatment is treatment is to convey a sense of refreshment to the skin in a human.
- The term “treatment,” as used herein in the context of treating a disorder, pertains generally to treatment of a human or an animal (e.g., in veterinary applications), in which some desired therapeutic effect is achieved, for example, the inhibition of the progress of the disorder, and includes a reduction in the rate of progress, a halt in the rate of progress, alleviation of symptoms of the disorder, amelioration of the disorder, and cure of the disorder. Treatment as a prophylactic measure (i.e., prophylaxis) is also included. For example, use with patients who have not yet developed the disorder, but who are at risk of developing the disorder, is encompassed by the term “treatment.” Treatment to enhance the basal levels of cognitive or physical performance of individuals who are considered normal or healthy is also included.
- The term “therapeutically-effective amount,” as used herein, pertains to that amount of a compound, or a material, composition or dosage form comprising a compound, which is effective for producing some desired therapeutic effect, commensurate with a reasonable benefit/risk ratio, when administered in accordance with a desired treatment regimen.
- The term “treatment” includes combination treatments and therapies, in which two or more treatments or therapies are combined, for example, sequentially or simultaneously. For example, the compounds described herein may also be used in combination therapies, e.g., in conjunction with other agents. One aspect of the present discovery pertains to a DIPA compound as described herein, in combination with one or more (e.g., 1, 2, 3, 4, etc.) additional therapeutic agents. The particular combination would be at the discretion of the physician or the pharmacist who would select dosages using his common general knowledge and dosing regimens known to a skilled practitioner.
- Examples of additional therapeutic agents include: an anti-inflammatory glucocorticosteroid; an analgesic; a sympathomimetic amine decongestant; an anti-histamine; a local anesthetic; an ophthalmic lubricant; a sunscreen ingredient; an anti-acne agent; a keratolytic agent; an anti-hemorrhoidal agent; an agent for vulvar itch or discomfort; an antibiotic; a skin moisturizer; or an anti-skin ageing agent.
- The DIPA compound or pharmaceutical composition comprising the DIPA compound may suitably be administered to a subject topically, for example, as described herein.
- The term “topical application”, as used herein, refers to delivery onto surfaces of the body in contact with air, which includes the skin, the anogenital surfaces, the transitional epithelial surfaces of the orbit, the lips, the nose, and the anus, and the aerodigestive tract (nasal membranes, oral cavity, pharyngeal and esophageal surfaces), lower respiratory tracts, and the lumen of the gastrointestinal tract. Particularly preferred sites of application are the surfaces innervated by the trigeminal and glossopharyngeal nerves which include the scalp, facial skin, periorbital skin, lips, nasal and oral cavities, and the throat. Additional preferred sites are the surfaces of the neck, elbows and knees, which are frequently associated with the pruritus of atopic eczema and psoriasis. Yet another preferred site is the scalp, which can be a site of inflammation in psoriasis and seborrheic dermatitis.
- In one embodiment (e.g., of use in methods of therapy, of use in the manufacture of medicaments, of methods of treatment), the treatment is treatment by topical administration. In one embodiment, the treatment is treatment by topical administration to skin. In one embodiment, the treatment is treatment by topical administration to facial skin. In one embodiment, the treatment is treatment by topical administration to periorbital skin, eyelid skin, zygomatic skin, malar skin, forehead skin, or scalp. In one embodiment, the treatment is treatment by topical administration to skin surface of the orbit, frontal bone, or zygomatic. In one embodiment, the treatment is treatment by topical administration to skin surface of the anus and/or the male or female genitalia. In one embodiment, the treatment is treatment by topical administration to skin above the supraclavicular fossa or the steronomastoid muscle.
- The subject/patient may be a mammal, for example, a marsupial (e.g., kangaroo, wombat), a rodent (e.g., a guinea pig, a hamster, a rat, a mouse), murine (e.g., a mouse), a lagomorph (e.g., a rabbit), avian (e.g., a bird), canine (e.g., a dog), feline (e.g., a cat), equine (e.g., a horse), porcine (e.g., a pig), ovine (e.g., a sheep), bovine (e.g., a cow), a primate, simian (e.g., a monkey or ape), a monkey (e.g., marmoset, baboon), an ape (e.g., gorilla, chimpanzee, orangutang, gibbon), or a human. In one preferred embodiment, the subject/patient is a human.
- While it is possible for a DIPA compound to be administered alone, for example, dissolved in saline or water, it may also be prepared as a pharmaceutical formulation (e.g., composition, preparation, medicament) comprising at least one DIPA compound, as described herein, together with one or more other pharmaceutically acceptable ingredients well known to those skilled in the art, including, but not limited to, pharmaceutically acceptable carriers, diluents, excipients, adjuvants, fillers, buffers, preservatives, anti-oxidants, lubricants, stabilisers, solubilisers, surfactants (e.g., wetting agents), masking agents, colouring agents, flavoring agents, and sweetening agents. The formulation may further comprise other active agents.
- Thus, the present discovery further provides pharmaceutical compositions, as described above, and methods of making pharmaceutical compositions, as described above. If formulated as discrete units (e.g., swab, wipe, pads, towellettes, gels, lotion, cream, etc.), each unit contains a predetermined amount (dosage) of the compound.
- The term “pharmaceutically acceptable,” as used herein, pertains to compounds, ingredients, materials, compositions, dosage forms, etc., which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of the subject in question (e.g., human) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. Each carrier, diluent, excipient, etc. must also be “acceptable” in the sense of being compatible with the other ingredients of the formulation.
- Suitable carriers, diluents, excipients, etc. can be found in standard pharmaceutical texts, for example, Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing Company, Easton, Pa., 1990; and Handbook of Pharmaceutical Excipients, 5th edition, 2005.
- The formulations may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the compound with a carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the compound with carriers (e.g., liquid carriers, finely divided solid carrier, etc.), and then shaping the product, if necessary. Formulations may suitably be in the form of liquids, solutions (e.g., aqueous, non-aqueous), suspensions (e.g., aqueous, non-aqueous), emulsions (e.g., oil-in-water, water-in-oil); elixirs, syrups, electuaries, mouthwashes, drops, tablets (including, e.g., coated tablets), granules, powders, lozenges, pastilles, capsules (including, e.g., hard and soft gelatin capsules), cachets, pills, ampoules, boluses, suppositories, pessaries, tinctures, gels, pastes, ointments, creams, lotions, oils, foams, sprays, mists, or aerosols.
- Additionally, the DIPA compound may be used as an adjunct in a pharmaceutical formulation or cosmetic formulation.
- It will be appreciated by one of skill in the art that appropriate dosages of the DIPA compounds, and compositions comprising the DIPA compounds, can vary from patient to patient. Determining the optimal dosage will generally involve the balancing of the level of therapeutic benefit against any risk or deleterious side effects. The selected dosage level will depend on a variety of factors including, but not limited to, the activity of the particular DIPA compound, the route of administration, the time of administration, the duration of the treatment, other drugs, compounds, and/or materials used in combination, the severity of the disorder, and the species, sex, age, weight, condition, general health, and prior medical history of the patient. The amount of DIPA compound and route of administration will ultimately be at the discretion of the physician, pharmacist, veterinarian, or clinician, although generally the dosage will be selected to achieve local concentrations at the site of action which achieve the desired effect without causing substantial harmful or deleterious side-effects.
- Administration can be effected in one dose, continuously or intermittently (e.g., in divided doses at appropriate intervals) throughout the course of treatment. Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the formulation used for therapy, the purpose of the therapy, the target cell(s) being treated, and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician, veterinarian, or clinician.
- Epithelial cells line ducts, cavities and surfaces of organs throughout the body. When there are two or more layers of epithelia, it is called stratified epithelium. Historically, stratified epithelia were divided into two broad categories: keratinized stratified epithelia, and non-keratinized stratified epithelia. Keratinized epithelium, such as the epidermis of the skin, has an exterior layer of dead cells [stratum corneum] composed of keratin proteins that are tough and water-impermeable. By contrast, non-keratinizing stratified epithelia are located on “soft tissues” of the body such as the lining of the nasal and throat cavities and the oesophageal surface. Keratinizing tissues withstand injury better than non-keratinizing tissues. Non-keratinizing epithelial surfaces must be kept moist by glandular (serous and mucous) secretions in order to avoid desiccation.
- The stratum corneum (keratinized layer of dead cells) is a formidable barrier to drug penetration to neuronal receptive fields embedded in epithelial tissues underneath the keratin. The barrier thickness and the layers of dead cells vary. The heel and palm have the most dead cell layers (˜82 layers). The genitalia (e.g. penile shaft) and eyelids have fewer layers (4 to 8 layers). The skin of the face has about 10 to 14 layers, and the torso has about 12 to 16. The limbs have somewhat more layers (˜15+). Dermatitis occurs frequently occur on the extremeties (e.g. elbow and knee flexures in atopic dermatitis) and on the trunk and scalp for psoriasis. Hand eczema frequently occurs on the hand (contact dermatitis). Urticaria can occur all over the body, the wheals appearing on the torso, neck and buttocks.
- However, the stratum corneum is not a solid brick and mortar wall, but has water pores, like limestone, through which water soluble molecules may pass between cells and through cells. The intracellular water transport channels on keratinocytes are called aquaporins (Patel R et al. Aquaporins in the Skin. Adv Exp Med Biol. 2017; 969:173-191). The active ingredient must reach the nerve endings, which are located in the basal layer of the skin (stratum basale). A surprising finding here was the ability of DIPA compounds to inhibit dysesthesia when applied as a water solution on a wipe. The likely explanation is that the DIPA is passing between cells through water channels, and not across cells. The current topical antinociceptive (pain-suppressant) compounds that have efficacy on sensory discomfort of keratinized skin are high concentrations of I-menthol (36% alcoholic solution) or a local anesthetic gel. But these two types of topical medications have problems of greasy feel and irritation, and of hypersensitivity reactions.
- The targets for topical delivery of the DIPA compounds are located on the nerve endings of the receptive fields of peripheral and cranial sensory nerves. For the face, the receptive fields of the ophthalmic and maxillary branches of the trigeminal nerve are the preferred target sites.
-
FIG. 1 . is an illustration of the human face showing the innervation of the cheekbone skin by the zygomatic facial nerve (ZFN) and the infraorbital nerve (ION). The receptive fields of these nerve endings were used for testing compounds applied to the cheekbone skin. Diagram adapted from Hwang et al. [Cutaneous intervention of the lower eyelid. J. Craniofacial Surgery 19: 1675-1677, 2008]. - In these studies, the primary site of testing was the zygomatic (cheekbone) skin. Alternatively, if the cooling agent is to be used for flushing and/or night sweats (vasomotor symptoms) in post-menopausal women, it may also be applied to the skin above the supraclavicular fossa or the chest. To reduce sensory discomfort on the skin, the cooling agent may be directly applied to the sites of injury and/or inflammation.
- Secondary sites are the skin over the frontal bone and the scalp, but higher concentrations of cooling agent are required for these sites. In practice, the cooling agent can be sprayed or applied (e.g., with a swab or pad or within a gel, lotion, cream or ointment) over the skin of the orbit, the cheekbone (zygomatic), or on the skin beneath the eye, between the cheekbone and nose. The important receptive fields are from the sub-divisions of the trigeminal nerve, namely, the zygomaticfacial nerve of the maxillary nerve (V2) and the supraorbital and supratrochlear branches of the frontal nerve (V1).
- One unusual feature of DIPA compounds is that they leave a reservoir in the skin after application, so that after the initial sensations have dissipated, the dynamic cooling sensation returns when the skin is moist again. This feature is especially beneficial for use of DIPA-1-7 and DIPA-1-8 in conditions of elevated environmental temperature. When sweating is activated by heat, the sweat re-solubilizes DIPA-1-7 and DIPA-1-8 and enhances and perpetuates the sensory effect. This self-regulating feedback mechanism makes the effect of DIPA-1-7 and DIPA-1-8 more robust, efficacious, and prolonged.
- The delivery of the DIPA compounds can be achieved with the compound dissolved in a liquid vehicle, e.g., in water or saline, or a solution, a hydrogel, a lotion, on a swab, wet wipe, or as an aerosolized mist in a solid or semi-solid vehicle, e.g., a cream or an ointment. Gels are semisolid, jelly-like formulations with varying degrees of viscosity. A gel forms a solid three-dimensional network that spans the volume of a liquid medium. Gels are made with gelling agents that cross-link or associate with a liquid phase. Examples of gelling agents are: cellulose derivatives [methylcellulose, carboxymethylcellulose, hydroxylpropylcellulose; carbomers [carbopol®910, carbopol®941]; poloxamers [Pluronic®, Tween]; carbomer polymers, and natural polymers such as tragacanth, acacia, gelatin, sodium alginate, alginic acid, and xanthan gum. A single-phase system is a gelling agent plus an active ingredient that dissolves [in water] without visible particles and looks clear. A topical gel optimally liquefies when in contact with skin or mucous membranes. The compounds of
Formula 1 are attractive for delivery as gels because they dissolve in water and form a one-phase system at therapeutic concentrations. The methods for formulating topical gels are well-known to the art and extensively described in such sites in Lubrizol.com [a company that manufactures ingredients for cosmetics, personal care, skin care, and eye care]. - For a solid or semi-solid vehicle, a preferred concentration of the DIPA compound is 0.01 to 2.0% wt/vol. Unless otherwise stated, wt/vol is measured in units of g/cm3 or g/mL and so 0.01% wt/vol is obtained from 0.1 mg (0.0001 g) DIPA compound in 1 cm3 of composition; and 2% wt/vol is obtained from 20 mg (0.02 g) DIPA compound in 1 cm3 of composition.
- For a liquid vehicle, a preferred delivered volume is 0.02 to 0.15 mL. Such a volume, delivered for example as a lotion or a wipe, does not cause much residual liquid at the delivery site, as the liquid is absorbed.
- For a liquid vehicle, a preferred concentration of the DIPA compound is in the range of 0.5 to 30 mg/mL. For the orbit, a preferred concentration is 1 to 5 mg/mL. For the zygomatic and infraorbital skin, a preferred concentration is 5 to 10 mg/mL. For the forehead skin and scalp, a preferred concentration is 10 to 30 mg/mL.
- A preferred amount of the DIPA compound delivered at the site of application is 0.01 to 5 mg; for example, 0.1 to 5 mg.
- Wiping of the DIPA compound on the target skin can be done with pre-medicated wipes, which are well-known in personal care products, for example, to wipe a baby's skin after a diaper change, or to remove make-up on the face (e.g., Pond's 6″×8″ (15 cm×20 cm) Clean Sweep Cleansing and Make-up Remover Towelettes). Usually, these wipes are packaged as a single-use sealed unit or in a multi-unit dispenser. For single units, suitable wrapper materials are those which are relatively vapor impermeable, to prevent drying out of the wipe, and able to form a “peelable” seal. Examples of suitable wipe materials for practicing this discovery include polyamide (20% Nylon)-polyester, rayon (70%)-polyester (30%) formed fabric, polypropylene nonwoven, polyethylene terephthalate (PET), polyester polypropylene blends, cotton, viscose, rayon, or microfibers (synthetic fibers that measure less than one denier or one decitex).
- Alternatively, a solution containing a DIPA compound may be supplied in a reservoir bottle with individual applicators, or as a pre-packaged individual unit. For example, Puritan 803-PCL applicators are ideal cotton-tipped applicators attached to a 3-inch (˜7.5 cm) polystyrene rod for delivery of a DIPA compound onto the periorbital skin. Examples of how such applicators can be individually packaged are the SwabDose™ from Unicep Corporation (1702 Industrial Drive, Sandpoint, Id., USA), and the Pro-Swabs from American Empire Manufacturing (3828 Hawthorne Court, Waukegan, Ill., USA). Each applicator tip is saturated by dipping the absorbent material of the tip (e.g., 40 to 100 mg of cotton) in 0.1 to 1.5 mL of an aqueous solution of a DIPA compound and packaged in an individual container.
- For application to the face, the individual is instructed to gently apply the cream, lotion, gel, or wet wipe onto, or to spray, to the target facial skin with the eyelids shut, or other skin surface(s). The instructions for application may include teaching the individual to repeat application, or “topping up”, to ensure that sufficient composition is delivered to the target. Once the subject has learned what to expect, the individual can adjust the dosage (e.g., by dabbing at the medial or lateral edges of the orbit), as needed, to achieve the desired effect. It has been observed that individuals learn how to effectively apply the cooling agent after one or two trials and do so without risks of discomfort (e.g., eye discomfort).
- For application to the anogenital skin or other highly sensitive surfaces, the DIPA compound may be wiped or sprayed, for example, to deliver volumes of approximately 0.15 mL per unit. Alternatively, a dropper may be used with a wipe with an ultrasoft material such as 100% viscose or cotton.
- The peripheral sensory neurons express receptors and ion channels on their membranes and detect various stimuli. Stimuli (chemical or physical) are converted by the receptor to electrical signals which are transmitted to the central nervous system (brain) and become a sensation. These sensory receptors are transducers and the process is called transduction.
- DIPA compounds applied topically relieve heat stress and skin discomfort by evoking a sense of “dynamic cool” at sites of application. The feeling is of robust freshness, as if suddenly a fresh, cool breeze was blown on the skin (e.g., on the face) or cold water was splashed onto the skin. This effect especially with DIPA-1-7 is intense. This transduction process, receptor mechanisms, and the significance of dynamic cooling for anti-fatigue, anti-heat stress, and anti-pruritic actions are further discussed herein.
- Small myelinated (Aδ) and unmyelinated fibers (C fibers) increase afferent firing rate when skin temperature is lowered, for example, between 35° C. and 15° C. These neuronal signals that detect heat abstraction are transmitted to the central nervous system and generate conscious perception of coolness and cold. When skin temperature is raised from 35° C. and 40° C., firing rates are increased in C fibers and these fibers signal warmth [Hutchinson et al. Quantitative analysis of orofacial thermoreceptive neurons in the superficial medullary dorsal horn of the rat. J. Neurophysiol.77, 3252-66, 1997]. The receptive mechanisms and “cable lines” for cool/cold and warm are separate and distinct, but reciprocally inhibit each other in the brain and perhaps also in the periphery. The sensory receptors are modality specific and do not respond to mechanical stimulation. At the molecular level, the target binding sites for cooling agents are thought to be located on TRP ion channel receptors that depolarize in response to a drop in temperature. Heat abstraction decreases the threshold for discharge of the receptor, and the facilitated depolarization initiates the axonal responses that create the neuronal signal.
- The central response of these neurons has been recorded and studied from rat superficial medullar dorsal horn that responds to innocuous thermal stimulation of the rat's face and tongue [Hutchinson et al., 1997]. Step changes of −Δ5° C. stimulated cells with both static firing rates and cells that had mainly dynamic properties [Davies et al. Sensory processing in a thermal afferent pathway. J. Neurophysiol. 53: 429-434, 1985]. Similar studies in cats and humans showed that step decreases in temperatures (dynamic changes), as low as Δ0.5° C./second, were readily detectable by neurons and by psychophysical measurements [Davies et al. Facial sensitivity to rates of temperature change: neurophysiological and psychophysical evidence from cats and humans. J. Physiol. 344: 161-175, 1983].
- From a study of the spike patterns of neuronal discharge (impulses/second), it was clear that dynamic, and not static firing responses to a change in temperature were the most powerful stimuli for generating coolness/cold sensations That is, the brain “sees” −Δ° C./t and not absolute ° C. Thus, a cooling agent that simulates −Δ° C./t on nerve discharge will produce “dynamic cooling”.
- Dynamic cooling (versus static cooling/cold) is essential for a robust sensory effect. For example, if one is tired and driving a vehicle, turning on the air-conditioning and blasting the air onto the face will counteract fatigue [dynamic cooling]. But just turning on the air conditioner to lower ambient temperature and being chilled inside the vehicle [static cooling] will not make much of a difference. The benefits of the topical sensory therapy are illustrated by the Case Studies described herein.
- There is a general view that “TRP-” ion channel receptors (A1, M8, and V1 to 4) are the principal physiological elements for physiological temperature detection. The TRPM8 receptor is the one that responds to sensory/cooling agents such as menthol and icilin [McKemy et al. Identification of a cold receptor reveals a general role for TRP channels in thermosensation, Nature, 416, 52-58, 2002]. TRPM8 is a protein with 1104-amino acid residues and has six transmembrane domains. Activation of this receptor by lowering ambient temperature results in opening of pores of transmembrane loop and non-specific cation entry into the cell. Depolarization of TRPM8 receptors on sensory neurons may then transmit signals primarily via Aδ (and some C) fibres to the brain.
- While this concept for the role of TRPM8 in sensory physiology may be valid for physical changes in temperature, the interpretation of the sensory effects of chemical agents such as menthol and icilin are more complex. Menthol not only stimulates TRPM8 in vitro, but also TRPV3, a receptor associated with warmth and glycinergic transmission [Macpherson et al. More than cool: promiscuous relationships of menthol and other sensory compounds. Mol Cell Neurosci 32:335-343, 2006: Sherkheli et al., Supercooling agent icilin blocks a warmth-sensing ion channel TRPV3, Scientific World Journal, 2012; Cho et al. TRPA1-like channels enhance glycinergic transmission in medullary dorsal horn neurons. J Neurochem 122:691-701, 2012]. Thus, menthol and icilin are “promiscuous” cooling agents and their specific sensory effects may not be associated with any one particular receptor protein. A laboratory reagent specific and selective for TRPM8 will be valuable for experiment and is not currently available.
- The Applicant has screened a large database of cooling agents but, surprisingly, only the DIPA compounds produced super-robust dynamic cooling on skin. DIPA-1-8 and DIPA-1-9 also produces strong cooling and its actions are prolonged, but it does not quite have the super “wow” cooling effects of DIPA-1-6 and DIPA-1-7. Other cooling agents are less stimulating or have shorter durations of action and thus less suitable for the uses contemplated herein. Thus, the DIPA compounds, by contrast to menthol and icilin, are ideal selective reagents on TRPM8 function.
- It may be concluded that DIPA-1-7, DIPA-1-8, and DIPA-1-9 bind to a site on a voltage-gated ion channel receptor located on a nerve ending that is sensitive to a decrement in physical temperature. This event facilitates neuronal depolarization to a cooling/cold signal, and an action potential is transmitted via Aδ and C fibers towards the central nervous system. If the nerve ending is located on the facial skin, the signal is recordable from dorsal surface of the trigeminal nucleus in the brainstem. Further rostral transmission and integration of signals give rise to the perception of coolness/cold and its topographical association with the site of stimulation.
- When one examines the structure-activity relationships (SAR) of the DIPA compounds, it is noted that when R1═R2=isopropyl and R3═C6 to C9, then cooling is observed. Strong cooling of long duration is obtained with R3=n-octyl (C8). Refreshing cooling of long duration is obtained with R3=n-nonyl (C9). The special attribute of the n-nonyl analog is the absence of any burning/tingling sensations, even at high concentrations of 5% in water. By contrast, the sec-butyl containing analogs are much less potent. As shown in the studies described herein, this distinction between di-sec-butyl and di-iso-propyl compounds is also seen in animal studies on shaking behavior, an indicator of cooling actions in the rat (because shaking is inhibited by heat).
- The shaking behavior assay is manifested as a rapid alternating contraction of the supination and pronation muscles about the spinal axis, like a wet dog, can be readily observed and counted. All fur-coated and feathered animals—when wet and cold—shake, like a wet dog [Dickerson et al., Wet mammals shake at tuned frequencies to dry. J. Royal Society,
Interface 9, 3208-3218, 2012; Ortega-Jimenez, V. M. et al. Aerial shaking performance of wet Anna's hummingbirds. J. Royal Society,Interface 9, 1093-9, 2012; Wei, Pharmacological aspects of shaking behavior produced by TRH, AG-3-5, and morphine withdrawal, Federation Proc. 40: 1491-1496, 1981]. - “Wet-dog shaking” has been studied in detail in animals. Rats can shake their head, the upper torso, or the shaking can be sufficiently violent to affect the whole body and make the animal lose its balance. DIPA-1-7 and DIPA-1-8 elicit the vigorous type of shaking. The purpose or survival value of shaking to fur-coated and feathered organisms is to remove water droplets trapped on or near the skin. Removal of the water droplets on or near the skin by shaking reduces the organism's need to expend energy to remove the water by evaporation. The likely equivalent behaviour to shaking in humans is shivering, a condition caused by generalized sensations of coolness/cold. Human subjects recovering from the deep hypothermia of anaesthesia manifest vigorous shaking; a condition called post-anaesthetic shivering. Human subjects can also do a “wet shake” by deliberate effort when coming out of a swimming pool.
- Icilin (1-[2-hydroxy]-4-[3-nitrophenyl]-1,2,3,6-tetrahydropyrimidine-2-one) induces vigorous shaking in rats [Wei. Chemical stimulants of shaking behavior. J. Pharmacy and Pharmacology 28: 722-724, 1976], Surprisingly, two potent p-menthane carboxamide cooling agents [(R)-2-[((1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-propionic acid ethyl ester, and [((1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester], which have EC50 values similar to icilin at the TRPM8 receptor, do not evoke shaking (when injected at 50 mg/kg s.c. in male rats and observed for 1 hour. Icilin activation at the TRPM8 receptor is abrogated by a G805A mutation at the second to third transmembrane loop, but the effects of menthol are not affected. It is likely that DIPA-1-6, DIPA-1-7, and DIPA-1-8 also have specific sites of binding and activation on the TRPM8 receptor which are not shared by menthol or p-menthane carboxamides. Recent studies by Wei and Kuhn have shown that DIPA-1-6 and DIPA-1-7 are still active on TRPM8 receptors with the G805A mutation.
- Studies by Watson et al., 1978 [New compounds with the menthol cooling effect. J. Soc. Cosmet. Chem. 29: 185-200, 1978] show that a polar oxygen moiety capable of hydrogen bonding is an essential structural requirement for bioactivity. A Hückel molecular orbital calculation (using Molecular Modelling Pro v6.0.3, ChemSW Inc, Fairfield, Calif. 94534, USA) on the isopropyl analogs versus the sec-butyl analogues favours a slightly higher partial negative charge (0.007 e) on the oxygen in the sec-butyl entities, suggesting that the sec-butyl substituents facilitate a higher affinity of the oxygen to the hydrogen binding site of the receptor. Thus it is possible that isopropyl, with a “looser” affinity can associate and disassociate with the receptor more rapidly, favouring the generation of a dynamic onset and offset response of the receptor. This rapid interaction with the binding site will favour a more “dynamic” and intense stimulation of cooling and give rise to the phenomenon known as shaking.
- Another possibility is that DIPA-1-7 has a dual action on TRP receptors, so that it stimulates TRPM8 and, at higher concentrations, stimulates TRPV1. The dual action will give a cold-hot synergy that might lead to a more dynamic cooling sensation.
- TRPM8, TRPA1, and TRPV1 Receptor Assays TRPM8 is a nonselective cation channel activated by cold temperatures and cooling compounds such as menthol and icilin. Here, the in vitro effects of test compounds were evaluated on cloned hTRPM8 channel (encoded by the human TRPM8 gene, expressed in CHO cells) using a Fluo-8 calcium kit and a Fluorescence Imaging Plate Reader (FLIPRTETRA™) instrument. To examine the specificity of the test compounds, further tests were conducted on TRPV1 channels (human TRPV1 gene expressed in HEK293 cells) and TRPA1 channels (human TRPA1 gene expressed in CHO cells). The assays were conducted by ChanTest Corporation, 14656 Neo Parkway, Cleveland, Ohio 44128, USA.
- In a second set of experiments, cells, grown in culture, were seeded at an approximate density of 30,000 cells/well overnight, and loaded for ˜1 hr with 2 M Fura-2 (Molecular Probes, Leiden, The Netherlands), and then placed on glass coverslips. Test solutions were added with a micropipette positioned close to the cells. Emission intensity from cells was measured for 90 sec, at every 4 or 5 sec, using excitation wavelengths of 340 and 380 nm and an emission of 520 nm. Fluorescence emission intensity ratios at 340 nm/380 nm excitation (R, in individual cells) were recorded with a FlexStation and the ImageMaster suite of software (PTI, South Brunswick, N.J.). Samples were tested in triplicate at each concentration and the averaged values analyzed by non-linear regression using an a sigmoidal function fit of the points to obtain an estimated EC50 (median effective concentration) (GraphPad Prism software, La Jolla, Calif.).
- The receptor assays in vitro provide information of relative activity, but do not yield too much information.
- Ideally, an active pharmaceutical ingredient (API) formulated for delivery to the keratinized skin should be stable, non-toxic, and sufficiently long-acting and potent to activate the mechanisms that result in an anti-fatigue, anti-heat, or anti-nociceptive effect. The API should be dissolved and evenly dispersed in a composition so that during manufacture the formulation maintains a constant concentration. The final product should meet standards of cleanliness and sterility. For purposes of formulation, the API can be a liquid at standard conditions of temperature and pressure (STP) and that is evenly dissolved in aqueous solutions at neutral pH and/or isotonicity. Sterility of the final product can be optimally achieved by using purified reagents and filtration through micropore filters, heating, or irradiation. Standard excipients, such as emulsifying agents, isotonic saline, solvents, stabilizing agents, and preservatives, may be added to optimize the formulations, but the important ingredients should be preferably soluble in aqueous media such as purified water or a standard dermatological solvent.
- For a given individual, the perceived sensation is a function of the particular cooling agent, the dose, the vehicle used to carry the cooling agent, the method of topical delivery, and the nature of the target surfaces. The Applicant has screened a number of candidate compounds, such as p-menthane carboxamides, on the facial skin (Wei. Sensory/cooling agents for skin discomfort. Journal Skin Barrier Research 14: 5-12, 2012). The studies here identify DIPA compounds as having the preferred desired properties of an ideal anti-fatigue, anti-heat, and anti-nociceptive agent.
- To summarize, the design concepts for the selection of DIPA compounds are:
-
- The definition of a rationale for using a “dynamic cool” sensation on skin to relieve sensory discomfort and a description of the neurophysiology and receptor mechanisms of this action. This sensory effect in unusual and found in the DIPA compounds but not found with structurally similar compounds.
- Devising a delivery method for the ideal compound which exploits the water solubility of these analogs, and reduces the need to use excipients.
- Finding an ideal compound by experiment: DIPA-1-7, DIPA-1-8, and DIPA-1-9 are water soluble (a clear solution is obtained at up to 20 mg/mL in distilled water), stable to heat, and may exert a “robust cool” sensation for up to five to seven hours at an applied concentration of 1 to 10 mg/mL. Tachyphylaxis does not develop to repeat applications.
- Defining the receptor targets of these compounds in vitro, and conducting experiments to show the selectivity of the chosen DIPA.
- Defining an in vitro isolated nerve preparation that shows an anti-nociceptive action of DIPA-1-7 in a peripheral nerve, and showing that this effect is abrogated on the nerve from a TRPM8 knockout mouse.
- Defining an animal model (of “wet-dog shakes”) that will illustrate the “dynamic cool” properties and allow further study of mechanisms of action and the selective differentiation of various analogs.
- Conducting tests in human volunteers that show efficacy of the DIPA compounds for reducing skin dysesthesia caused by various dermatological disorders.
- Conducting tests in human volunteers that show DIPA compounds, especially DIPA-1-7, is effective for relieving sensory discomfort of the skin, and thus may be used as an anti-nociceptive or anti-pruritic agent to treat dermatological disorders.
- The DIPA compounds, when applied to keratinized skin, have sensory/cooling effects that mimic heat abstraction, but without a change in tissue temperatures. These compounds, can also penetrate the skin barrier, reach nerve endings in the epidermis and dermis, and enter the systemic circulation to exert cooling actions. These effects are obtained at small volumes, e.g., 0.1 to 0.5 mL, applied at a concentration of 1 to 20 mg/mL, or 0.1 to 2% wt/vol. The onset of effect is rapid, less than 5 minutes, and the sense of coolness is robust, refreshing, and strong. Compounds with similar bioactivity on the keratinized skin are not currently known or used in cosmetic or therapeutic applications. A number of new applications are possible with a molecule having such unusual properties.
- For conditions of increased sensations of perceived heat stress, DIPA-1-7 can be used, for example, to increase athletic performance, to counteract the discomfort of vasomotor symptoms, and to counteract the discomfort of inflammation. In normothermic conditions, DIPA-1-7 applied to the facial skin may be used to enhance cognition and to alert and increase vigilance. DIPA-1-7 may also be used as a diagnostic agent for cold allodynia and hyperalgesia, as a laboratory reagent to characterize TRPM8 functions, and as an adjunct in the formulations of numerous topical pharmaceuticals. Furthermore, DIPA compounds can be used for dermatological disorders.
- Thermal comfort is a technical term used by air-conditioning engineers to define “a state of mind in humans that expresses satisfaction with the surrounding environment.” Maintaining thermal comfort for occupants of buildings or other enclosures is one of the important goals of architects and design engineers. For most people, the room temperature for thermal comfort is 25° C. (77° F.). Careful studies have documented that work performance and productivity (output/input) drop by 2% for every increment of +1° C. above 25° C. up to 33° C. At office temperatures of 28-30° C. (82-86° F.), there is increased sweating and complaints of headache, drowsiness and dullness, difficulty in concentrating, and physical discomfort. For example, studies have shown that increasing the indoor air temperature of a call center from 25° C. to 26° C. decreased the call response rate from 7.79 to 7.64 calls/hr, a 1.9% loss [Tanabe et al., 2007]. An ambient temperature above 25° C. is thus a form of heat stress.
- Energy consumption of buildings in China account for at least one-quarter of the country's energy use, and sales of air-conditioning systems in Brazil and India are on an exponential increase. This rise in energy use has raised further concerns about global warming, but as most populations now work indoors, energy costs must be balanced against worker productivity. Basically, a worker's efficiency is better when he or she is kept cool. A method for combating mental lassitude from a hot environment, without incurring expenditures for energy, would have economic benefits. In the Case Studies describe herein, it was found that application of DIPA-1-7 to the facial skin of a student preparing for exams was useful in overcoming the discomforts of heat. The application of a DIPA-1-7 0.5% gel onto the facial skin, especially on the skin of the eyelids, and also on the skin of the neck, also provides relief from heat.
- It is a natural desire of humans to want to perform better, either physically or mentally. Recently, there has been an enthusiastic surge of interest in the use of cryotherapy to improve athletic performance. Cryotherapy is defined as “ . . . the lowering of tissue temperature (locally or generally) by the withdrawal of heat from the body to achieve a therapeutic objective . . . ” External pre-cooling by heat abstraction, for example, by immersion in ice or by wearing a vest packed with ice, can improve work endurance in a hot environment (see, e.g., Marino et al., 2002). An increase in physical work output of ˜5% can be shown for tasks of approximately 30 min [Grahn D A et al. Heat extraction through the palm of one hand improves aerobic exercise endurance in a hot environment. J Appl Physiol 99:972-978, 2005] Heat exhaustion limits work and this occurs when core body temperature approaches 40° C. (104° F.). Pre-cooling (or internal cooling, for example, by drinking an ice slurry) slows down the rate of heat accumulation.
- Surprisingly, the improvement in athletic performance can be attained by increasing the perception of coolness, without modifying core temperature. Investigators showed that trained marathon runners wearing a commercial cooling collar (Black Ice LLC, Lakeland Tenn.) extended the time to reach volitional exhaustion by 13.5% [Tyler et al. Cooling the neck region during exercise in heat. J. Athletic Training, 46, 61-68, 2011]. Cooling of the neck dampened the perceived level of thermal strain and delayed the point of voluntary termination of exercise. Participants tolerated a higher body temperature and heart rate when their neck regions were cooled.
- In several studies with menthol, a chemical that produces sensations of coolness without a change in skin or core temperatures, it was noticed that an increased perception of cooling, without a change in core body temperature, may also enhance better physical performance. This effect was unexpected and attributed to menthol being a “positive” placebo [Gillis D J et al. The influence of menthol on thermoregulation and perception during exercise in warm, humid conditions. Eur J Appl Physiol 2010; 110:609-618; Schlader et al. The independent roles of temperature and thermal perception in the control of human thermoregulatory behavior. Physiol Behav 103:217-224, 2011]. The surface of the face is densely innervated with nerve endings that detect temperature. The peripheral cool/cold detection system is associated with specific nerve fiber discharges and precisely regulated so ±1° C. is easily discriminated. Over 92% of thermoceptive units on the face, especially around the lips, respond to cooling and these neurons are tonically active at room temperature (see, e.g., Hutchison et al., 1997).
- It is likely than an agent such as DIPA-1-7 or DIPA-1-8, applied to the face, neck region, or chest will decrease heat discomfort and improve athletic performance.
- Flushing (vasodilation) and sweating occur on the body when the brain's thermoregulatory system perceives a need to lower body temperature. After menopause, at least one-third of women experience “hot flushes” (i.e., brief but repetitive episodes of feeling warm and flushed, and daytime and nighttime sweating). Replacement estrogens may alleviate symptoms but there are uncertainties if hormone replacement therapy (HRT) is safe. Sweating episodes that occur at night and in the early morning hours are especially inconvenient because the bed-sheets become wet and it is burdensome to change the bed-sheets on a daily or frequent basis. Episodes of “hot flushes/night sweats” can occur as often as on average 14 episodes per week. Aside from HRT, current alternative methods of therapy, such as yoga, acupuncture, and phytoestrogens, have limited if any effectiveness.
- The DIPA compounds are potent agents that can cross the skin barrier and be absorbed into the bloodstream and exert systemic effects. One possible method of treating vasomotor symptoms may be to topically administer DIPA-1-6 or DIPA-1-7 via a controlled-release patch. The systemic effects of the DIPA compound will then give rise to cooling sensations to counteract activation of central heat-loss mechanisms (vasodilatation and sweating). The patch may be applied at night to a convenient location of the body, e.g., the skin above the supraclavicular fossa or the skin above the sternomastoid muscle, and the released DIPA compound would then inhibit the “night sweats.” Alternatively, the DIPA compound (e.g., DIPA-1-5, DIPA-1-6, or DIPA-1-7) can be applied locally to the skin as a gel, lotion, or cream.
- The best population for studying the possible benefits of DIPA therapy would be breast cancer survivor who cannot receive HRT. This patient population has severe problems with hot flushes.
- Topical application of DIPA compounds on skin refresh and invigorate the psyche. These analogs were further evaluated for anti-itch (and other anti-nociceptive) effects on skin. As shown in the Case Studies described herein, a 20 mg/mL solution, applied with a cotton-tipped applicator potently stopped itching and discomfort caused by contact dermatitis in three individuals. A most surprising recent event was the discovery that these compounds can act on intact skin to stop the discomforts of urticaria. Another surprise was the utility of these compounds for treating the itch of liver disease and cholestasis. The DIPA-1-7 was also effective against milaria rubra (prickly heat), and against a recalcitrant case of prurigo nodularis (a form of chronic atopic dermatitis). These results were surprising because there are no topical medications that work quickly against these conditions, especially urticaria and cholestatic itch.
- A topical medication that can relieve skin discomfort has many applications in dermatological disorders including:
-
- a) alleviation of irritation, itch and pain from various forms of dermatitis (atopic dermatitis, contact dermatitis, and irritant dermatitis, various forms eczema);
- b) itch and discomfort from skin infections, insect bites, sunburn, photodynamic treatment of skin (e.g., actinic keratoses, basal cell carcinoma), lichen sclerosus;
- c) pruritus due to xerosis [especially dry skin itch of the elderly], psoriasis, or seborrheic dermatitis;
- d) pruritus ani, hemorrhoidal discomfort, pain from anal fissures, pain or itch from anal fistulas, pain from hemorrhoidectomy, perineal inflammation, anogenital skin inflammation and discomfort due to various local causes such as incontinence, diaper rashes, prickly heat rash, and perineal inflammation;
- e) pain from burned, traumatized, diseased, anoxic, or irritated skin (e.g., skin damaged by laser surgery, diabetic ulcers, sunburn, radiation), and from procedures related to wound debridement and wound healing;
- f) stomatitis, cheilitis, itching of the lips from cold sores or gingivitis;
- g) vulval pruritus and pain (e.g., from candidiasis or idiopathic, such as vulva vestibulitis and vulvodynia), dyspareunia, anogenital infections, including warts and sexually transmitted diseases, fungal infections, viral infections of the skin (especially in immunocompromised patients);
- h) nostril and nasal or upper airway discomfort from breathing obstruction, e.g., congestion, rhinitis, asthma, bronchitis, emphysema and chronic obstructive pulmonary diseases, dyspnea, sleep apnea and snoring; and
- i) conjunctivitis, ocular surface irritation, pain from trauma and corneal abrasions, and pain from eye surgery.
- Of special interest, is the use of DIPA-1-7 and DIPA-1-8 for scalp itch, e.g., in seborrheic dermatitis and psoriasis; these end-points being unmet medical needs. DIPA-1-7 may also be used to refresh the skin before application, or after removal of, cosmetics from the skin, to reduce the irritant effects of benzoyl peroxide in the treatment of acne, and to reduce sebum secretion and the appearance of an “oily” skin.
- Itch (also called pruritus) is the sensation that causes the desire or reflex to scratch. Itch can be quite intense, and evokes obsessive behavior. For example, I have seen a person scratch his ankles until it bleeds because of the itch caused by insect bites (midges or sand flies). Scratching may have survival value because it rids fur-coated animals of parasites and insects on skin, but for humans excessive scratching exacerbates skin damage in dermatological disorders. That is, scratching injures the skin and the injury provokes more itch and scratching, a phenomenon called the “itch-scratch cycle”.
- MacDonald et al. has proposed a mechanism by which the itch-scratch cycle exacerbates tissue injury (Acta Dermato-Venereologica 97 (8): 1010, 2017). He stated that double-stranded RNA released from injured keratinocytes stimulates TOLL-3 receptors to generate more cytokines and chemokines, and thus inflammation is enhanced and perpetuated.
- An anti-itch molecule may therefore not only provide symptomatic relief but also have a more subtle disease-modifying therapeutic effect in disorders such as atopic dermatitis wherein itch is localized and the itch-scratch cycle is a vicious contributor to the pathology of excoriations and lichenification. The irritated skin thickens and becomes chronically inflamed and fragile because of scratching, and is likely to breakdown with more scratching and rubbing. The ability to add a break to scratching is not restricted only to atopic dermatitis but also applicable to other dermatological disorders such as seborrheic dermatitis, acne or acneiform eruptions. Here, for example, the acne lesion is an inflammatory disorder of the sebaceous glands in the skin, and the subject picks and squeezes the lesions constantly. The mechanical damage to the inflamed skin aggravates the underlying tissue reactions. If a break can be applied to the tissue manipulation, then the lesion is given time to heal more quickly.
- Itch prevents a good night's sleep and an atopic dermatitis patient will scratch themselves vigorously even when asleep. An effective medication should prevent itch within minutes after application and act sufficiently long to allow the subject to go to sleep. The subject should be instructed to apply the medication after washing, to use on an as-needed basis, and to apply thoroughly at night at sites of itch before sleep, because scratching can take place after the subject is asleep. This is especially important for children because the desire to scratch is instinctive and automatic, but will also damage the skin.
- In pharmaceuticals or cosmeceuticals, the term “adjunct” is an additional substance, treatment, or procedure used for increasing the efficacy or safety of the primary substance, treatment, or procedure or for facilitating its performance. The DIPA compounds relieve sensory discomfort of the skin, have anti-nociceptive activity, and are active at less than 1 minute after application. They are ideal adjuncts for pharmaceuticals and for cosmetics applied to the skin.
- If the primary substance is an irritant, the adjunct may be used to decrease irritancy, and hence improve patient tolerance and compliance. For example, an adjunct such as DIPA-1-7 can be added an anti-acne preparation containing benzoyl peroxide. Benzoyl peroxide, the primary substance, works as a skin peeling agent, increases cell turnover, and reduces P. acnes, but it is an irritant and can cause burning, swelling, and pain when applied to the skin. Similarly, imiquimod (Aldara®), which is used as a primary substance to treat genital warts and skin cancer can cause blistering and pain, and an adjunct such as DIPA-1-7, DIPA-1-8 or DIPA-1-9 may increase patient acceptance and compliance in the use of this drug.
- An adjunct such as DIPA-1-7 may be used to increase the “apparent” efficacy of another primary ingredient, and thereby improve patient satisfaction and adherence to a dosage schedule. For example, DIPA-1-7 at about 0.5 to 2%, stops itching within minutes after application. If combined with an anti-inflammatory steroid, the preparation may be more desirable than the anti-inflammatory steroid alone, which takes longer to act. Anti-inflammatory steroids, such as hydrocortisone, triamcinolone, and clobetasol are used for sensory discomfort of the skin in disorders such as insect stings, contact dermatitis, atopic eczema, and psoriasis. The presence of DIPA-1-7 as an adjunct, in addition to helping to stop the itch, may help reduce the dose or the frequency of application of the primary ingredient, yet achieve an equivalent therapeutic effect. This adjunct benefit will be especially beneficial in the use of skin steroids because of the well-known undesirable effects of collagen degradation, tissue thinning, and increased susceptibility to infections. An adjunct that reduces dosage or promote greater efficacy of the primary ingredient has value. Other primary anti-pruritics are aluminum acetate, and strontium chloride or strontium nitrate.
- For skin disorders, compositions of the present discovery may also be used as adjuncts for procedures such as phototherapy, laser therapy, cryotherapy, or UV-therapy of the skin.
- Pharmaceuticals that may be used, in combination or in sequence with adjunct DIPA compounds include anti-inflammatory steroidal agents, anti-inflammatory analgesic agents, antihistamines, sympathomimetic amine vasoconstrictors, local anesthetics, antibiotics, anti-acne agents, topical retinoids, drug for genital warts and skin cancer, drugs for wrinkles and ageing skin, anti-hemorrhoidal agents, drugs for vulvar itch, drugs to stimulate hypertrichosis, skin moisturizers, and agents for keratolysis.
- Examples of steroidal anti-inflammatory agents include hydrocortisone, clobetasol, clobetasol propionate, halobetasol, prednisolone, dexamethasone, triamcinolone acetonide, fluocinolone acetonide, fluocinonide, hydrocortisone acetate, prednisolone acetate, methylprednisolone, dexamethasone acetate, betamethasone, betamethasone valerate, flumetasone, fluticasone, fluorometholone, beclomethasone dipropionate, etc.
- Examples of anti-inflammatory analgesic agents include methyl salicylate, monoglycol salicylate, aspirin, indomethacin, diclofenac, ibuprofen, ketoprofen, naproxen, pranoprofen, fenoprofen, sulindac, fenclofenac, clidanac, flurbiprofen, fentiazac, bufexamac, piroxicam, pentazocine, etc.
- Examples of antihistamines include azelastine hydrochloride, diphenhydramine hydrochloride, diphenhydramine salicylate, diphenhydramine, chlorpheniramine maleate, promethazine hydrochloride, etc.
- Examples of sympathomimetic amine vasoconstrictors include phenylephrine hydrochloride, oxymetazoline, naphazoline, and other imidazoline receptor agonists used for nasal decongestant activity and for redness and vasodilatation on the ocular surfaces.
- Examples of skin moisturizer ingredients include the three categories of humectants, emollients and preservatives. Humectants, such as urea, glycerin and alpha hydroxy acids, help absorb moisture from the air and hold it in the skin. Emollients, such as lanolin, mineral oil and petrolatum, help fill in spaces between skin cells, lubricating and smoothing the skin. Preservatives help prevent bacteria growth in moisturizers. Other ingredients that moisturizers may contain include vitamins, minerals, plant extracts and fragrances.
- Example of an agent for hypertrichosis is bimatoprost.
- Preliminary toxicological studies were conducted on DIPA 1-7. It was not mutagenic in the Ames test (Strains TA 98 and TA100, with and without liver activation) (tests conducted by Apredica, Watertown, Mass., USA).
- DIPA-1-7, dissolved in 3% ethanol/97% 1,2-propanediol, or vehicle alone, was administered at 20 mg/kg perioral for 7 days (n=10 per group) to male rats, and on the 8th day, the animals were euthanized with sodium pentobarbital and the major organs (body, heart, liver, lungs, kidney, testes, brain) were removed and weighed. Heart tissues (ventricle and heart valves) and liver samples were stained with hematoxylin and eosin and the histology examined. There was no significant difference in body or organ weights between the two groups and the heart and liver histology were normal.
- The compounds of the present discovery simulate the sensations of heat abstraction, but do not alter tissue temperatures. The average forehead skin temperature of subjects (N=5) was measured following application of DIPA-1-7 (with a wipe at a concentration of 20 mg/mL in distilled water) to the forehead skin. The results are summarized in Table 5. The subjects noted the cooling effect of DIPA-1-7 on the skin which lasted for 30-45 minutes; however, skin temperatures were not affected.
-
TABLE 5 Skin temperatures of human forehead after DIPA-1-7, 20 mg/mL. Temperature (° C.) Time Control DIPA-1-7 Before 37.3 37.4 0 minutes 37.2 37.4 15 minutes 37.5 37.5 30 minutes 37.1 37.1 45 minutes 37.4 37.2 60 minutes 37.0 37.1 - Study 3
- Sensory Effects of Compounds on Facial Skin
- When a test compound is applied to the skin, it is possible to characterize the resulting sensations. The quality of the sensations produced by individual compounds favours certain characteristics that are distinct. The quality of the sensations evoked, their descriptors, and their proposed mechanism of action, are summarised in Table 6. For any compound, there may be some overlap in activity, but usually one compound occupies only one or two categories of sensations. For example, icilin is exclusively cool, with very little “cold”. DIPA-1-6 and DIPA-1-7 are exceptional in producing pleasant, robust “dynamic cool.” DIPA-1-8 and DIPA-1-9 are strong cold-producing agents.
-
TABLE 6 Descriptor and proposed mechanisms of DIPA compounds on skin. Proposed Mechanisms on Type of Sensation Descriptor Sensory Neurons Inactive No effect — Cool, steady and pleasant Cool Balanced stimulation of static and dynamic Cold, constant, but limited Cold Higher stimulation of static by desensitization Dynamic cooling, robust Dynamic Higher stimulation of dynamic cool/cold, strong refreshing cool Stinging cold, sometimes Icy cold Stimulation of dynamic and with irritation static, and also nociceptive sites - Even after the offset of the cooling/cold action, some of the compounds have a “reservoir effect.” Experimentally, this is measured 1 hour after offset by placing a hot and then a cold towel over the site of application and determining if the onset of cooling/cold returns for at least 30 minutes. If this occurs, then there is a positive “reservoir effect”. The “reservoir effect” can also be provoked with air movement, but the conditions for air movement are difficult to standardize. The “reservoir effect” of DIPA-compounds in skin is most likely due to residual drug that is reactivated to stimulate dynamic/static sensory neurons.
- In the studies described herein, the sensation of coolness/cold is rated as 0, 1, 2, or 3 with: 0 as no change; 1 as slight coolness, or cold; 2 as clear-cut signal of coolness or cold; and 3 as strong cooling or cold. The sensations are recorded at intervals of 5 to 15 minutes, until at least two successive zeroes are obtained.
- The onset of drug action is taken as the time to reach 2 units of coolness intensity.
- The duration of sensory action is defined as the offset time minus the onset time. The offset of drug action is defined here as the time when coolness intensity drops below 2, after previously surpassing 2 units. An inactive compound is defined as one that does not exceed 2 units of cooling for 5 minutes or more after application. The offset endpoint is sometimes unstable for compounds that act for two or more hours, because the coolness/cold sensation may fluctuate due to environmental variables such as sunlight, ventilation, activity, and the “reservoir effect.” For example, DIPA-1-8 and 2-8 are exceptionally long-acting on the skin.
- The effects of test compounds on facial skin were determined. Compounds were tested on zygomatic. Test compounds were applied to the skin of the zygomatic using cotton gauze (0.4 g, rectangular, 50 mm×60 mm; from CS-being, Daisan Cotton, Japan). The test compounds were used at a concentration of 20 mg/mL in distilled water. The onset and duration of the sensory effect was measured with a stopwatch. The degree of “dynamic cool” was graded from 0 to +++, with intermediate steps of + and ++. An anti-fatigue effect was present only if there was sufficient “dynamic cool.” The results are summarized in Table 7 & 8.
-
TABLE 7 & 8 Sensory effects after application to zygomatic and forehead skin. Car- Re- bon Onset Sensory Anti- Duration servoir Code R3 atoms (min) Quality Fatigue (hr) Effect DIPA-1-5 5 11 ~1 dynamic 0 0.5 No DIPA-1-6 6 12 ~1 dynamic ++ 1.3 Yes DIPA-1-7 7 13 ~1 dynamic- +++ 3.2 Yes icy DIPA-1-8 8 14 ~1 cold-icy ++ 4.0 Yes DIPA-1-9 9 15 ~2 cool 0 2.0 No 2-4 4 12 ~1 cool 0 0.3 No 2-5 5 13 ~1 cool 0 1.1 Yes 2-6 6 14 ~2 cold + 1.5 Yes 2-7 7 15 ~2 cold + 2.4 Yes 2-8 8 16 5 cold 0 5.6 Yes - Each of 3-1 and 3-2 was also tested and found to be inactive on periorbital, and zygomatic/forehead skin.
- For further comparisons, the newly synthesized “mixed” 1-isopropyl-sec-butyl-phosphorylalkanes (3,4-6, 3,4-7, 3,4-8 and 3,4-9) were tested on zygomatic skin (
FIG. 1 ). The test procedures were modified because of the limited quantities of these analogs. To deliver the solution to the skin, a 80%-polyester-20%-viscose rayon wipe was cut into squares (7×8 cm, 0.45 g each) and a precise volume (2.5 mL) of test solution is added to the wipe using a dropper bottle. Delivery and scoring of effect. An average 74±2 μL volume containing the test ingredient was wiped onto the receptive fields of the nerves on the zygomatic process (cheek-bone). As before, the sensory effects of cool/cold were recorded at 5 and 10 min intervals. Quarter and half point scores are allowed. Scoring is stopped when two zeroes are observed in a 10 min interval. At least four trials are conducted for each concentration with two to three volunteer test subjects for each compound. - Results from the testing of DIPA-1-8 at three concentrations is shown in
FIG. 2 . -
FIG. 2 . shows the cooling sensations evoked by topical wiping of different concentrations of DIPA-1-8 onto the skin above the zygomatic process. The cooling activity can be measured as the intensity/duration area-under-curve (AUC) or as time for half maximal effect (T-1/2), using software of the GraphPad Prism package. The graph shows the AUC dose-response curve for the compound DIPA-1-8 applied at 0.5, 1 and 2% (5, 10, and 20 mg/mL dissolved in distilled water). - A comparison of the DIPA diisopropyl analogs (3,3-X) versus the mixed propyl-sec-butyl analogs (3,4-X) are shown in
FIG. 3 . Statistical significant difference (P<0.01) are seen between 3,3-x and the asymmetrical chiral 3,4-x analogs. The 3,4-8 and 3,4-9 formed a milky/small oil droplet emulsion at 20 mg/mL. - Notably, DIPA-1-7 selectively produced the unusual sensation of “dynamic cool” and also had anti-fatigue effects. From the data shown above, it can be seen that, among these compounds, DIPA-1-7 evoked “dynamic cool” on both periorbital and zygomatic/forehead surface. Another compound with similar properties was DIPA-1-8, but this compound is was more cold/icy cold, although it had the desirable property of a longer duration of action on the zygomatic/forehead surface. The long duration of action of DIPA-1-7 and DIPA-1-8 on the skin adds value as an anti-fatigue agent, especially for the fatigue of chronic illness. As shown in the case studies described below, a single application of DIPA-1-7 is sufficient to counteract fatigue and heat stress for at least three to four hours.
- A special value of DIPA-1-9 is the comfortable cooling it provides and its long duration of action after zygomatic and periorbital application, and the absence of any stinging. Thus, it has a special therapeutic niche for the relief of skin discomfort.
- The results here for the selective attributes of DIPA-1-7 and DIPA-1-8 are unexpected, surprising, and has practical applications for counter-acting fatigue and anti-nociception. A special value of DIPA-1-9 is the comfortable cooling it provides and its long duration of action after periorbital application, and the absence of any stinging. Thus, it has a special therapeutic niche for the relief of ocular discomfort.
- The in vitro effects of a first set of test compounds (Table x) were evaluated on cloned hTRPM8 channel (encoded by the human TRPM8 gene, expressed in CHO cells) using a Fluo-8 calcium kit and a Fluorescence Imaging Plate Reader (FLIPRTETRA™) instrument. The assays were conducted by ChanTest Corporation (14656 Neo Parkway, Cleveland, Ohio 44128, USA).
- Test compounds and positive control solutions were prepared by diluting stock solutions in a HEPES-buffered physiological saline (HBPS) solution. The test compound and control formulations were loaded in polypropylene or glass-lined 384-well plates, and placed into the FLIPR instrument (Molecular Devices Corporation, Union City, Calif., USA). The test compounds were evaluated at 4 or 8 concentrations with n=4 replicates per determination. The positive control reference compound was L-menthol, a known TRPM8 agonist. The test cells were Chinese Hamster Ovary (CHO) cells stably transfected with human TRPM8 cDNAs.
- For FLIPRTETRA™ assay, cells were plated in 384-well black wall, flat clear-bottom microtiter plates (Type: BD Biocoat Poly-D-Lysine Multiwell Cell Culture Plate) at approximately 30,000 cells per well. Cells were incubated at 37° C. overnight to reach a near confluent monolayer appropriate for use in a fluorescence assay. The test procedure was to remove the growth media and to add 40 μL of HBPS containing Fluo-8 for 30 minutes at 37° C. 10 μL of test compound, vehicle, or control solutions in HBPS were added to each well and read for 4 minutes.
-
- Concentration-response data were analyzed via the FLIPR Control software that is supplied with the FLIPR System (MDS-AT) and fitted to a Hill equation of the following form:
-
- where: “Base” is the response at low concentrations of test compound; “Max” is the maximum response at high concentrations; “xhalf” is the EC50, the concentration of test compound producing half-maximal activation; and “rate” is the Hill coefficient. Nonlinear least squares fits were made assuming a simple one-to-one binding model. The 95% Confidence Interval was obtained using the
GraphPad Prism 6 software. The results are summarized in Table 9. -
TABLE 9 EC50 and relative potency of compounds on TRPM8.. 95% Confidence Relative Code EC50 μM Interval Potency Menthol 3.8 2.5 to 5.6 1.0 DIPA-1-5 5.6 4.4 to 7.2 0.7 DIPA-1-6 2.4 1.5 to 4.0 1.6 DIPA-1-7 0.7 0.5 to 1.0 5.4 DIPA-1-8 0.7 0.5 to 1.0 5.4 DIPA-1-9 0.9 0.4 to 2.5 4.0 2-4 14.5 7 to 29 0.3 2-5 1.7 1.0 to 2.9 2.2 2-6 0.8 0.5 to 1.3 4.7 2-7 1.1 0.6 to 2.3 3.4 2-8 1.3 0.7 to 2.3 2.9 3-1 24 8 to 76 0.2 3-2 4.2 1.6 to 10.8 0.9 - Of the 12 compounds tested, all showed full efficacy on the TRPM8 receptor, i.e., at higher tested concentrations there was ˜100% stimulation of calcium entry, and the data fitted a sigmoidal dose-response curve. The results for the “di-isopropyl” compounds of this invention are illustrated in
FIG. 3 . -
FIG. 3 is a graph of response (Relative Fluorescence Units; % of maximum) as a function of the logarithm of the concentration of the test compound (denoted agonist), expressed in μM, for each of DIPA-1-5 (circles), DIPA-1-6 (squares), DIPA-1-7 (inverted triangle), DIPA-1-8 (diamonds), or DIPA-1-9 (up-right triangle). - The EC50 of the more potent compounds (DIPA-1-7, DIPA-1-8, DIPA-1-9, 2-5, 2-6, 2-7, 2-8) fell within a narrow range with overlapping 95% Confidence Intervals. The potency of DIPA-1-7, DIPA-1-8, and DIPA-1-9 are similar and significantly greater than the potencies of DIPA-1-5 and DIPA-1-6. By contrast the structural modifications of comparative compounds 3-1 and 3-2 resulted in a significant loss of bioactivity
- To examine the specificity of the test compounds, further studies were conducted on TRPV1 channels (human TRPV1 gene expressed in HEK293 cells) and TRPA1 channels (human TRPA1 gene expressed in CHO cells). The test cells were Chinese Hamster Ovary (CHO) cells or Human Embyronic Kidney (HEK) 293 cells transfected with human TRPV1 or TRPA1 cDNAs. The positive control reference compound was capsaicin (a known TRPV1 agonist) or mustard oil (a known TRPA1 agonist). DIPA-1-7 and DIPA-1-8 did not exhibit any agonist on antagonist activity on TRPA1 channels at maximum tested concentrations of 100 μM. A weak TRPV1 agonist activity was found for DIPA-1-7, but this was not dose-dependent.
- In bioactivity studies, potency was not correlated to the TRPM8 EC50. For example, DIPA-1-5 and DIPA-1-6 are more potent in producing shaking behavior than DIPA-1-7 and DIPA-1-8 [see Study 6]. There were no distinguishing features in the TRPM8 EC50 data which enabled prediction of which compounds have potent “dynamic cool” properties in vivo.
- Further tests were conducted on “mixed” isopropyl-sec-butylphosphorylhexane and heptane analogs. The data were collected by Andersson et al. of King's College, London, UK, using his methods described in “Modulation of the cold-activated channel TRPM8 by lysophospholipids and polyunsaturated fatty acids. Journal Neuroscience 27 (12): 3347-3355, 2007. Here, the cellular entry of the calcium-sensitive dye Fura-2 was used to study the effect of the test compounds on TRPM8 expressed in Chinese hamster ovary cells. Cells, grown in culture, were seeded at an approximate density of 30,000 cells/well overnight, and loaded for ˜1 hr with 2 M Fura-2 (Molecular Probes, Leiden, The Netherlands), and then placed on glass coverslips. Test solutions were added with a micropipette positioned close to the cells. Emission intensity from cells was measured for 90 sec, at every 4 or 5 sec, using excitation wavelengths of 340 and 380 nm and an emission of 520 nm. Fluorescence emission intensity ratios at 340 nm/380 nm excitation (R, in individual cells) were recorded with a FlexStation and the ImageMaster suite of software (PTI, South Brunswick, N.J.). Samples were tested in triplicate at each concentration and the averaged values analyzed by non-linear regression using an a sigmoidal function fit of the points to obtain an estimated EC50 (median effective concentration) (GraphPad Prism software, La Jolla, Calif.).
- The potency of three analogs for activation of TRPM8 (cooling receptor) in transfected cells is shown in
FIG. 4 . The units (Δ ratio) on the ordinate measures entry of fluorescent calcium probes into transfected cells. -
FIG. 4 . is a graph of fluorescence response (Δ ratio 340/380) in TRPM8 transfected cells as a function of the logarithm of the concentration of the test compound, expressed in μM, for DIPA-1-7 (black circle), 3,4-7 (open squares), or 3,4-6 (open triangles). The assays were conducted by Andersson et al. of King's College, London, UK, using his methods described in “Modulation of the cold-activated channel TRPM8 by lysophospholipids and polyunsaturated fatty acids. Journal Neuroscience 27 (12): 3347-3355, 2007. - The 3,3-7 (DIPA-1-7) is substantially more potent (˜10× and ˜5×) than 3,4-6 and 3,4-7. Note that 3,4-6 and 3,4-7 species do not reach the same degree maximal efficacy on activation of the receptor, even at supra-maximal concentrations.
- From these results, it appears that the EC50 values do not give information on the quality of the heat abstraction sensation, the duration of action, or the accessibility of the molecule to tissue targets. The identification of selective agents requires bioassays that more directly address these questions.
- To determine if DIPA-1-7 acted directly on sensory nerves, it was tested in an isolated nerve model developed at the Imperial College, London, U.K. [Birrell et al. TrpA1 agonists evoke coughing in guinea pig and human volunteers. Amer. J. respiratory and critical care medicine 180, 1042-7, 2009; Patel, H. J. et al. Inhibition of guinea-pig and human sensory nerve activity and the cough reflex in guinea-pigs by cannabinoid (CB2) receptor activation. Brit. J. Pharmacol. 140, 261-8, 2003]. In this in vitro assay, segments of the mouse vagus nerve are placed on a platform and the electrical activity is recorded after topical application of capsaicin. Capsaicin is a known irritant that elicits pain when it is applied to the skin and it will depolarize the isolated vagus. The ability of substances to inhibit this capsaicin-induced depolarization is measured.
- Briefly, segments of vagus nerve, caudal to the nodose ganglion, were removed from mice with fine forceps and segments placed in oxygenated Krebs solution and bubbled with 95% O2/5% CO2. The desheathed nerve trunk was mounted in a ‘grease-gap’ recording chamber and constantly superfused with Krebs solution with a flow rate of approximately 2 mL/min, and the electrical activity of the nerve monitored with electrodes. The temperature of the perfusate was kept constant at 37° C. by a water bath. Nerve depolarizations were induced by superfusion of the nerve with capsaicin (1 μM). After two reproducible depolarization responses to capsaicin, DIPA-1-7 was applied at 1 mg/mL (4 μM) for 10 minutes in the perfusate followed by capsaicin. The nerves were then washed with Krebs until the responses had returned to baseline and challenged again with capsaicin. The results and tracings obtained in normal and TRPM8 knockout mouse are shown in
FIG. 5 . -
FIG. 5 shows chart traces that illustrate, in the first trace (“Wild Type”), the inhibition of capsaicin-induced depolarization of the isolated mouse vagus by DIPA-1-7, superfused at a concentration of 1 mg/mL, and, in the second trace (“TRPM8 KO”), the significant absence of inhibition in the isolated TRPM8 KO (knockout) mouse vagus by DIPA-1-7, superfused at a concentration of 1 mg/mL. - In the tracings shown in the
FIG. 5 , the first two peaks show the depolarization response of the mouse vagus to capsaicin (“Caps”). After DIPA-1-7 is applied (1 mg/mL), the response is suppressed in the normal mouse vagus (“Wild Type”), but not in the TRPM8 knock-out (“TRPM8 KO”) mouse vagus. - The percent inhibition of capsaicin-induced depolarization of the isolated normal mouse vagus caused by DIPA-1-7 was about 75%; the percent inhibition of capsaicin-induced depolarization of the isolated TRPM8 knock-out mouse vagus caused by DIPA-1-7 was about 20%.
- This experiment clearly demonstrates a direct peripheral pharmacological action of the DIPA-1-7 on the sensory nerve, which is a surprising and unexpected result. Normally, one thinks of cold transduction gating the nociceptive signals in the central nervous system. That is, coolness felt in the brain inhibits the perception of pain and discomfort in the brain. Here, we find a direct peripheral mechanism of action, suggesting that transduction of the pain signal is impaired by DIPA-1-7 in the peripheral nerve. Furthermore, the diminished response in the TRPM8 KO mouse indicated that the receptor target was TRPM8. These results provide strong evidence that DIPA-1-7 can be used as a peripheral anti-nociceptive agent and the target receptor is TRPM8.
- Capsaicin is a TRPV1 agonist and the search for an effective TRPV1 antagonist has been the super-intense quest of many pharmaceutical companies for the past ten or more year. Here, it is shown that DIPA-1-7 is an effective “physiological” antagonist of TRPV1 at low concentrations. DIPA-1-7, by itself, did not evoke depolarization, indicating that it is free of agonist activity at this “pain” receptor. These results strongly indicate the usefulness of DIPA-1-7 as an anti-nociceptive agent.
- Fur-coated and feathered animals—when wet and cold—shake, like a wet dog (see, e.g., Dickerson et al., 2012; Ortega-Jimenez et al., 2012; Wei, 1981). These shakes are rapid alternating contractions of the supination and pronation muscles about the spinal axis, and can be readily observed and counted. “Wet-dog shaking” has been studied in detail in animals and this behaviour is interpreted to have survival value because shaking, by removing the water off the skin, reduces the need to expend evaporative energy to remove wetness. The triggering sensation for shaking is thus having water trapped in between hair follicles or feathers. Humans have little hair on skin and normally do not shake, but this wet shaking can be mimicked by some individuals who exit a cold swimming pool. The likely equivalent behaviour to shaking in humans is shivering, a condition caused by generalized sensations of coolness/cold and wetness.
- Drug-induced shaking in animals has been reviewed (see, e.g., Wei, 1981). Under the right conditions, drug-induced shaking can be observed in the pentobarbital-anesthetized rat, enhanced by hypothermia and cold, and inhibited by elevating body temperature.
- Test compounds were evaluated for “wet-dog shaking” as a model of dynamic cooling. Using a standardized procedure, test compounds were compared in their ability to stimulate the shaking response by perioral administration and by topical delivery to the abdominal skin
- Perioral. Test compounds were dissolved in saline and administered by oral gavage to pentobarbital-anesthetized male albino rats at 20 mg/kg at a volume of 0.1 mL/100 g body weight [N=3 to 4 rats per compound]. Shaking was counted over a 40 min period and recorded at 10-min intervals.
- Three of the four “di-isopropyl” compounds caused vigorous shaking. The “di-sec-butyl” compounds were relatively inactive, except 2-5 which elicited an average of 4 shakes in the 40 min observation period. By contrast, DIPA-1-5, DIPA-1-6, and DIPA-1-7 produced an average shaking frequency of 86, 56, and 36 shakes, respectively. The strong activity of DIPA-1-5 was unusual. Applied to the skin, DIPA-1-5 has a refreshing “dynamic cool”, but the duration of action of only about 30 min was significantly less than that for DIPA-1-6 and DIPA-1-7. The shorter duration of action of DIPA-1-5 limits its practical utility. It is possible that its smaller molecular size facilitates absorption and allows greater access to systemic receptors, and therefore more shaking.
- The relationship of the shake response to temperature sensation was further studied [in pentobarbital-anesthetized rats]. After injection of the anesthetic, rectal temperature drops, and reaches approximately 35° C. in about 10 min. This hypothermia can be reversed by placing the animal on a heated surface and body temperature maintained at 38° C. DIPA-1-7 20 mg/kg perioral elicited 36±5 shakes (N=6) in the anesthetized rat, but in the heated animals, the shaking frequency was significantly reduced to 5±2 shakes (N=6) [P<0.001]. The reduction of shaking frequency by ⅔ under heat indicated that the shake response was linked to cold sensations and shivering.
- Topical. Shaking is an excellent indicator of in vivo effect. Methods were developed to determine if shaking was seen after topical application of DIPA compounds. The abdominal skin of the pentobarbital-anesthetized rat was shaved and 20 μL of the pure unadulterated DIPA chemical was applied with a micropipette on a ˜1 cm diameter circle of skin, enclosed with a ring of cream [Baby cream “Nevskaya kosmetika Detskyi” Nevskaya Kosmetika Inc., Saint-Petrsburg 192029], as shown in the
FIG. 6 . The number of shakes was counted for 1 hr after application. -
FIG. 6 shows the method for measuring the transdermal activity of DIPA-compounds applied 20 μL with a micropipette to the center of a circle enclosed by cream on the abdominal skin of an anesthetized rat. Shaking frequency was counted for 1 hr after topical application. The data and results for topical for perioral responses are summarized in the Table 10. The data are further plotted graphically inFIG. 6 , to show the lack of correlation of TRPM8 potency to in vivo bioactivity. - The data in Table 10 and
FIG. 6 provide the STRONGEST evidence for the novelty and exceptional properties for the compounds of this discovery. It is clear that these compounds penetrate biological membranes and rapidly evoke responses; events that are not seen with the comparative di-sec-butyl analogs. Furthermore, the bioactivity is not correlated to the potency measurement [EC50] on the TRPM8 receptor. This is the first time that shaking responses of such magnitude have been shown after topical [dermal] application of a chemical. -
TABLE 10 Shaking frequency after perioral [per 20 mg/kg body weight] or topical delivery of 20 μl test compounds [per animal] to the anesthetized rat. Mol # Code Wt Cs Sensation Perioral Topical xMenthol DIPA-1-5 204 11 dynamic cool 86 ± 7 138 ± 15 0.7 DIPA-1-6 218 12 dynamic cool 56 ± 5 69 ± 8 1.6 DIPA-1-7 232 13 dynamic cool 36 ± 4 79 ± 8 5.4 DIPA-1-8 246 14 cool 0 7 ± 2 5.4 DIPA-1-9 260 15 mild cool 0 0 4.0 2-4 218 12 cool 0 0 0.3 2-5 232 13 cool 4 ± 1 0 2.2 2-6 246 14 cool 0 0 4.7 2-7 260 15 cool 0 0 3.4 2-8 274 16 cool 0 0 2.9 - Surprisingly, vigorous shaking was evoked with inventive embodiments DIPA-1-5, DIPA-1-6, and DIPA-1-7. Only a weak response was seen with DIPA-1-8, and the comparative di-sec-butyl analogs, 2-5, 2-6, and 2-7, were inactive. The shaking induced by DIPA-1-7 was dose-dependent. Topical application of 5 μl, 10 μl, 20 μl, or 50 μl of DIPA-1-7 elicited an average of 25±3, 53±6, 79±8 and 118±12 shakes, respectively, in 1 hr. Shaking was seen if DIPA-1-7 was diluted 50-50 with either water or saline (at the 10 μl dose), but it was completely inhibited if 50% (R)-1,2-propanediol was added to the DIPA-1-7 (at the 10 μl dose) as a diluent. This surprising result shows that DIPA-1-7 penetrates the skin in aqueous solution and is retarded by an alcoholic solvent. This facile permeability of DIPA-1-7 is reminiscent of menthol, and suggests DIPA-1-7 is easily delivered into the dermis by topical application. Furthermore, DIPA-1-7 may be used to penetrate thick keratotic skin lesions, for example in psoriasis or in contact dermatitis of the hands, to alleviate itch and pain. The adjustment of DIPA-1-7 concentrations in polyhydric solvent such as 1,2-propanediol can be used to control the degree of absorption of DIPA-1-7, an art well-known to formulation experts.
- The surprising potency of DIPA-1-5 and DIPA-1-6 was unexpected. These molecules work for a shorter time on skin cooling than DIPA1-7. These smaller molecules may penetrate faster through the skin barrier and go into the systemic circulation. However, the value of this fast action is uncertain. In most contemplated topical applications of this discovery, the preference is for the drug action to remain localized and not systemic.
- When the relative activities of the analogs for producing shaking are compared to the EC50 for TRPM8 activation, it can be seen that the two variables are not correlated. The limitations of the TRPM8 EC50 for predicting bioactivity were discussed on page.
- The results here provide the strongest objective laboratory evidence that the DIPA compounds of
Formula 1 selectively produce vigorous “dynamic cool”. The total number of carbons, or the number of carbons in the largest alkyl group, did not correlate to the magnitude of bioactivity. The key factor to penetration was to avoid masking the phosphine oxide group with a butyl instead of a propyl group. - The receptor targets on the nerve endings are embedded in the epithelial cell layers. The epidermis is only ˜1 mm thick, but a number of dead cell layers (stratum corneum), of denatured proteins impede access of the agonist molecule to the nerve endings. The heel of the feet is the thickest barrier, 86 cell layers for the heel, and followed by the palm of the hand, then the back of the hand. If you put an ice cube on the heel, you feel a bit of cold: but you will jump when you put it on the sole of the feet which has fewer layers. Unless the skin of these surface are structurally damaged, e.g. by inflammation, applying a cooling agent will not work, because the molecules do not access the nerve endings. For other surfaces, the genital skin (glans of the penis and vulva) and the eyelids are the thinnest, with 4 to 8 cell layers. The extremities, arms and legs, and the trunk (back) have thicker surfaces. The scalp is intermediate. The face varies: the cheek is relatively insensitive, but areas around cheekbone and nasolabial folds are thin and sensitive. These differences are important for drug action! For itching of the flexures of the limbs, e.g. elbow and knees, you need good drug penetration. For the eyelids and genital skin, you must choose your molecule carefully to get the desired effects: avoid too much stimulation and exert gentle cooling.
- By contrast to the compounds tested by '496, applicant's preferred embodiments of DIPA-1-7, DIPA-1-8, and DIPA-1-9, wherein two of the alkyl groups (e.g. R2 and R3) are both isopropyl, have high water solubility and skin penetration. Increasing water solubility to increase bioactivity is counterintuitive in standard drug design for enhancement of transdermal drug permeation. Normally, formulation experts try to break down the stratum corneum with enhancers and chemists try to increase lipid solubility of the molecule (e.g. M. Prausnitz et al. Skin barrier and transdermal drug delivery. Chpt. 124, Medical Therapy, 2012). Nevertheless, the strategy used here was met with clinical success.
- For the equivalent number of total carbons and hence equal molecular weights, applicant find that Dipa are at least 2 to 3× more water soluble than Dapa. In the Dipa series the polar phosphine oxide is not masked by the extra branched chain carbons. The Dipa are more hydrophilic than Dapa. Studies of skin permeation in vitro on hairless mouse skin confirmed the unusual penetrating power of the Dipa structure. In in vivo laboratory animals the pharmacological differences of the Dipa from Dapa congeners were strikingly different. Both Dipa and Dapa were active by intravenous injection, but only Dipa was active by or topical or oral routes of administration, indicating penetration across the dermal and gastrointestinal membranes of the Dipa, but not Dapa structures.
- To further study the skin permeation of DIPA compounds, tests were conducted on the flux of DIPA-1-7 and DIPA-1-9 through excised hairless mouse skin in vitro (
FIG. 7 ). -
FIG. 7 . shows the flux of DIPA-1-7 and DIPA-1-9 through excised hairless mouse skin in vitro. Test chemicals dissolved in a gel were placed in an incubation for 8 hr and the permeated amount of the chemical measured by a high pressure liquid chromatograph equipped with a refractive detector. These tests were conducted by Prof Choi of Chosun University, Korea. The flux of 1-7 was ˜5× greater than 1-9. Standard enhancers with polyhydric alcohols, such as a propylene glycol-oleyl alcohol mixture (50:50) or Lauroglycol 90, designed to increase permeation added to the 1-7 gel decreased the rate of permeation by ˜50%, indicating the importance of water solubility for permeation. - Standard enhancers with polyhydric alcohols, such as a propylene glycol-oleyl alcohol mixture (50:50) or Lauroglycol 90, designed to increase permeation added to the 1-7 gel DECREASED the rate of permeation by ˜50%, indicating the importance of water solubility for permeation. In studies on the abdominal skin of anesthetized rat, it was found that a 50:50 propylene glycol-DIPA-1-7 mixture was inactive when tested on the skin of animals, with shaking as an endpoint, whereas the pure DIPA-1-7 was very active. Thus, normal solvents or enhancers of dermatological molecules impede rather than facilitate passage of the DIPA through the skin barriers.
- The mobility of the DIPA molecules in an aqueous environment through a skin barrier is unusual and surprising. Apparently, if the polar “head” is masked by one or more carbon (e.g. methyl) groups, water solubility and permeability decrease. Alternatively, the symmetrical (achiral) arms (the isopropyl groups) may enable an efficient swimming of the DIPA through the pores of the stratum corneum and into the extracellular fluid, until the TRPM8 receptors in the stratum basale are reached. The DIPA configuration may be viewed as a “sperm” like head (the oxygen cloud about the phosphorus atom) that permits a polar interaction with water. The “swimming” motion may be impaired if the branched arms are asymmetrical (chiral).
- DIPA-1-7, the most potent compound for dynamic cooling, was tested at other topical sites on the cranium. A 20 mg/mL solution was applied, using a cotton wipe, onto the skin above the buccal cheek, the parotid-masseteric cheek, temple, and the skin above the periauricular region, and the posterior mandible using the appropriate craniometric points (pterion, coronion, condylion, and gonion, respectively) as landmarks. Surprisingly, at all of these sites, other than the buccal cheek, little cooling, if any, was observed. Mild cooling was observed on the buccal cheek for approximately 30 minutes, but this effect may have been due to the spread of the solution onto the receptive field of the infraorbital nerve. It should be noted, however, the sensory effects of topical application of DIPA-1-7 may be influenced by inflammatory lesions that can alter permeability, for example, acne or acneiform lesions on the skin of the cheek.
- The head is known to be a site where cooling helps relieve heat discomfort. In a study described in Nakamura et al. [2012], eleven male subjects were exposed to mild heat. Subjects, clothed in only short pants, entered a climatic chamber maintained at 32.5±0.5° C. with a relative humidity of 50%. About 1.5 hours after entry into the chamber, a local cooling protocol was initiated with water-perfused stimulators placed on the head, chest, abdomen, or thigh. Cooling of the face and thigh was felt by the subjects to be more effective than cooling of the chest and abdomen in reducing the heat discomfort.
- In a study described by Essick et al.[Site-dependent and subject-related variations in perioral thermal sensitivity. Somatosensory & motor research 21, 159-75, 2004] the thresholds for detection of cooling and cold pain on various sites of the face, ventral forearm, and scalp was determined for 34 young adults. The most sensitive sites were on the vermilion which could detect a temperature change of about 0.5° C., followed by areas around the mouth (upper and lower hairy lip, mouth corner) and lateral chin. The mid-cheek and periauricular skin were less sensitive (able to detect a temperature change of about 2° C.), and the forearm and scalp were least sensitive (able to detect a temperature change of about 3° C.). The sensitivities of the orbital, zygomatic and forehead skin were not tested.
- Use of DIPA-1-7 on the orbital and zygomatic/forehead skin, for example, in an office environment or in heat stress, may be inconvenient if the subjects uses cosmetic make-up at these sites. Surprisingly, it was found that DIPA-1-7, at 20 mg/mL, can produce a dynamic cooling effect when applied on the scalp, especially near the hairline. This effect is sufficient to counter fatigue caused by heat. Likewise, rubbing DIPA-1-7 on the skin in the centre of the chest, above the sternum, can counteract the discomforts of heat. At these application sites, cosmetics are not affected, yet an invigorating coolness, that counteracts the debilitating effect of heat, is achieved.
- The ability of DIPA-1-7 to cause cooling of the scalp and hairline is also important for treating itch at these sites in conditions such as psoriasis, dandruff, and seborrheic dermatitis.
- Case studies are described below which demonstrate the use of DIPA compounds in dermatological disorders and other conditions: (a) to counteract skin itch and pain in subject experiencing these dermatological symptoms (b) to break the “itch-scratch” cycle in a patient with atopic dermatitis, (c) to reduce the symptoms of urticaria, (d) to reduce the symptoms of cholestatic itch in a patient with liver disease, (e) to attenuate the discomfort of eyelid inflammation, (f) reduce the severity of “night sweats”, and (g) to counteract the discomfort from heat stress (h) to treat the discomfort of genital inflammation. For several of these conditions, including urticaria and cholestatic itch, the surprise was the DIPA compounds were effective even when the keratinized skin is “intact”, i.e. the stratum corneum is normal, and one would not expect a topical medication to penetrate and to be active.
- In these studies, subjects were given dosages units containing 1.5 to 1.75 mL of DIPA-1-7 stored in 2.0 mL microcentrifuge tubes (Nova Biostorage Plus, Canonsburg, Pa. 15317) and cotton gauze (0.4 g, rectangular, 50 mm×60 mml; from CS-being, Daisan Cotton, Japan). The DIPA-1-7 was provided as a solution in distilled water, at a DIPA-1-7 concentration of 5 mg/mL to 20 mg/mL. The subjects were given instructions on how to place wet the gauze and how to wipe over the skin. Approximately 0.15 mL to 0.35 mL per unit wipe were delivered by these methods of application. Subjects were instructed to rinse with water if any surface become irritable; however, irritation and discomfort were not seen with DIPA-1-7, DIPA-1-8, or DIPA-1-9 at the test concentrations.
- Contact dermatitis. Two scientists working in the laboratory had allergic dermatitis of the hand in response to detergents and soaps. The hands were inflamed and extremely itchy. Applications of DIPA-1-7, 20 mg/mL, with a cotton-tipped applicator or gauze immediately stopped the itch and this effect lasted for at least 2 hours, and the suppression could be renewed by repeated application. One scientist, a world-renowned dermatologist with many publications on itch, noted that the DIPA-1-7 produced an “icy-cool” feeling on the inflamed skin and he had never encountered such a compound that was so effective in stopping itch so quickly.
- A pharmacologist liked to work in the garden, but the thorns from bougainvillea stems and rose bushes, and the hair from azalea leaves, irritated his skin and caused intense itch. He noted that the sensory discomfort on the skin could be instantly stopped by DIPA-1-6 or DIPA-1-7, applied either as a 20 mg/mL aqueous solution, or as a cream (mixed with Eucerin Moisturizing Cream). These effects could also be obtained with DIPA-1-8. He also noted that the irritation and itch caused by insect bites could be immediately stopped by these agents.
- Atopic dermatitis A 8-year old boy had atopic dermatitis since childhood and exhibited the standard scars on the flexures of his elbow and knees. He had been treated with topical steroids, but the skin had become thin and easily broken. He objected to topical ointments because of the excessive “greasy” feel and stickiness, and because he felt they were not effective in stopping the itch. He also used moisturizers. The itch interfered with his sleep, especially during periods when his allergic rhinitis flared up. His parents were concerned with the scratching at night, poor scholastic performance, and lack of concentration. The subject was given 8×8 cm wipes saturated with 2 mL of DIPA-1-7 at 10 mg/mL in water, and given instructions to use the wipes after washing, to wipe over skin sites that itched in the evening, as he prepared for sleep. The wipes were immediately effective in reducing itch and scratching and facilitated sleep. Over a 2-week period of use, the skin lesions became less red, formed scabs, and progressed to heal. It was clear that the itch-scratch cycle had been attenuated. The boy became more cheerful and he paid more attention to his schoolwork. His parents were extremely pleased.
- Pruritis and Xerosis of the Elderly An eighty-six year old retired widower decided to move from California to a hotel suite in Hong Kong for permanent residence. He had been an avid and skilled golfer for many years and had actinic keratosis and a dry skin. Over time, his skin became itchy, especially on the forearms and back torso. Scratching with a wooden stick on his back at first helped, but the skin became damaged, infected, and inflamed. He applied Eucerin's “Atopic Control” which helped relieve the dryness, but found it to be expensive, heavy and “greasy”, although it definitely provided some protection and relief. The itching and inflamed skin became unbearable during the hot summer months in Hong Kong, when the air conditioning was on full blast, and during the dryness of the fall season. His dermatologist prescribed a potent topical steroid, but his skin became fragile, infected, and ulcerated in some areas. His life was miserable because of the skin discomfort. He agreed to try a DIPA-1-8 solution, 10 mg/mL in isotonic saline. He applied about 20 drops of the DIPA-1-8 onto a 8×8 cm wipe made of 100
% viscose 50 grams per square meter. After wiping, the volume off-loaded onto his skin was about 0.2 to 0.25 mL, so the total dose per wiping was 2 to 2.5 mg. The topical application of the DIPA-1-8 relieved his itch within 3 to 5 min after wiping, and he stopped complaining of skin discomfort. He said the wipes when applied to the face, also gave the sensation of wetness, and thus may be useful for cosmetic applications. He continued the use of the wipes on an as need basis and his skin, formed scabs, healed, and resumed a normal appearance. His only negative comment was that the solution made him feel too cool when the air conditioning was on a high setting. He continued using the wipes until death from a bulbar stroke three years later. - Urticaria Urticaria (hives) is an allergic condition in humans manifested by skin rashes (wheals). The symptoms of redness, swelling, and itch on the skin are caused primarily by release of histamine from mast cells into the dermal layers. A frequent trigger for hives is the ingestion of seafood. Here is a description of a case of urticaria treated with DIPA-1-7, formulated 1.5% wt/vol in a gel made by Dong Wha Pharmaceuticals (Seoul, Korea). A female subject with a history of hives went to a seaside resort in the South of France and consumed over two days seafood pasta, minced crab, and mixed seafood soups. She developed extensive welts on her buttocks with the classic signs of inflammation, namely, “calor” (heat on touch of the inflamed tissues), “rubor” (redness caused by vasodilatation), “tumor” (swelling) and “dolor” (pain and itch). Wheals also appeared on the skin above the clavicle and on her neck. It was distressing. Application of the gel on the skin diminished all four signs of inflammation beginning about 5 to 10 min after application. The subject described the effect as “burning cold” and then robust cool, but excellent for decreasing the sense of itch and “heat” from the red welts. Swelling, redness, and “flare” were visibly diminished 30 min after application. The gel was applied again 3.5 hr later, and then the subject given three tablets of fexofenadine (120 mg) and a tablet of chlorphenhydramine (4 mg). All the signs and symptoms of the hives were viewed as being diminished by at least 50% and “under the control” by the subject in 12 hr, and the skin rashes disappeared after three days and did not recur.
- This is the first report in which the skin dysesthesia (itch and a sense of heat) and other signs of inflammation caused by urticaria are reduced rapidly after topical medication (1.5% DIPA-1-7 in a gel). The rapid effectiveness of DIPA-1-7 applied to the relatively thick skin of the buttocks (15 to 18 cell layers of stratum corneum) indicated permeation to the nerve endings that allowed the symptoms and signs of inflammation to be alleviated. The therapeutic effect and rapid onset is of sufficient intensity to benefit the patient.
- Additional case studies with DIPA-1-7 gel in 8 cases of urticarial dermatoses were obtained by an established dermatologist in a leading hospital in Seoul, Korea. The satisfactory suppression of itch was obtained in 75% of patients. In this study, there were also 5 cases of atopic dermatitis, 6 cases of seborrheic dermatitis, 3 cases of prurigo nodularis, and 3 cases of herpes zoster. In the cases tested, the skin dysesthesia intensity was assessed on a visual analog scale after use of DIPA-1-7 for one week. It was clear that the DIPA-1-7 gel had benefits in a variety of dermatological disorders.
- Cholestatic Itch A 80-year renowned Professor of History was diagnosed with terminal liver cirrhosis. His children learned of the anti-itch medication and requested samples because he was constantly itching and scratching. At first, the condition was incorrectly called eczema, but upon examination the skin was in fact intact. The subject was suffering from cholestatic itch. The subject was given cotton gauze squares and 30 mL plastic dropper bottles containing 2% DIPA-1-7 in water. He was instructed to wet the squares and wipe the solution on the site of itch on an as needed basis. The subject declared after his first trial that this was the best medication he had ever tried for the itch and that it worked. He used about one 30 mL bottle every three days and demanded more. This regimen continued until the subject expired three months later.
- A 28-year old female subject visited her optometrist with the typical complaints of dry eye disease disorder, namely, a sense of discomfort from the eye surface, blurring of vision, sensitivity to light, and problems with reading, driving, and using the smartphone screen. Upon examination, she was found to have hyperemia of the eyelid margins, blockage of the Meibomian gland ducts, some thickening of the eyelid
- Further questioning revealed that she was using a bimatoprost solution to induce hypertrichosis, but was applying the solution two or three times of a day (instead of the suggested single application per day) because she was dissatisfied with the slow rate of eyelash growth.
- She was instructed not to use eye makeup and given Blephaclean™ eye wipes, which are single unit wipes with a cleansing solution, to clear the Meibomian gland ducts and to maintain eye hygiene. The subject, however, objected vehemently to the irritation caused by the cleansing wipes and her inability to continue use of the bimatoprost solution, which was quite expensive. The subject was recruited into a clinical trial of a DIPA-1-9 wipe, 2 mg/mL in water, and instructed to use the wipe once in the morning, once in the evening, and two more wipes on an as needed basis during the day. She felt immediately better upon using the DIPA-1-9 wipes and commented on the cooling and refreshing sensations that were now present on her ocular surface and margins. She said her bimatoprost solution now no longer irritated and her eyelashes were now thick and luxurious. She recommended that the DIPA-1-9 be added to the bimatoprost solution as an adjunct. She offered to pay for a continued supply of the DIPA-1-9 wipes.
- Heat stress In a series of studies, a towelette was used for delivery instead of a wipe. The towelette consisted of a plastic wrap (weight 1.1 g), a 23 cm×26 cm towel of non-woven lace (weight 3.4 to 3.5 g) and a liquid composition (14 to 15 mL) which was automatically added to and sealed off in the wrapper. Automated machinery for producing towelettes are well-known to the art. Here, the towelettes were produced by Kank Factor, LLC, San Francisco (721 Commercial Street, San Francisco Calif. 94108, www.3LWipes.com). These towelettes were then further treated to form either embodiments for practicing the present invention or as placebo controls, as follows. Distilled water (as placebo controls) or DIPA-1-7 dissolved in distilled water (at a concentration of 1 to 5 mg/mL) was incorporated into the towelette. The volume per self-application depended on the application site, but was about 0.3 mL to 0.5 mL for the face and brow, but could be higher if wiping of the torso was also included.
- The towelettes were stored in a refrigerator but then stored at room temperature for at least 1 hour before use. Effective sterilization of the towelette could be obtained by placement in a microwave oven for 1 min [Tanaka, Y. et al. Warming and sterilizing towels by microwave irradiation. Yonago Acta Medica 41: 83-88, 1998]. Subjects were instructed to hold the towelette with both hands, and bring the towelette against the face, like how one would use a small wet face towel, and to keep the eyes closed. The skin of the face is moistened and medicated by this procedure. Once the subject has learned what to expect, the subject can adjust the dosage (e.g., by dabbing), as needed, to achieve the desired anti-fatigue/anti-heat effects. After one or two trials, individuals quickly learn how to apply the sensory agent without any risks of discomfort.
- During an “Indian Summer” heat wave in the San Francisco Bay Area, the outside temperature was 30 to 33° C. with a cloudless sky and an intense bright sun. The towelette, described above, was used as a substrate to deliver DIPA-1-7 to the skin of the chest and armpits of several individuals who complained vigorously about heat stress and discomfort. Comfortable cooling was noted for more than 3.5 hours with decreased sweating. These Individuals were able to work normally in the heat in an office environment without need for additional cooling.
- A 70-year old from Northern California went on a 7-day golf vacation to Las Vegas in September. He played at least one round of golf each day and sometimes two. He did not wear a hat or use sunscreen. On the third day of vacation, the subject showed the classic signs and symptoms of sunburn: redness and flushing of the facial skin, a sense of persistent warmth, pain, and tenderness of the face, a mild degree of swelling around the eyes, and a throbbing headache. He volunteered to try a cream containing 1% wt/vol DIPA-1-8 and wiped about 0.5 mL of the cream over his cheeks and cheekbone. Surprisingly, he noted an immediate relief of skin discomfort which lasted for at least four hours. His headache was gone, and he said his face felt “comfortable and normal”. He used the cream on an “as needed” basis and reduced his exposure to direct sunlight by wearing a wide-brimmed hat and applying copious amounts of sunscreen products. He said that the cream would be especially useful for the dry hot climates of Los Angeles, Phoenix and other parts of Arizona, and for Texas, and for countries such as Australia and the Middle East, because it also relieved the sense of dryness on the face and gave a feeling of “wetness” after repeated use. This relief of “post-sunburn” pain, burning, redness, and discomfort was confirmed in ten other cases.
- Lichen sclerosus atrophicus A 40-year old suffered from penile lichen sclerosus. This is an inflammatory dermatosis of the glans penis and foreskin and, in this particular case, was associated with intense pruritus and dysesthesias (burning sensations). The patient, under the supervision and care of his dermatologist, volunteered to try DIPA-1-8 on his lesion and he was supplied with various concentrations of DIPA-1-8 dissolved in distilled water. After self-experiment, he concluded that concentrations of 1 to 1.5 mg/mL of DIPA-1-8 produced significant relief, but a concentration of 2 mg/mL of DIPA-1-8 was too cold and uncomfortable. The solutions were applied with cotton-tipped applicators or gauze wipes. The advantage of using DIPA formulations for genital skin is water solubility. This minimizes the need for excipients and the likelihood of further irritation. The subject suggested that an aerosolized spray may also be a convenient method of drug delivery.
- These studies illustrate the anti-nociceptive properties of DIPA-1-7 and DIPA-1-8, especially on itching. DIPA-1-8 had a longer duration of action than DIPA-1-7, and may be the preferred agent for dermatological applications. Further studies showed that DIPA-1-9 at 2 mg/mL applied with with a wipe on the glans or on the vulva produced that a gentle cooling and refreshing sensation that counteracted any inflammatory discomfort.
- Three subjects decided to systemically compare DIPA-1-6, DIPA-1-7, DIPA-1-8, and DIPA-1-9 for their sensory effects on the ocular surface. Each compound was prepared at 1 mg/mL in distilled water. A cotton tipped applicator of a specific size (Puritan 803-PCL) consisting of a 55 to 75 mg ball of cotton wound around the tip of a three inch polystyrene rod was dipped into the solution. The tip was then applied, with the eyelids closed, to the lower aspect of the upper eyelid, onto the eyelashes, with two lateral to medial wiping motions. The subjects were then instructed to blink. By blinking, the solution is then evenly distributed over the pre-corneal film. This “swab” delivery method off-loaded a total of ˜35 μL of liquid onto the surface of both eyes. DIPA-1-6 caused significant stinging and discomfort and was therefore not further studied. DIPA-1-7 and DIPA-1-8 produced strong and refreshing cooling, which counter-acted eye irritation, and increased cognitive functions. For example, subjects felt they could focus on distant objects and enjoy the view. They felt mentally alert and refreshed. But, with both DIPA-1-7 and DIPA-1-8, there was a small residue left on the eyelid; subsequently using a towel to wash the face can cause eye irritation. Surprisingly, DIPA-1-9 did not produce any eye irritation when wiped over the eyelid, nor did it leave a residue. It also produced refreshing cooling, but not with the same intensity as DIPA-1-7 or DIPA-1-8. On the other hand, DIPA-1-9 has ideal properties for the treatment of ocular discomfort, e.g., discomfort caused by eye strain; eye fatigue; eye surgery; an airborne irritant or pollutant that interacts with the eye surface; extended wear of contact lenses; excessive exposure to the sun; conjunctivitis; or the dry eyes syndrome.
- The structures of Rowsell and Spring '496 were described 40+ years ago, but were not developed for use. The applicant found that diisopropyl analogs were not described in '496. He then synthesized and tested these analogs. The “head” of the prototypical DIPA molecule is polar (hydrophilic) and soluble in the polar environment of water. This increased water-solubility of the analogs facilitates permeation past dead cell layers of the stratum corneum to access skin nerve endings. The preferred embodiments, 1-7 and 1-8 exert a robust cold sensation that can modulate skin dysesthesia caused, for example, by various dermatitis (e.g. atopic or urticaria) and by dryness (xerosis). The '496 structures have their “head” covered by more lipophilic groups and are chiral, and are less able to permeate to target receptors in the basal layers of the skin to achieve the same therapeutic endpoints as the preferred embodiments. Increasing water solubility is counterintuitive in standard drug design for enhancement of transdermal drug permeation. Normally, formulation experts try to break down the stratum corneum with enhancers and chemists try to increase lipid solubility of the molecule (e.g. M. Prausnitz et al. Skin barrier and transdermal drug delivery. Chpt. 124, Medical Therapy, 2012). Nevertheless, the strategy used here was met with clinical success. Thus, the applicant opines that the discovery of the DIPA embodiments is not obvious and is a quantum improvement in the discovery process.
- For the equivalent number of total carbons and hence equal molecular weights, applicant find that DIPA are about 10× more water soluble. Studies of skin permeation in vitro on hairless mouse skin confirmed the penetrating power of the DIPA. In in vivo laboratory animals the pharmacological differences of the DIPA from the mixed isopropyl/sec-butyl and di-sec-butyl congeners were strikingly different. Both DIPA and di-sec-butyl were active by intravenous injection, but only DIPA was active by or topical or oral routes of administration, indicating better penetration across the dermal and gastrointestinal membranes of the DIPA, but not di-sec-butyl structures. The ability of the DIPA structures to relieve skin discomfort in patients with an intact stratum corneum and a dermatological disorder was rapid, dramatic, and unexpected.
- A number of publications are cited herein in order to more fully describe and disclose the discovery and the state of the art to which the discovery pertains. Each of these publications is incorporated herein by reference in its entirety into the present disclosure
Claims (21)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/350,559 US20190105335A1 (en) | 2014-12-29 | 2018-11-30 | Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of sensory discomfort |
US16/501,056 US11406649B2 (en) | 2018-11-30 | 2019-02-14 | Treatment of upper aerodigestive tract disorders and cough |
CN201910281448.8A CN111249287A (en) | 2018-11-30 | 2019-04-09 | Treatment of aerodigestive disorders and cough |
US16/873,626 US11389462B2 (en) | 2017-03-31 | 2020-05-21 | Method to reduce face mask and respirator discomfort |
US17/472,611 US11684628B2 (en) | 2014-12-29 | 2021-09-11 | Di-isopropyl-phosphinoyl-alkanes (DAPA) compounds as topical agents for the treatment of sensory discomfort |
US17/573,577 US20220193097A1 (en) | 2013-10-22 | 2022-01-11 | Use of 1-di-isopropyl-phosphinoyl-alkane compounds for treatment of ocular discomfort |
US17/803,311 US20220265687A1 (en) | 2018-11-30 | 2022-05-03 | Di-Isopropyl-Phosphinoyl -Alkanes as topical agents for the treatment of sensory discomfort |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/544,355 US10195217B2 (en) | 2013-10-22 | 2014-12-29 | Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of sensory discomfort |
US16/350,559 US20190105335A1 (en) | 2014-12-29 | 2018-11-30 | Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of sensory discomfort |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/544,355 Continuation-In-Part US10195217B2 (en) | 2013-10-13 | 2014-12-29 | Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of sensory discomfort |
US15/530,976 Continuation-In-Part US10722477B2 (en) | 2014-12-29 | 2017-03-31 | Cooling adjunct for medications to treat disorders in the nasal cavity |
Related Child Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/530,976 Continuation-In-Part US10722477B2 (en) | 2014-12-29 | 2017-03-31 | Cooling adjunct for medications to treat disorders in the nasal cavity |
US16/501,056 Continuation-In-Part US11406649B2 (en) | 2018-11-30 | 2019-02-14 | Treatment of upper aerodigestive tract disorders and cough |
US16/873,626 Continuation US11389462B2 (en) | 2013-10-22 | 2020-05-21 | Method to reduce face mask and respirator discomfort |
US16/873,626 Continuation-In-Part US11389462B2 (en) | 2013-10-22 | 2020-05-21 | Method to reduce face mask and respirator discomfort |
US17/472,611 Division US11684628B2 (en) | 2014-12-29 | 2021-09-11 | Di-isopropyl-phosphinoyl-alkanes (DAPA) compounds as topical agents for the treatment of sensory discomfort |
US17/472,611 Continuation-In-Part US11684628B2 (en) | 2014-12-29 | 2021-09-11 | Di-isopropyl-phosphinoyl-alkanes (DAPA) compounds as topical agents for the treatment of sensory discomfort |
US17/803,311 Continuation-In-Part US20220265687A1 (en) | 2018-11-30 | 2022-05-03 | Di-Isopropyl-Phosphinoyl -Alkanes as topical agents for the treatment of sensory discomfort |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190105335A1 true US20190105335A1 (en) | 2019-04-11 |
Family
ID=65992334
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/350,559 Pending US20190105335A1 (en) | 2013-10-22 | 2018-11-30 | Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of sensory discomfort |
US17/472,611 Active US11684628B2 (en) | 2014-12-29 | 2021-09-11 | Di-isopropyl-phosphinoyl-alkanes (DAPA) compounds as topical agents for the treatment of sensory discomfort |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/472,611 Active US11684628B2 (en) | 2014-12-29 | 2021-09-11 | Di-isopropyl-phosphinoyl-alkanes (DAPA) compounds as topical agents for the treatment of sensory discomfort |
Country Status (1)
Country | Link |
---|---|
US (2) | US20190105335A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022150789A1 (en) * | 2021-01-11 | 2022-07-14 | Iview Therapeutics, Inc. | Use of 1-di-isopropyl-phosphinoyl-alkane compounds for treatment of ocular discomfort |
US11389397B2 (en) * | 2020-05-21 | 2022-07-19 | Edward Tak Wei | Method to reduce face mask and respirator discomfort |
US11389462B2 (en) * | 2017-03-31 | 2022-07-19 | Edward Tak Wei | Method to reduce face mask and respirator discomfort |
WO2023215407A3 (en) * | 2022-05-03 | 2024-02-08 | Iview Therapeutics, Inc. | Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of eye diseases |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1434728A (en) * | 1972-09-27 | 1976-05-05 | Wilkinson Sword Ltd | Compositions and articles containing phospine oxides having a physiological cooling effect and phosphine oxides for use therein |
US20050059639A1 (en) * | 2003-09-11 | 2005-03-17 | Wei Edward T. | Ophthalmic compositions and method for treating eye discomfort and pain |
US9895382B2 (en) * | 2013-10-13 | 2018-02-20 | Edward T. Wei | Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of sensory discomfort |
US9642868B2 (en) * | 2013-10-22 | 2017-05-09 | Edward T. Wei | Topical agents for the treatment of sensory discomfort in the nasal cavity |
AU2013403622B2 (en) * | 2013-10-22 | 2019-05-16 | Edward Tak Wei | Di-isopropyl-phosphinoyl-alkane (DAPA) compounds as topical agents for the treatment of sensory discomfort |
US10722477B2 (en) * | 2014-12-29 | 2020-07-28 | Edward Tak Wei | Cooling adjunct for medications to treat disorders in the nasal cavity |
-
2018
- 2018-11-30 US US16/350,559 patent/US20190105335A1/en active Pending
-
2021
- 2021-09-11 US US17/472,611 patent/US11684628B2/en active Active
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11389462B2 (en) * | 2017-03-31 | 2022-07-19 | Edward Tak Wei | Method to reduce face mask and respirator discomfort |
US11389397B2 (en) * | 2020-05-21 | 2022-07-19 | Edward Tak Wei | Method to reduce face mask and respirator discomfort |
WO2022150789A1 (en) * | 2021-01-11 | 2022-07-14 | Iview Therapeutics, Inc. | Use of 1-di-isopropyl-phosphinoyl-alkane compounds for treatment of ocular discomfort |
WO2022150730A1 (en) * | 2021-01-11 | 2022-07-14 | Iview Therapeutics, Inc. | Treatment of neuropathic sensitization disorders |
WO2023215407A3 (en) * | 2022-05-03 | 2024-02-08 | Iview Therapeutics, Inc. | Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of eye diseases |
Also Published As
Publication number | Publication date |
---|---|
US20210401857A1 (en) | 2021-12-30 |
US11684628B2 (en) | 2023-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10195217B2 (en) | Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of sensory discomfort | |
US20190105335A1 (en) | Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of sensory discomfort | |
US6919348B2 (en) | Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith | |
US9642868B2 (en) | Topical agents for the treatment of sensory discomfort in the nasal cavity | |
US9895382B2 (en) | Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of sensory discomfort | |
US20150111852A1 (en) | 1-Di(sec-butyl)-phosphinoyl-pentane (dapa-2-5) as a topical agent... | |
US20220265687A1 (en) | Di-Isopropyl-Phosphinoyl -Alkanes as topical agents for the treatment of sensory discomfort | |
WO2022150789A1 (en) | Use of 1-di-isopropyl-phosphinoyl-alkane compounds for treatment of ocular discomfort | |
CN114533745A (en) | Diisopropylphosphonoalkanes as topical agents for the treatment of sensory discomfort | |
US20150105349A1 (en) | (R)-(-)-1,2-propanediol compositions and methods | |
US20220193097A1 (en) | Use of 1-di-isopropyl-phosphinoyl-alkane compounds for treatment of ocular discomfort | |
WO2023215407A2 (en) | Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of eye diseases | |
CN103458928A (en) | (R)-1,2-propanediol for use as solvent in therapeutic cooling agent compositions | |
JP6564498B2 (en) | Di-isopropyl-alkane (DAPA) compounds as topical agents for the treatment of sensory discomfort | |
KR20130124349A (en) | [((1r,2s,5r)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester and related compounds and their use in therapy | |
KR20140037045A (en) | (r)-1,2-propanediol for use as a solvent in therapeutic cooling agent compositions | |
Cash | Dermatology Guidelines | |
AU2011356169A1 (en) | (R)-1,2-propanediol for use as a solvent in therapeutic cooling agent compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
AS | Assignment |
Owner name: IVIEW THERAPEUTICS, INC., PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ORINDA PHARMA, INC.;REEL/FRAME:055859/0145 Effective date: 20210122 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
AS | Assignment |
Owner name: WEI, EDWARD T., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:IVIEW THERAPEUTICS, INC.;REEL/FRAME:059688/0298 Effective date: 20220424 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONMENT FOR FAILURE TO CORRECT DRAWINGS/OATH/NONPUB REQUEST |
|
AS | Assignment |
Owner name: IVIEW THERAPEUTICS, INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WEI, EDWARD T.;REEL/FRAME:067536/0565 Effective date: 20240527 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: AWAITING TC RESP, ISSUE FEE PAYMENT VERIFIED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |